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General Introduction 
Introduction 
Rheumatoid arthritis (RA) is a chronic multi-systemic disease of unknown etiology 
characterized by a chronic synovitis and extra-articular manifestations which can 
involve virtually any organ. The traditional pharmacological approach to treating RA 
consists of combinations of non-steroidal anti-inflammatory drugs (NSAIDs) and 
slow-acting or disease-modifying antirheumatic drugs (SAARDs or DMARDs) with 
or without corticosteroids. Recently, it has been proposed that all these agents be 
designated as symptom-modifying antirheumatic drugs (SMARDs), and to reserve 
the denomination of disease controlling antirheumatic therapy (DC-ART) for those 
agents which prove not only to relieve clinical symptoms but also to modify 
radiological and functional disease outcome (1). 
Among the SAARDs, methotrexate (MTX, 4-amino 4-deoxy-N10-methylpteroyl-
glutamic acid), is being increasingly used because of its proven clinical efficacy, 
relative rapid onset of action and acceptable toxicity profile. Despite the broad 
clinical experience with this drug, the mode of action of MTX in RA is still poorly 
understood, and whether this drug is mainly anti-inflammatory or immuno-
modulatory has been recently debated (2). MTX and its polyglutamate metabolites 
inhibit several folate-dependent enzymes involved in DNA, RNA and protein 
synthesis. This explains the cytotoxicity induced by high doses of MTX used in 
oncology, and probably some of the toxic effects seen with lower doses of the drug 
(3). The interference with folate pathways may result in inhibition of transmethyla-
tion reactions and polyamine synthesis (4), and stimulation of adenosine release (5). 
Moreover, MTX decreases neutrophil Chemotaxis, 5-lipooxygenase activity, 
leukotriene B4 and superoxide generation (6,7), and inhibits angiogenesis (8) and 
collagenase gene expression in the synovial membrane (9). All these actions may be 
beneficial but, so far, there is no unifying theory which fully explains the therapeutic 
efficacy of this drug in RA. In this respect, MTX is not an exception to the rule: 
most SAARDs have been shown to modulate some aspects of inflammation or 
immunoregulation either in vitro or in vivo, though their mechanism of action 
remains obscure. 
Cytokines and rheumatoid arthritis 
Our knowledge about the mediators of inflammation has expanded rapidly in recent 
years. This is especially true for cytokines, a complex family of low-weight peptides 
which modulate intercellular signalling. Cytokines such as interleukin-1 (IL-1) and 
tumor necrosis factor (TNF) are key mediators of inflammation, and growing 
evidence suggests that an imbalance between these cytokines and other anti-inflam-
matory cytokines or cytokine antagonists plays a key role in the pathogenesis of RA. 
This concept has driven the development of specific strategies aimed at shifting this 
imbalance to a physiological situation and has opened the way for research on the 
effects of traditional anti-rheumatic drugs on this network. 
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Aim and contents of this thesis 
It has been proposed that MTX downregulates the production or activity of IL-1 
which may be relevant for the therapeutic efficacy of this drug in RA (3). This 
statement was based on in-vitro studies and sporadic observations in patients with 
RA. The lack of longitudinal, controlled studies about the effects of MTX therapy 
on cytokines stimulated the present studies the aim of which was to address the 
following questions: 
a) what is known about the effects of MTX and other SAARDs on cytokines ? 
b) does MTX therapy modulate cytokines in RA or systemic sclerosis (SSc) ? 
c) do cytokines differ between patients with RA and Ssc and healthy controls ? 
d) do cytokine measurements correlate with disease activity parameters ? 
The issues addressed in each chapter of this thesis can be summarized as follows: 
Chapter 2 is a review of the literature concerning the effects of MTX and other 
SAARDs on cytokines, and the use of cytokines and anticytokine therapies in RA. 
Chapter 3 describes longitudinal measurements of circulating cytokines and soluble 
cytokine receptors performed during a 48-week, double-blind, randomized trial of 
MTX versus azathioprine in RA. 
Chapter 4 addresses the in vitro effects of MTX, azathioprine and sulfasalazine on 
IL-6 bioactivity, and the influence of therapy with these SAARDs on IL-6 measure-
ments in patients with RA. 
Chapter 5 concerns the effects of a single MTX dose on circulating cytokines and 
cytokine production by blood cells in RA patients. 
Chapter 6 describes longitudinal measurements of circulating cytokines and cytokine 
production by peripheral blood mononuclear cells during a 24-week trial comparing 
the efficacy of MTX versus the combination of MTX and sulfasalazine in RA. 
Chapter 7 reports the results of longitudinal measurements of circulating cytokines 
and soluble cytokine receptors in patients with systemic sclerosis participating in a 
24-week, double-blind trial of MTX versus placebo. 
Chapter 8 is a letter commenting the results of an article by Ward et al. (10) 
concerning the value of longitudinal assessments of soluble interleukin-2 receptors 
in RA. 
Chapter 9 is a methodological study which describes the use of in-vitro dialysis to 
remove IL-1 and tumor necrosis factor from plasma. This method was applied for 
the cytokine radioimmunoassays in the present studies. 
Chapter 10 is dedicated to the conclusions and summary of this thesis. 
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EFFECTS OF ANTIRHEUMATIC AGENTS 
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Antirheumatic agents and cytokines 
Summary 
A review of the literature concerning the effects of traditional antirheumatic drugs 
on cytokines and the cytokine and anti-cytokine approaches already used in the 
therapy of rheumatoid arthritis (RA) is presented. 
Many antirheumatic drugs are capable of cytokine modulation in vitro. Corticoste­
roids inhibit the transcription of a broad spectrum of genes including those 
encoding monocyte-, Τ cell-derived cytokines and several hemopoietic growth 
factors, whereas drugs as cyclosporin A and D-penicillamine interfere with Τ cell 
activation more specifically by suppressing interleukin-2 (IL-2) production. 
The in vivo effects of drug therapy on cytokines in RA patients are less well 
established. Gold compounds reduce circulating IL-6 levels and the expression of 
monocyte-derived cytokines, such as IL-1, tumor necrosis factor (TNF) and IL-6, 
in the rheumatoid synovium. Decreases in circulating IL-6, soluble IL-2 (sIL-2R) 
and TNF receptors and in synovial fluid IL-1 levels have been reported with 
methotrexate. Reductions in circulating IL-6 and sIL-2R concentrations have also 
been observed with cyclosporin and corticosteroids whereas azathioprine reduces 
IL-6 but not sIL-2R. Studies on sulfasalazine are conflicting and the in vivo effects 
of D-penicillamine and antimalarials have not been studied yet. 
Interferon y therapy is not effective in RA but may prove an useful antifibrotic for 
systemic sclerosis. Colony stimulating factors improve the granulocytopenia 
associated with Felty 's syndrome or drug toxicities but can induce arthritis flares 
and should be reserved to treat infectious complications. Promising results are 
being obtained with selective antagonism of TNF and IL-1 in RA and combina­
tions of anti-cytokine strategies with traditional anti-rheumatic drugs have been 
already envisaged. These should preferably be based in a broader knowledge of 
the effects of antirheumatic agents on the cytokine network. 
Introduction 
The pharmacological agents used in the therapy of rheumatoid arthritis (RA) have 
been traditionally subdivided in non-steroidal anti-inflammatory drugs (NSAIDs), 
disease modifying or slow-acting antirheumatic drugs (DMARDs or SAARDs), 
and corticosteroids. All these drugs are clinically effective and, according to a 
recent classification, they can be denominated symptom-modifying anti-rheumatic 
drugs (SMARDs). The term disease-controlling antirheumatic therapy (DC-ART) 
is reserved for those SAARDs capable to modify not only clinical symptoms, but 
also radiological and functional disease outcome (1) (Figure 1). Despite the broad 
experience with antirheumatic drugs, their mechanism of action are only partially 
understood. This is especially true for the SAARDs, a heterogeneous group that 
includes antimalarials, thiol compounds, sulfonamides, antimetabolites as well as 
cytotoxic and immunosuppressive agents. Many SAARDs interfere with cellular 
metabolic processes and have nonspecific anti-inflammatory, immunoregulatory 
and anti-angiogenic effects, which may contribute to their efficacy or toxicity, but 
usually do not fully explain their therapeutical effects. 
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Cytokines are a complex family of peptides with specific receptors which mediate 
intercellular communication and play a crucial role in immunologic and inflam­
matory reactions. The evidence implicating cytokines in the pathogenesis of RA 
and other autoimmune diseases has had several repercussions on the treatment of 
these disorders. It is now known that several drugs, including SAARDs, have 
modulatory effects on the cytokine network. This may be important since 
cytokines control the proliferation, activation, traffic and homing of immunocom­
petent cells in the joint as well as the growth and function of synovial, cartilage, 
bone and endothelial cells. Furthermore, some circulating cytokines or cytokine 
receptors may behave as markers of disease activity or immuneactivation and 
prove useful in monitoring the effects of treatment. Finally, and more important­
ly, selected cytokines and anticytokines are been used to treat RA and the search 
for pharmacological agents with specific cytokine-suppressive properties has just 
started. 
In this report, we review the modulatory properties of several SAARDs and other 
pharmacological agents on the cytokine network, and summarize the clinical 
experience with cytokine and anticytokine strategies in the treatment of RA. 
The cytokine network in RA 
A detailed review of the cytokine network is beyond the scope of this paper, 
therefore only relevant aspects will be briefly mentioned. According to their 
biological effects, cytokines can be classified as pro- or anti-inflammatory, 
fibrotic, growth- and chemotactic factors (Table 1). Such a functional classifi­
cation is an oversimplification since cytokines are characterized by pleiotropism 
(one cytokine possesses multiple functions), overlap (several cytokines share 
similar effects) and mutual regulation. Nevertheless, by considering their 
function, we can gain a better insight into the links between cytokines and other 
processes involved in RA and their potential consequences for therapy. 
Because of their systemic and local effects, interleukin-l (IL-1) and tumor 
necrosis factor α (TNFa) are the prototypes of pro-inflammatory cytokines (2). 
Compelling evidence from in-vitro studies and experimental arthritis models 
shows that tissue destruction and joint inflammation are independently regulated 
by IL-1 and TNF and that these mediators orchestrate the arthritic process (2,3). 
The IL-1 "family" consists of three related peptides: IL-la which is primarily 
cell bound, IL-lß which is primarily secreted and the IL-1 receptor antagonist 
(IL-IRa). These three molecules are each capable of binding to the membrane 
receptors, but only IL-la and ß are biologically active. The IL-IRa occupies the 
receptor but does not activate signal transduction, and therefore acts as a compe-
titive IL-1 inhibitor (4). There are two types of IL-1 receptors. Type I (IL-1RI) 
mediates signalling activity and has a higher affinity for IL-la and IL-IRa, 
whereas type II (IL-1RII) is a decoy receptor, which lacks signalling capacity and 
has a higher affinity for IL-lß (5). Membrane-bound and soluble forms of the 
IL-1RII decoy receptor and the IL-IRa together represent natural mechanisms for 
counteracting the potentially toxic role of IL-1 in vivo. 
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TNFa ала the related lymphotoxin (TNFß) bind to two forms of membrane 
receptors, type 1 or p55 and type 2 or p75 which are active in signal trans-
duction, and can be cleaved from the cell membrane yielding soluble forms 
(sTNFR). The sTNFRs behave as endogenous antagonists by binding TNFa, 
preventing it from attaching to the membrane receptors, but may also function as 
carrier molecules that preclude TNF degradation (6). 
IRREVERSIBLE 
DESTRUCTION 
RADIOLOGICAL 
AND FUNCTIONAL 
DAMAGE 
DC-ART: 
SAARDs ? 
Uri, TNF 
IL-6, HF, Chemökines 
H-2 ,1FNÏöF,C$F 
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THERAPIES 
INFLAMMATION PROLIFERATION 
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Figure 1. Schematic representation of the pathogenesis, manifestations and therapies in RA. 
Joint inflammation and the proliferation of synovial tissue, pannus and angiogenesis in the joint 
eventually result in irreversible destruction of cartilage, bone and periarticular structures. 
Non-steroidal anti-inflammatory drugs (NSAIDs), steroids and slow-acting antrheumatic drugs 
(SAARDs) are symptom-modifiers (SMARDs) capable to alleviate the local and systemic 
manifestations of the disease. Only those SAARDs capable to alter disease outcome should be 
considered disease-controlling antirheumatic therapies (DC-ARTs). The involvement of cytokines 
in the initiation and perpetuation of synovitis has prompted the introduction of anti-cytokine 
therapies for RA. 
Interleukin (IL); tumor necrosis factor (TNF); leukemia inhibitor factor (LIF); interferon^ (IFNp); 
growth- and colony-stimulating factors (GF, CSF). 
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IL-1, IL-IRa aiid TNFa are present in the rheumatoid synovial membrane and 
can be detected in plasma and in synovial exudates of RA patients together with 
soluble forms of bodi TNFR and type II IL-1R. Compared with IL-IRa and 
sTNFR, the concentrations of IL-1 and TNF in biological fluids are low but this 
excess of antagonists may not be sufficient to block the activity of IL-1 and TNF 
completely (2). 
IL-1 and TNFa are artliritogenic in several animal models, and antagonizing their 
effects reduces the severity, or even prevents arthritis (2,3). Moreover, these 
cytokines occupy a high position in the cytokine hierarchy since they stimulate 
the production of each other and of many pro-inflammatory cytokines including 
GM-CSF, IL-6, LIF, IL-8 and other chemotactic factors (7). It is therefore not 
surprising that ongoing anti-cytokine strategies for RA are primarily focused on 
suppressing the actions of IL-1 and TNF. 
IL-6 stimulates В and Τ cell differentiation and activation, immunoglobulin 
production, and shares pro-inflammatory activities with IL-1, TNF and colony 
stimulating factors. However, IL-6 is not arthritogenic, does not induce local 
prostaglandin-^ or collagenase production and is anti-inflammatory by promoting 
the acute phase reaction, upregulating metalloproteinase inhibitors (7), suppres­
sing IL-1 and TNF synthesis in vitro, and inducing IL-1 and TNF endogenous 
antagonists in vivo (8). Moreover, IL-6 is readily detected in biological fluids and 
may be a useful marker of disease activity. 
Several outer cytokines including colony-stimulating and growth factors, chemo-
taxins, and the leukemia-inhibitor factor (LIF), are also present in the rheumatoid 
synovial membrane and are thought to perpetuate the ongoing inflammation by 
stimulating cell recruitment and activation (7). 
In contrast to the abundance of monocyte-derived cytokines, Τ cell products are 
scant in the inflamed joint (9,10) which has led to speculation about the role of Τ 
cells in RA. Τ helper cells can be divided into Thl (secreting IL-2 and IFNY) 
and Th2 subsets (secreting IL-4 and IL-5). Other cytokines such as transforming 
growth factor ß (TGFß), IL-10 and IL-13 are not confined to these subsets and 
are also produced by non-T cells (11,12). 
IL-2 is implicated in the activation and proliferation of Τ, B, and natural killer 
(NK) cells, whereas IFNY induces the expression of class II HLA and adhesion 
molecules, activates macrophages, lymphocytes and NK cell activity and has 
antiproliferative and anti-fibrotic effects. Lymphocytes from RA patients have a 
defective production of IL-2 and ΙΡΝγ, and are hyporresponsive to IL-2 which 
could account for the low proliferative responses to mitogens and delayed type 
hypersensitivity in RA. Because of its immunostimulatory properties, IL-2 has 
been used in the therapy of malignancies, whereas several studies have examined 
the effects of IL-2 inhibition (13) and IFN? therapy in RA (14). 
In contrast with the low levels of IL-2, high concentrations of its soluble receptor 
(sIL-2R) have been detected in several autoimmune diseases including RA. These 
are considered to reflect lymphocyte activation and could be useful in monitoring 
disease activity (15). 
Finally, cytokines such as IL-4, IL-10, IL-13 and TGFß are considered anti-
inflammatory since they inhibit die production of pro-inflammatory cytokines 
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such as IL-1 and TNF and upregulate their inhibitors (12,16). These anti­
inflammatory cytokines are being tested in animal models and may find 
therapeutic application in human autoimmune diseases. 
Effects of SAARDs and other antirheumatic drugs in cytokine 
modulation 
Our knowledge of the cellular and soluble mediators of inflammation has advan­
ced our understanding of the mode of action of SAARDs in RA. Knowing that 
cytokines play a key role in the cascade of inflammatory responses, has stimula­
ted research on the effects of antirheumatic drugs on these mediators. Several in­
vitto studies and observations in animal models and in patients treated with 
SAARDs, suggest that some of these agents do indeed have cytokine-modulating 
properties. The present section summarizes the literature on several SAARDs, 
corticosteroids and other drugs with "cytokine suppressive" properties. 
Antimalarials 
The antimalarials hydroxychloroquine (HCQ) and chloroquine (CQ) are quinoline 
derivatives that exert a variety of effects on immunocompetent cells. These agents 
accumulate in lysosomes, inhibit several enzymes and interfere with the function 
of monocyte-macrophages which may represent their main mode of action. 
Early studies showed that HCQ and CQ inhibit the cartilage degradation induced 
by IL-1 (17). More recently, it was shown that therapeutic concentrations of 
HCQ suppress the production of IL-1 and IL-6 by monocytes, probably acting at 
a post-transcriptional level (18,19). The effects of these drugs on TNFa 
production are more controversial, although combinations of HCQ with 
sulfasalazine inhibit IL-1 and TNF production synergistically (18,19). HCQ does 
not alter either IL-8 gene expression or synthesis by endothelial cells and 
monocytes (20) or the production of IL-2, IL-4 or IFN7 by Τ cells (18). 
However, the drug inhibits IL-6 synthesis by Τ cells, suggesting a selective effect 
of HCQ on some proinflammatory cytokines (IL-1 and IL-6) (18). The effects of 
HCQ therapy on cytokines in RA have not been investigated yet, but in patients 
with SLE, Wallace et al. observed lower circulating concentrations of IL-6 and 
sIL-2R in patients treated with HCQ than in those receiving only corticosteroids 
or no therapy (21). In a prospective study by the same authors, significant 
decreases in serum IL-6 levels occurred after 6 and 12 weeks of treatment with 
HCQ, though sIL-2R concentrations remained unchanged (22). This seems to 
confirm the relative lack of effect of HCQ on Τ cell activation. 
CQ and HCQ have similar effects on monocytes, though the former may have 
additional effects on Τ cells. CQ inhibits monocyte production of IL-1 (23), 
TNFa and IL-6 (24) and acts synergistically with cyclosporin in suppressing 
IFN> production by Τ cells (25). CQ therapy does not affect IL-1 production in 
animal models of adjuvant arthritis (26) or hemorrhagic shock but inhibits TNF, 
IL-6 and prostaglandin release in the latter (27). 
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Gold compounds 
Gold compounds modulate the functional activities of virtually every immuno-
competent cell, but it has been proposed that inhibition of mononuclear phagocyte 
function is of paramount importance for their effects. This is supported by the 
suppressive action of these agents on the production or activity of monocyte-
derived pro-inflammatory cytokines. 
Most in-vitro studies have shown that gold sodium thiomalate (GST) and aurano-
fin (AF) inhibit the synthesis of IL-1 by monocytes (28-32) and act synergistically 
when combined (19). Gold compounds also antagonize some of the biological 
effects of IL-1 (28,33,34), and therapy with these agents decreases IL-1 produc-
tion in adjuvant arthritis (26,35). Danis et al. studied the production of IL-1 by 
monocytes from RA patients treated with GST. Patients considered "high IL-1 
producers" at baseline, had transient clinical improvements associated with 
decreases in IL-1 secretion, whereas "low producers" had a better clinical 
response and showed an increase in IL-1 secretion during therapy (36). The 
authors suggested that IL-1 production before treatment might be predictive for 
clinical response to GST, but several confounding factors, including the use 
concomitant medications, render this study inconclusive. 
Gold does not alter IL-IRa synthesis by normal monocytes (32) though increases 
have been reported in patients with RA (37). Further studies should elucidate 
whether gold therapy induces beneficial shift in the IL-1/IL-lRa balance. 
Gold compounds may modulate other pro-inflammatory cytokines besides IL-1. 
GST inhibits the production of IL-6, but not of TNF, by monocytes (32), 
suppresses the synthesis of IL-8 and monocyte chemoattractant protein (MCP-1) 
by rheumatoid synoviocytes (38), and interferes with the production of IL-8 by 
monocytes and endothelial cells (20,39), whereas AF inhibits the production of 
TNFa by monocytes (40), and several effects of this cytokine on neutrophils 
(41,42). Serial studies in patients with RA receiving chrysotherapy have reported 
reductions in circulating IL-6 levels (43,44), monocyte production of IL-6 (45) 
and, interestingly, also cytokine expression in die synovial membrane as recently 
demonstrated by Yanni et al. Using sequential synovial biopsies, the authors 
observed a striking decrease in the expression of monocyte-derived cytokines, 
including IL-lß, IL-Ια, IL-6 and TNFa, and in the number of infiltrating 
monocytes and macrophages after 12 weeks treatment with GST, whereas the 
number of Τ and В cells remained unchanged (46). Whether such reduction in 
monocyte infiltration results from systemic effects, like inhibition of myelopoiesis 
(47), or from a local action of gold, is unknown but these results strongly point 
to the monocyte-macrophage as principal target cell for gold compounds. 
Nevertheless, Τ cell proliferation, activation and cytokine production are also 
affected by these drugs at least in vitro. Gold compounds inhibit Τ cell prolifera­
tion induced by mitogens, antigens (48,49) and IL-2 (50,51) and suppress the 
synthesis of IL-2 and the expression and release of IL-2R by activated Τ cells at 
a transcriptional level (49). Some of these effects might require low intracellular 
glutathione concentrations (52). The effect of gold on IFNY production is contro­
versial (53,54) but GST inhibits several IFN? activities such as the induction of 
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class II HLA expression in monocytes (55) and endothelial cells (51). This, 
together with the inhibition of endothelial cell proliferation (56) and expression of 
adhesion molecules by gold compounds (57), may result in decreased angiogene-
sis and cell recruitment in the joint. 
Chrysotherapy normalizes the depressed IL-2 production in adjuvant arthritis (35) 
and in patients with pemphigus vulgaris (58). In contrast, circulating sIL-2R 
levels in RA remain unchanged after 24 weeks gold therapy, despite clinical 
improvement (59-61) and only one study reported lower sIL-2R levels in patients 
with clinical remission than in those with active disease after prolonged treatment 
(60). It seems therefore, that despite the inhibitory effects of gold on Τ cells in 
vitro, chrysodierapy for RA affects neither Τ cell infiltration in the joint (46) nor 
lymphocyte activation evidenced by SIL-2R, at least in the short term. 
D-penicillamine 
D-penicillamine (D-PEN) and the related drug bucillamine (BUC), are structural 
analogues of cysteine which, in contrast to gold and antimalarials, may predomi­
nantly affect lymphocytes (especially Τ helper cells), without altering macrophage 
function. Whether therapy with these drugs results in cytokine modulation in RA 
has not been assessed, but available in-vitro studies corroborate this hypothesis. 
The drugs' effect on Τ cell function is mediated by their capacity to generate 
hydrogen peroxide in the presence of copper salts. This results in a direct 
inhibition of Τ cell activation and production of IFNy and IL-2, and indirectly in 
decreased immunoglobulin synthesis by В lymphocytes (62,63). 
Initial in-vitro studies suggested that D-PEN might decrease the production of 
monocyte products with IL-1-like activity (64). Later, it was shown that IL-1 
synthesis and bioactivity can be suppressed only with high concentrations of the 
drug (33) but, therapeutic concentrations do not alter the production of either 
IL-1 (23,30,65) or TNF (19) by human monocytes. Moreover therapy with D-
PEN does not inhibit IL-1 production in the adjuvant arthritis model (26,66). 
D-PEN blocks the binding of IL-Iß to alpha 2-macrogIobulin, an acute phase 
protein which may function as carrier for IL-1 and other cytokines (67). This 
dissociating effect is not specific for IL-1 (68) and its relevance for the 
therapeutic effect of the drug is a matter for speculation. In the presence of 
copper, D-PEN and other thiol compounds inhibit spontaneous and IL-1-induced 
fibroblast proliferation. This is due to the production of hydrogen peroxide rather 
than suppression of IL-1 synthesis (69). 
D-PEN inhibits the proliferation and IL-8 gene expression and synthesis by 
endothelial cells (20), and decreases neovascularization in vivo (70). These anti-
angiogenic and anti-fibrotic properties may be important for the therapeutic 
efficacy in RA and systemic sclerosis. 
It has been suggested that BUC is superior to D-PEN in treating RA (71), 
possibly be due to its additional immunosuppressive effects. In vitro, both drugs 
inhibit Τ cell function, including IL-2 and IFN? production, in the presence of 
copper (72), but only BUC forms an intramolecular disulfide and inhibits В cell 
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function whether or not copper salts are present (62,72). This effect is not due to 
decreased IL-6 production by В cells (62). Furthermore BUC, like D-PEN, does 
not affect IL-1 production by human monocytes (30,65). 
Sulfasalazine 
Sulfasalazine (SASP) is an disulfide compound of sulfapyridine and 5-aminosali-
cylic acid. Sulfapyridine seems the active component in RA, though SASP itself 
might also have anti-rheumatic properties. The exact mechanism of action of this 
drug remains also unclear despite its multiple anti-inflammatory and immuno-
regulatory effects. 
In vitro, SASP inhibits the production of IL-lß and TNFa by monocytes (19,30, 
,73-75) and may suppress the binding of TNFa to its receptors (76). Neither the 
production (45,74,77) nor the activity of IL-6 are markedly altered by SASP 
(78). However, the drug down-regulates the synthesis of IL-2 and IFNy by Τ 
cells (79,80) which may explain its inhibitory effect on lymphocyte proliferation 
and antibody production. Moreover, SASP inhibits the proliferation as well as 
IL-8 gene expression and synthesis (20) in endothelial cells which may account 
for its anti-angiogenic effects. Interestingly, most of the effects of SASP on 
cytokines and immunoregulation are not shared by its metabolites, which suggest 
that the parent compound possesses therapeutic effects. 
Studies on the effect of SASP therapy on circulating cytokines in RA have 
yielded conflicting results. In a 6-month, placebo-controlled study, Danis et al. 
observed decreases in IL-la, IL-lß and TNFa but unchanged IL-6 concentrations 
during SASP therapy (77), whereas other authors reported no changes in IL-lß 
and TNFa levels (81), and decreases in serum concentrations and monocyte 
production of IL-6 (45,81,82). Circulating sIL-2R concentrations did not change 
after 12 weeks therapy with SASP in several studies (61,81,82). The number of 
patients in these studies were mostly too small to draw definitive conclusions and 
the effects of SASP therapy need further investigation. 
Combinations of SAARDs are increasingly used to treat RA and there are in-vitro 
data suggesting that some of these combinations suppress cytokine production in a 
synergistic manner (19). In an open study conducted in our centre, the combina-
tion of SASP with methotrexate (MTX) proved clinically superior than MTX 
alone (83). Serial cytokine measurements showed decreases in IL-6 and sIL-2R 
levels with both therapies, but the concentrations of sTNFR and the production of 
IL-lß and IL-IRa by monocytes fell only in patients treated additionally with 
SASP. These results suggest an additional or specific SASP on these cytokines 
(84) and encourage further studies on the effects of other SAARD combinations. 
Methotrexate 
The past years have seen intensive efforts made to elucidate the mechanism of 
action of methotrexate (MTX). Due to its antifolate effect, MTX may impair 
DNA, RNA and protein synthesis, inhibit transmethylation reactions and polyami-
ne synthesis and stimulate adenosine release. Moreover, the drug can inhibit the 
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activity of 5-lipoxygenase and has modulatory effects on cytokines (85). 
MTX inhibits some biological activities of IL-1 including the proliferation 
thymocytes (86,87) and synovial fibroblasts but does not affect the production of 
collagenase, prostaglandin E, hyaluronic acid or metalloproteinase inhibitors 
induced by IL-1 (88,89). This suggests that the drug antagonizes the proliferative 
but not the secretory activities of IL-1 (88). The suppression of IL-1 bioactivity 
by MTX is due to its antifolate effect since it can be reversed by folinic acid 
(87), though binding of MTX to IL-1, which has structural homology with 
dihydrofolate reductase (DHFR), or receptor downregulation have been also 
proposed to explain this effect (90). MTX therapy decreases the production of 
IL-1 in adjuvant arthritis (91-93), although this has not been consistently obser-
ved in RA. Two studies have assessed the effect of a single dose of MTX on 
monocyte IL-lß production: Segal et al. reported no changes in 9 patients treated 
with MTX for variable periods of time (86), whereas we observed significant 
decreases after the first MTX dose, but not in patients treated for longer than one 
year who already had a lower IL-lß production and less active disease (94). In 
another study, Chang et al. reported decreases in IL-1 production in 4 out of 8 
patients after 6 weeks of therapy with MTX (95). These studies suggest that, if 
MTX down-regulates IL-1 production the effect occurs in the early phase of 
treatment. To test this hypothesis, we monitored 26 patients treated with MTX 
for 24 weeks. Some decrease in IL-1 production occurred after 4 weeks but the 
effect was not progressive and measurements after 24 weeks were not significant-
ly lower than those at baseline (84). Therapy with MTX did not alter circulating 
IL-lß concentrations in this and other study (84,95), but decreases in serum (96) 
and in synovial fluid concentrations have been described (97). Taken together, 
MTX may inhibit the proliferative effects of IL-1, and decrease monocyte IL-1 
production in the short term in certain patients, though this effect is not sustained 
and unlikely explains the long-term efficacy of MTX. Further investigation is 
needed to elucidate whether therapy with MTX decreases the production of IL-1 
in the joint. 
In-vitro, MTX inhibits IL-6 but not TNF bioactivity (86) and decreases the 
production of IL-8 by monocytes (39). The synthesis of IL-8 by endothelial cells 
(20) or RA synoviocytes (38) is not affected by the drug. Treatment with MTX 
reduces circulating IL-6 (84,96,98,99), IL-8 (96) and p55 soluble TNF receptor 
(sTNFR) concentrations (98) in patients with RA but does not affect circulating 
levels (84,98) or monocyte production of TNFa (84,94). Decreases in IL-6, IL-8 
and p55 sTNFR levels probably reflect clinical improvement and are not a 
specific effect of MTX. 
Several studies have also investigated the effects of MTX on Τ cell derived 
cytokines. In-vitro MTX enhances the cytotoxic (100) and proliferative (86) 
effects of IL-2 and the production of this cytokine by lymphocytes (101). MTX 
therapy normalizes die defective production of IL-2 in the adjuvant and strepto­
coccal cell wall arthritis models (91,93). In patients with RA, increased lympho­
cyte IL-2 synthesis has been reported after a single dose of MTX (102) as well as 
in patients receiving the drug for longer periods (96, 103). Kremer et al. reported 
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increases in serum IL-2 concentrations during treatment with MTX (96) and 
decreases associated with disease flares 4 weeks after withholding the drug (104). 
The defective IL-2 production in RA might be due to excessive polyamine 
production (105) which is inhibited by MTX (106). This effect could explain the 
enhanced IL-2 production observed during MTX therapy (107). In contrast with 
this up-regulation of IL-2, treatment with MTX reduces the circulating sIL-2R 
levels in patients with RA (84,98,99,108) and juvenile chronic arthritis (109). 
This effect does not predict response to treatment (108) but rather reflects clinical 
improvement (98). 
Recent studies suggest that MTX may not only upregulate Thl-cytokines, like 
IL-2, but also may downregulate Th2-derived cytokines. Taylor et al. observed 
an increased mRNA expression of IL-4 and IL-10 in mononuclear cells from RA 
patients compared to healthy controls. Treatment with MTX reduced IL-4 and 
IL-10 but enhanced IFNy expression in patients with RA (110). Consistent with 
these effects, Kremer et al. reported decreases in serum IL-4 during MTX 
therapy (96) and increases in circulating IL-4 levels associated with disease flares 
after stopping treatment (102). The effects of MTX on IL-2, IL-4 and IL-10 are 
puzzling, since they suggest a shift in cytokine expression towards a "proinflam­
matory" pattern. 
Azathioprine 
The purine analogue azathioprine (AZA) is converted in 6-mercaptopurine (6-
MP) which follows pathways similar to endogenous purines is incorporated in 
DNA and RNA. The cytotoxicity of AZA is unlikely to account for its therapeu­
tic efficacy in RA, but the levels of endogenous purine enzymes responsible for 
its metabolism may influence its toxicity (111). 
In-vitro studies suggest that AZA does not alter the production of IL-2 (112,113), 
whereas both AZA and 6-MP inhibit IL-6 bioactivity (78). Studies concerning the 
effect of therapy with AZA on cytokines in patients with RA are scant. 
In a 48-week trial of AZA versus MTX, we observed no significant changes in 
the circulating concentrations of either TNFa or the soluble TNF and IL-2 
receptors during treatment with AZA. Decreases in IL-6 concentrations reflected 
clinical improvement and were not specific to the drug (98). In a smaller study, 
Crilly et al. reported no changes in either circulating sIL-2R levels or in the 
production of IL-6 by monocytes after 24 weeks of therapy with AZA (114). 
Cyclosporin A 
Cyclosporin (CsA) is an immunosuppressive agent which specifically interferes 
with Τ cell activation. Complexes of CsA with its specific receptor, cyclophilin, 
bind to and block the activity of calcineurin, preventing the activation of trans­
cription factors involved in cytokine gene expression (115). The major effect of 
CsA is the suppression of Τ cell activation which is due to inhibition of the trans­
cription and synthesis of IL-2 and the expression of receptors for IL-2 in lympho­
cytes (115,116). This results in secondary inhibition of В lymphocytes, natural 
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killer (NK) cells and macrophage activities. Besides its effect on IL-2, CsA 
inhibits the transcription of IL-3, IL-4, IL-5, IFN7, (116) and TNFa (117) in Τ 
cells. The synthesis of IL-1 by monocytes is not affected by CsA (23), although 
the drug may antagonize some of this cytokines's effects in bone and cartilage 
(116). Under certain conditions, CsA decreases monocyte TNFa production 
(116,118). Decreases in the number of circulating cells bearing the IL-2R (119) 
and in circulating SÍL-2R and IL-6 concentrations (120,121) have been reported 
in RA patients treated with CsA. Decreases in sIL-2R levels associated with 
clinical improvement have also been observed during CsA therapy for Crohn's 
disease (122) but not in systemic sclerosis (123). 
Corticosteroids 
Glucocorticoids (GCs) affect virtually every cellular and humoral mechanism 
involved in inflammation and immune respoase, including cytokines. The mecha-
nism of action of GCs is complex but involves regulation of gene transcription. 
GCs form complexes with specific cytoplasmic receptors, which are translocated 
to the cell nucleus. Interestingly, mononuclear cells from patients with RA exhibit 
a low GC receptor density although this does not result in GC resistance (124). 
The binding of GC-receptor complexes to regulatory elements of DNA results in 
either positive or negative regulation of gene transcription. GCs interfere with 
cytokine production not only by suppressing their transcription, but also by 
decreasing MRNA stability and affecting other posttranscriptional events (125-
128). This results in inhibition of the synthesis of proinflammatory and chemotac-
tic cytokines such as IL-1, TNFa, IL-6, IL-8 and monocyte chemotactic and 
activating factor (MCAF) and hemopoietic growth factors such as IL-3 and GM-
CSF (20,38,128-132). In addition, GCs interfere with Τ cell activation by down-
regulating the gene expression of IL-2 and IL-2R, inhibit the production of IL-4 
and IFNy by lymphocytes (133,134), and induce IL-1 and IL-6 receptor 
expression in some cells (135-137). In vitro experiments have shown that the 
combination of Gcs with IL-4 suppresses the synthesis of IL-1 and TNFa by 
monocytes (138) and synovial tissue (139) synergistically and this could find 
applications in future therapies. 
Several studies have provided evidence for a modulatory role of GC therapy on 
cytokine production or release in vivo. In humans, therapy with GCs attenuates 
the toxicity induced by IL-2 and lymphokine activated killer cells, OKT3, and 
experimental endotoxinemia by reducing the release of TNFa, IFNY and IL-2 in 
the circulation (140-142). These drugs inhibit IL-4 and IL-5 expression by 
bronchoalveolar cells (143) and monocyte TNF production (144) in asthmatic 
patients and reduce circulating IL-6 levels in patients with polymyalgia 
rheumatica and giant cell arteritis (145). 
In patients with RA, circulating levels of IL-6, IL-8 and sIL-2R (146) and the 
production of IL-1 by monocytes (147) decrease significantly after pulse therapy 
with high-dose corticosteroids, and reductions in sIL-2R (148) and TNFa (149) 
levels are associated with improvement during treatment with low-dose GCs. 
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Other drugs 
The number of pharmacological agents with potential antirheumatic and cytokine 
modulating activities is too long to be fully enumerated. Several drugs used for 
other indications were discovered, by chance, to have antiarthritic effects. 
Among these agents, thalidomide, a sedative, and pentoxifylline, a phospho­
diesterase inhibitor used for peripheral vascular disorders, are worthy of mention 
because of their TNFa-suppressive activities. Thalidomide inhibits TNFa 
production, neutrophil Chemotaxis and superoxide generation, but its use in RA 
has been limited due to the drug's toxicity (150). Pentoxifylline (PTX) decreases 
TNFa production in vitro and in vivo (151) and has anti-inflammatory, immuno­
modulatory and anti-fibrotic properties. In an open, 3-month trial, performed in 
patients with severe RA refractory other therapies, additional treatment with PTX 
resulted in clinical improvement. TNF production remained unchanged after 3 
days of treatment but was, unfortunately, not measured thereafter (152). 
More selective cytokine inhibitors already used in clinical trials for RA include 
IX 207-887 and the dual cyclo-oxygenase/lipoxygenase inhibitor Tenidap. 
IX 207-887 inhibits IL-1, IL-6 and superoxide production and is effective in 
animal arthritis. A placebo-controlled study in RA, reported improvement in 
clinical and laboratory variables in patients treated with IX 207-887, though 
adverse reactions were frequent (153). Tenidap inhibits the synthesis of IL-1, 
IL-6 and TNFa by human monocytes and rheumatoid synovium (154-155) and 
decreases Τ cell proliferation and №Νγ synthesis (156). Furthermore, the drug 
inhibits metalloproteinase production by chondrocytes exposed to IL-1 (157), 
bone resorption induced by IL-1 and TNF (158), and die expression of HLA 
class II antigens in synoviocytes exposed to ΙΡΝγ (159). Patients with RA 
receiving tenidap show reductions in acute phase reaction and circulating IL-6 
and SIL-2R concentrations (160-161). 
Several immunoregulatory agents under current investigation for treating auto­
immune diseases may affect cytokine production. These encompass drugs with 
immune-enhancing effects such as levamisole, tilomisole and imuthiol, inhibitors 
of nucleotide synthesis for instance mycophenolate, brequinar and mizorbine and 
immunosuppressive agents as 15-deoxyspergualin, leflunomide, FK506 and 
rapamycin (162,163). Leflunomide, an isoxazol-derivative currently undergoing 
clinical trials for RA, inhibits lymphokine-dependent Τ and В cell proliferation 
and decreases IL-1 and TNFa induced proliferation of RA synovial fibroblasts 
(164). FK506 and rapamycin are cyclosporin-related drugs which share structural 
homology and the same immunophillin receptor but, interfere with Τ cell 
activation at a different level. Like cyclosporin, FK506 decreases the activity of 
calcineurin, is a potent suppressor of IL-2 production and receptor expression, 
and inhibits the transcription of cytokines as IL-3, IL-4, IL-5, IFNy, TNFa (118) 
and IL-8 (165), whereas rapamycin interferes with lymphokine signal 
transduction without affecting calcineurin activity. Both agents are effective in 
animal arthritis and are being evaluated in patients with autoimmune diseases and 
organ allografts. 
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Therapy with cytokines and anti-cytokines in RA 
Advances in molecular biology have provided new therapeutic approaches for 
autoimmune diseases. Among the immunomodulators, selected cytokines, like 
WNy, GM-CSF, and G-CSF have been used to treat RA or its complications and 
promising results are being obtained with specific antagonists of pro-inflamma­
tory cytokines. 
The rationale for the use of WNy therapy in RA was tenuous, being based on the 
relative deficiency of this cytokine in the joint and its inhibitory effects on В 
cells, neutrophils, fibroblasts and cytokine release. The lack of significant 
improvement observed in most studies for RA (14) is therefore not surprising. 
Considered the powerful immunostimulatory effects of IFNy, disease flares could 
be expected rather than improvement. Induction of antinuclear antibodies, and 
SLE in patients with RA (166-167), and disease exacerbations in patients with 
SLE may indeed occur during IFN7 therapy (168) and there is no clear indication 
for using IFNy in these disorders. In contrast, the improvement of skin fibrosis 
and pulmonary function observed in open trials with IFN7 for systemic sclerosis 
(169,170) suggest that IFNy may prove useful as antifibrotic therapy. 
The colony stimulating factors GM-CSF and G-CSF improve the granulo­
cytopenia associated with Felty's syndrome as well as that induced by anti­
rheumatic and cytostatic therapies but, since these agents may induce arthritis 
flares, their use should be restricted to treating or preventing infections associated 
with long-lasting neutropenia (171,172). 
To date, IL-1, TNF, IL-6 and IL-2 have been the target of specific anti-cytokine 
approaches in RA (Table 2). The experience with anti-IL-2 and anti-IL-6 treat­
ment is limited (171-178) and most attention has been drawn by therapies 
counteracting the two pivotal mediators TNFa and IL-1 (179-187). The initial 
results suggest that these anti-cytokine therapies are well tolerated and result in 
rapid improvement of clinical symptoms and laboratory parameters. Since these 
effects are transient, repeated administration is necessary. Besides the therapies 
listed in Table 2, other approaches including soluble IL-1 receptors, inhibitors of 
specific IL-1 convertases (16), anti-inflammatory cytokines such as IL-4, IL-10 
and IL-13, and the use of antisense oligonucleotides and gene therapy, are under 
investigation. 
Summary, conclusions and future prospects 
The search for evidence that antirheumatic drugs interfere with cytokines is 
hampered by several problems, not least among those being the difficulty in 
extrapolating experimental data obtained in-vitro to in-vivo conditions. Some 
SAARDs alter cytokine production or activity only at drag concentrations that are 
not attainable during therapy, and most in-vitro studies do not take on account the 
effect of drug metabolites or the complexity of the immune response in vivo. 
This can be exemplified by the bimodal effect of gold compounds on IL-1, IL-2 
and IL-8. While low concentrations of these agents seem to stimulate IL-1 and 
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IL-2 and inhibit IL-8 production, the converse occurs at higher drug concentra­
tions (19,20,31,52). Moreover, in the case of IL-2, either stimulation or strong 
inhibition can be attained with low concentrations of GST depending on the 
glutathione content of the cells studied (52). In-vitro results therefore, need to be 
confirmed by observations in vivo. Experience in animal models has taught us 
about the arthritogenic potential of cytokines and the effects of therapy with drugs 
and other anti-cytokine strategies, but the differences between human and animal 
arthritis emphasizes the necessity of human studies. Reports on the effects of 
SAARD therapy on cytokines in RA are relatively scarce and confront us again 
with several pitfalls involving methodological problems, interindividual variations 
in cytokine concentrations, and, most importantly, the need to quantify an 
increasing number of cytokines, preferably in the joint. Moreover, since 
SAARDs also modify disease activity in RA, changes in cytokine concentrations 
or expression during therapy with these agents may reflect clinical improvement 
rather than a specific effect of a given drug. 
Despite these problems, some conclusions on the cytokine-modulating effects of 
antirheumatic drugs can be drawn. First of all, it seems likely that many effects 
of antirheumatic agents on inflammation and immuneresponse are mediated by, or 
result in, cytokine modulation. Second, the effects of antirheumatic drugs, are 
mostly not confined to a single cytokine. Even cyclosporin, considered to 
downregulate IL-2 gene transcription most specifically, also inhibits the synthesis 
of other Τ cell-derived cytokines (116), whereas corticosteroids, have the most 
broad spectrum of activity and inhibit gene transcription of virtually every 
cytokine gene. Third, in contrast to the usually low levels of IL-1 and TNFa, 
high concentrations of IL-6, sIL-2R and sTNFR are present in the circulation and 
synovial fluid of RA patients, and correlate with several disease activity 
measures. Therapy with several SAARDs and corticosteroids decrease circulating 
IL-6 and sIL-2R concentrations and sTNFR levels apparently decrease with MTX 
given alone or in combination with SASP (84,94). These effects probably reflect 
clinical improvement and suggest that IL-6, sIL-2R and sTNFR may be useful 
markers of disease activity in RA. Fourth, preliminary evidence suggest that 
therapy with certain SAARDs may regulate cytokine production by circulating 
cells and, most importantly, cytokine expression in the joint, as has been recently 
demonstrated during gold therapy (46). 
The most important conclusion from previous studies might be that, at present, 
our knowledge of the effects of SAARD therapy on the cytokine network in RA 
is only patchy. Properly controlled, longitudinal studies assessing both cytokine 
concentrations in biological fluids and their expression in the joint during 
SAARD therapy are needed. 
A magic bullet for treating RA has yet to be found. Rheumatologists are familiar 
with combinations of NSAIDs, SAARDs and corticosteroids as well as with 
patients refractory to these treatments. This has resulted in a search for novel 
therapies, aimed at interfering with specific sites of immunoregulation, inflamma­
tion and tissue destruction. The targets envisaged include Τ cells, antigen presen­
tation, adhesion molecules, metalloproteinases, nitric oxide and cytokines. Trials 
with anti-cytokine therapies have reported rapid but transient clinical benefits in 
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RA and ongoing studies will show whether these effects can be maintained with 
repeated administration. 
There is a wide clinical experience with SAARD therapy for RA and it does not 
seem probable that novel therapies will supplant these agents in the near future, 
though combinations of cytokine-suppressive and traditional therapies offer 
interesting perspectives. The possibilities in this field are abundant but more 
knowledge on the effect of SAARDs on cytokines is needed before we arrive at 
selected combinations which complement each other's actions and translate this 
into better treatment for RA. 
Acknowledgement 
We are grateful to J.P. Donnelly, Ph.D. for his help in the preparation of this 
manuscript. 
27 
Chapter 2 
References 
1. Edmonds JP, Scott DL, Fürst DE, Brooks Ρ, Paulus HE. Antirheumatic drugs: A proposed 
new classification. Arthritis Rheum 36:336-339, 1993 
2. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor 
necrosis factor a in rheumatoid arthritis. Arthritis Rheum 38:151-160, 1995 
3. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of 
interleukin-l, tumor necrosis factor a, and interleukin-6 in cartilage proteoglycan metabo­
lism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced 
arthritis. Arthritis Rheum 38:164-172, 1995 
4. Dinarello CA. Interleukin-l and interleukin-l antagonism. Blood 77:1627-1652, 1991 
5. Collotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy' receptor: a novel 
regulatory pathway for interleukin 1. Immunology Today 15:562-566, 1994 
6. Cope AP, Maini RN. Soluble tumor necrosis factor receptors in arthritis. J Rheumatol 
22:382-384, 1995 
7. Koch AE, Kunkel SL, Slrieter RM. Cytokines in rheumatoid arthritis. J Invest Med 43:28-
38, 1995 
8. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti­
inflammatory cytokine: induction of circulating EL-1 receptor antagonist and soluble tumor 
necrosis factor receptor p55. Blood 83:113-118, 1994 
9. Firestein GS, Xu W, Townsend K, Broide D, Alvaro Gracia J, Glasebrook A, Zvaifler NJ. 
Cytokines in chronic inflammatory arthritis. I. Failure to detect Τ cell lymphokines 
(interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor 
(CSF-1) and a novel mast cell growth factor in rheumatoid arthritis. J Exp Med 168:1573-
1586, 1988 
10. Firestein GS, Zvaifler NJ. Peripheral blood and synovial fluid monocyte activation in 
inflammatory arthritis. Low levels of synovial fluid and synovial tissue interferon suggest 
that gamma interferon is not the primary macrophage activating factor. Arthritis Rheum 
30:864-871, 1987 
11. Simon AK, Seipelt E, Sieper J. Divergent T-ccll cytokine patterns in inflammatory 
arthritis. Proc Nail Acad Sci USA 91:8562-8566, 1995 
12. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on 
monocytes and В cells but not on Τ cells. Immunology Today 15:19-26, 1994 
13. Waldmann ТА. The IL-2/IL-2 receptor system: a target for rational immunointervention. 
Immunology Today 14:264-270, 1993 
14. Weinblatt ME. Biological agents in rheumatoid arthritis. J Rheumatol 19:84-88, 1992 
(suppl 32) 
15. Rubin LA, Nelson DL. The soluble inlerleukin-2 receptor: biology, function and clinical 
application. Ann Int Med 113:619-627, 1990 
16. Dinarello CA. Modalities for reducing interleukin 1 activity in disease. Immunology Today 
14:260-264, 1993 
17. Amer EC, Darnell LR, Pratta MA, Newton RC, Ackerman NR, Galbraith W. Effect of 
antiinflammatory drugs on human interleukin-l induced cartilage degradation. Agents 
Actions 21:334-336, 1987 
18. Sperber К, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of 
cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL·!-a) and 
IL-6 in human monocytes and Τ cells. J Rheumatol 20:803-808, 1993 
19. Danis VA, Franic GM, Brooks PM. The effect of slow-acting anti-rheumatic drugs 
(SAARDs) and combination of SAARDs on monokine production in vitro. Drugs Exp Clin 
Res 17:549-554, 1991 
20. Deleuran B, Kristensen M, Paludan K, Zachariae C, Larsen CG, Zachariae E, Thestrup-
Pedersen K. The effect of second-line antirheumatic drugs on interleukin-8 mRNA 
synthesis and protein secretion in human endothelial cells. Cytokine 4:403-409, 1992 
28 
Antirheumatic agents and cytokines 
21. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial 
therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 
2:13-15, 1993 (suppl 1) 
22. Wallace DJ, Linker-Israeli M, Ilyun S, Klinenberg JR, Stecher V. The effect of hydroxy­
chloroquine therapy on serum levels of immunoregulatory molecules in patients with 
systemic lupus erythematosus (letter). J Rheumatol 21:375-376, 1994 
23. Rordorf Adam C, Lazdins J, Woods Cook K, Alteri E, Henn R, Geiger Τ, Feige U, 
Towbin Η, Erard F. An assay for the detection of interleukin-1 synthesis inhibitors: effects 
of antirheumatic drugs. Drugs Exp Clin Res 15: 355-62, 1989 
24. Picot S, Peyron F, Donadille A, Vuillez JP, Barbe G, Ambroise-Thomas P. Chloroquine-
induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of 
iron metabolism. Immunology 80:127-133, 1993 
25. Landewe RB, Miltenburg AM, Breedveld FC, Daha MR, Dijkmans BA. Cyclosporin and 
chloroquine synergislically inhibit the ¡nlerferon-gamma production by CD4 positive and 
CD8 positive synovial Τ cell clones derived from a patient with rheumatoid arthritis. J 
Rheumatol 19:1353-1357, 1992 
26. Connolly KM, Stecher VJ, Danis E, Prüden DJ, UBrie T. Alteration of interleukin-1 
activity and the acute phase response in adjuvant arthritic rats treated with disease modify-
ing antirheumatic drugs. Agents Actions 25:94-105, 1988 
27. Ertel W, Morrison MH, Ayala A, Chaudry IH. Chloroquine attenuates hemorrhagic shock-
induced suppression of Kupffer cell antigen presentation and major histocompatibility 
complex class II expression through blockade of tumor necrosis factor and prostaglandin 
release. Blood 78:1781-1788, 1991 
28. Drakes ML, Harth M, Galsworthy SB, Mc Cain GA. Effects of gold on the production of 
and response to human interleukin-1. J Rheumatol 14:1123-1127, 1987 
29. Remvig L, Enk С, Bligaard N. Effect of auranofin and sodium aurothiomalate on interleu­
kin-1 production from human monocytes in vitro. Scand J Rheumatol 17:255-262, 1988 
30. Okamoto M, Sasano M, Goto M, Nishioka K, Aotsuka SI, Nakamura K, Yokohari R. 
Suppressive effect of anti-rheumatic drugs on interleukin-1 В release from human peripheral 
blood monocytes. Int J Immunopharmac 13:39-43, 1991 
31. Danis VA, Kulesz AJ, Nelson DS, Brooks PM. The effect of gold sodium thiomalate and 
auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in 
vitro: variation in healthy subjects and patients with arthritis. Clin Exp Immunol 79:335-
340, 1990 
32. Awad M, Corrigall VM, Dayer JM, Panayi GS. Effects of gold salts on monocytes 
maturation and their pattern of cytokine secretion. Br J Rheumatol 34:288, 1995 (suppl 1) 
33. Chang DM, Baptiste Ρ, Schur PH. The effect of antirheumatic drugs on interleukin 1 
(1L-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol. 
17:1148-57, 1990 
34. Williams DH, Jeffery LJ, Murray EJ. Aurothioglucose inhibits induced NF-kß and AP-1 
activity by acting as an IL-1 functional antagonist. Biochim Biophys Acta 1180:9-14, 1992 
35. Lee JC, Dimartino MJ, Votta BJ, Hanna N. Effect of auranofin treatment on aberrant 
splenic interleukin production in adjuvant arthritis rats. J Immunol 139:3268-3274, 1987 
36. Danis VA, Kulesz AJ, Kelly DE, Nelson DS, Brooks PM. The effect of gold treatment on 
monocyte interleukin-1 production in rheumatoid arthritis. A prospective study. Rheumatol 
Int 10:153-158, 1990 
37. Shingu M, Fujikawa Y, Wada T, Nonaka S, Nobunaga M. Increased IL-1 receptor 
antagonist (IL-Ira) production and decreased IL-lB/IL-lra ratio in mononuclear cells from 
rheumatoid arthritis patients. Br J Rheumatol 34:24-30, 1994 
38. I^oetscher P, Dewald B, Baggiolini M, Seitz M. Monocyte chemoattractant protein 1 and 
interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs. 
Cytokine 6:162-170, 1994 
29 
Chapter 2 
39 Seitz M, Dewald В, Ceska M, Gerber N. Baggiohni M Interleukin-8 in inflammatory 
rheumatic diseases synovial fluid levels, relation to rheumatoid factors, production by 
mononuclear cells, and effects of gold sodium thiomalale and methotrexate Rheumatol Int 
12 159-164, 1992 
40 Evans GF, Zuckerman SH Pharmacologic modulation of TNF production by endotoxin 
stimulated macrophages in vitro and in vivo effects of auranofin and other 
crysotherapeutic compounds Agents Actions 26 329-334, 1989 
41 Pichangkul S, Shick D, Jia FL, Berent S, Bollón A, Kahn A Binding of tumor necrosis 
factor alpha (TNF-alpha) to high affinity receptors on polymorphonuclear cells bxp 
Hematol 15 1055-1059, 1987 
42 Ritchex J Effect of auranofin on cytokine induced secretion of granule proteins from 
adherent human neutrophils in vitro Ann Rheum Dis 50 372-375, 1990 
43 Madhok R, Cnlly A, Murphy E, Smith J, Watson J, Capell HA Gold therapy lowers 
serum interleukin 6 levels in rheumatoid arthritis J Rheumatol 20 630-633, 1993 
44 Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G Serial estimation of interleukin 6 
as a measure of systemic disease in rheumatoid arthritis J Rheumatol 19 22-25, 1992 
45 Cnlly A, Madhok R, Watson J, Capell HA, Sturrock RD Production of interleukin-6 by 
monocytes isolated from rheumatoid arthritis patients receiving second line drug therapy 
Br J Rheumatol 33 821-825, 1994 
46 Yanni G, Nabíl M, Farahat MR, Poston RN, Panayi GS Intramuscular gold decreases 
cytokine expression and macrophage numbers in the rheumatoid synovial membrane Ann 
Rheum Dis 53 315-322, 1994 
47 Hamilton JA Rheumatoid arthritis opposing actions of haematopoietic growth factors and 
slow acting anti rheumatic drugs lancet 342 536 5339, 1993 
48 Hashimoto K, Whitehurst CE, Lipsky PE Synergistic inhibition of Τ cell proliferation by 
gold sodium thiomalate and auranofin J Rheumatol 21 1020-1026, 1994 
49 Sfikakis PP, Souhotis VL, Panayiotidis PP Suppression of mterlcukin-2 and interleukin-2 
receptor biosynthesis by gold compounds in in vitro activated human peripheral blood 
mononuclear cells Arthritis Rheum 36 208-212, 1993 
50 Harth M, Cousin K, McCain GA Sodium aurothiomalate inhibits Τ cell responses to 
interleukin-2 Immunopharmacol Immunotoxicol 10 141-156, 1988 
51 Wolf RE, Hall VC Inhibition of in vitro proliferation response of cultured Τ lymphocytes 
to interleukin-2 by gold sodium thiomalate Arthritis Rheum 31 176-181, 1988 
52 Vint AM, Chain BM, Foreman JC The interaction of auranofin and buthiomne 
sulfoximine blocks activation of human peripheral Τ lymphocytes Cell Immunol 152 152-
161, 1993 
53 Harth M, Cousin K, McCain GA In vitro effects of two gold compounds, and D penicilla­
mine on the production of interferon gamma Immunopharmacol Immunotoxicol 12 39-60, 
1990 
54 Moore NC, Gough A, Emery Ρ Co-treatment with gold enhances IFN production by 
stimulated PBMNC in vitro Br J Rheumatol 29 145, 1990 (suppl 2) 
55 Sanders KM, Carlson PL, Littmann BH Effects of gold sodium thiomalate on interferon 
stimulation of C2 synthesis and HLA DR expression by human monocytes Arthritis 
Rheum 30 1032-1039, 1987 
56 Kawakami A, bguchi K, Migita K, Nakao H, Otsubo T, Ueki Y, Shimomura C, Tezuka 
H, Matsunaga M, Ishimaru T, Nagataki S Inhibitory effects of gold sodium thiomalate on 
the proliferation and interferon-γ induced HLA-DR expression in human endothelial cells 
J Rheumatol 17 430-435, 1990 
57 Newman PN, To SST, Robinson BG, Hyland VJ, Schneber L Effect of gold sodium 
thiomalate and its thiomalate component on the in vitro expression of endothelial cell 
adhesion molecules Arthritis Rheum 37 S255, 1994 (suppl 9) 
58 Bhtstein-Willinger E Normalization of defective interleukin 1 and interleukin 2 production 
in patients with pemphigus vulgaris following chrysotherapy Clin Exp Immunol 62 705-
714, 1985 
30 
Antirheumatic agents and cytokines 
59. Kirkham BW, Davison SC, Cortili MM, Barbatis C, Panayi GS. Serial soluble interleukin 
2 receptor levels in rheumatoid arthritis: differences in response to glucocorticoid treatment 
and chrysotherapy. J Rheumatol 20:935-939, 1993 
60. Sheldon A, Ahem MJ, Smith MD, Zola H, Roberts-Thompson PJ. Response of soluble IL-
2 receptor levels during gold therapy for rheumatoid arthritis. Clin Exp Rheumatol 12:175-
178, 1994 
61. Crilly A, Madhok R, Watson J, Capell HA. Serum concentrations of soluble interleukin 2 
receptor in patients with rheumatoid arthritis: effect of second line drugs. Ann Rheum Dis 
52:58-60, 1993 
62. Hirohala S, Lipsky PE. Comparative inhibitory effects of bucillamine and D-penicillamine 
on the function of human В cells and Τ cells. Arthritis Rheum 37:942-950, 1994 
63. Petersen J. Inhibition of Τ cell-dependent antibody production by D-penicillamine. 
Different requirements for Cu2+ in suppression of polyclonal and antigen-specific В cell 
responses. Allergy 42: 37-45, 1987 
64. Brisset M, Pujol JP, Arcnzana Seisdedos F, Virelizier JL, Pcnfornis H, Farjanel J, Rattner 
A, Bocquet J, Beliard R, Loyau G. D-penicillamine inhibition of interleukin-1 production: 
a possible mechanism for its effect on synovial collagen synthesis?. Int J Tissue React 8: 
279-87, 1986 
65. Martinez F, Coleman JW. The effects of selected drugs, including chlorpromazine and 
non-steroidal anti-inflammatory agents, on polyclonal IgG synthesis and interleukin 1 
production by human peripheral blood mononuclear cells in vitro. Clin Exp Immunol 76: 
252-7, 1989 
66. DiMartino MJ, Johnson WJ, Votta B, Hanna N. Effect of antiarthrilic drugs on the 
enhanced interleukin-1 (IL-1) production by macrophages from adjuvant-induced arthritic 
(ЛА) rats. Agents Actions 21: 348-50, 1987 
67. Teodorescu M, McAfee M, Skosey JL, Wallman J, Shaw A, Hanly WC. Covalent 
disulfide binding of human IL-1 beta to alpha 2-macroglobulin: inhibition by D-penicillami­
ne. Mol Immunol. 28:323-31,1991 
68. Lyle WH. Penicillamine. Clin Rheum Dis 5:569-601, 1979 
69. Matsubara T, Hirohala K. Suppression of human fibroblast proliferation by D-penicilla­
mine and copper sulfate in vitro. Arthritis Rheum 31: 964-72, 1988 
70. Matsubara T, Saura R, Hirohata K, Ziff M. Inhibition of human endothelial cell proliferati­
on in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest 83:158-167, 
1989 
71. Kashiwazaki S, Shiokawa Y. Bucillamine: a new immunomodulator. Int J Immunother 3:1-
6, 1987 
72. Hirohata S, Lipsky PE. Regulation of В cell function by bucillamine, a novel disease 
modifying antirheumatic drug. Clin Immunol Immunopathol 66:43-51, 1993 
73. Remvig L, Andersen B. Salicylazosulfapyridine (Salazopyrin) effect on endotoxin-induced 
production of interleukin-1-like factor from human monocytes in-vitro. Scand J Rheumatol 
19:11-16, 1990 
74. Gronberg A, Isaksson P, Smcdcgárd G. Inhibitory effect of sulfasalazine on production of 
IL-lß, IL-6 and TNFa. Arthritis Rheum 37:S383, 1994 (suppl 9) 
75. Malfait AM, Verbruggen G, Almqvist KF, Broddelez C, Veys EM. Cytokine-cascade (IL-
1, TNF-alpha, IL-6) in the co-culture of mononuclear cells and articular chondrocytes. 
Influence of sulphasalazine. Clin Rheumatol 12:41, 1993 
76. Shanahan F, Niederlehner A, Carramanza N, Anton P. Sulfasalazine inhibits the binding of 
TNFa to its receptor. Immunopharmacoiogy 20:217-224, 1990 
77. Danis VA, Franic GM, Rathjen DA, Laurent RM, Brooks PM. Circulating cytokine levels 
in patients with rheumatoid arthritis: results of a double blind trial with sulfasalazine. Ann 
Rheum Dis 51:946-950, 1992 
78. Barrera Ρ, Boerbooms AMTh, Sauerwein RW, Demacker PNM, van de Putte LBA, van 
der Meer JWM. Interference of circulating azalhioprine but not methotrexate or 
sulfasalazine with measurements of interleukin-6 bioactivily. Lymphokine Cytokine Res 
13:155-159, 1994 
31 
Chapter 2 
79. Fujiwara M, Mitsui К, Ishida J, Yamamoto I. The effect of salazosulfapyridine on the in 
vitro antibody production in murine spleen cells. Immunopharmacology 19:15-21, 1990 
80. Carlin G, Nymar AK, Grönberg Α. Effects of sulfasalazine on cytokine production by 
mitogen-slimulated human T-cells. Arthritis Rheum 37:S383, 1994 (suppl 9) 
81. Luqmani R, Sheeran T, Robinson M, Richardson K, Winkles J, Emery P. Systemic 
cytokine measurements: their role in monitoring the response to therapy in patients with 
rheumatoid arthritis. Clin Exp Rheumatol 12:503-508, 1994 
82. Watson J, Crilly A, Madhok R, Capell H, Sturrock R. IL-6 and soluble IL-2 receptor in 
rheumatoid arthritis patients treated with second line drugs. Biochem Soc Trans 20:138S, 
1992 
83. Haagsma Ci, van Riel PLCM, de Rooij DJRAM, Vree TB, Rüssel FJM, van't Hof MA, 
van de Putte LBA. Combination of methotrexate and sulfasalazine vs methotrexate alone: A 
randomized open clinical trial in rheumatoid arthritis patients resistant to sulfasalazine 
therapy. Br J Rheumatol 33:1049-1055, 1994 
84. Barrera Ρ, Haagsma CJ, Boerbooms AMTh, van Riel PLCM, Borm GS, van de Putte 
LBA, van der Meer JWM. Effect of methotrexate alone or in combination with 
sulfasalazine on the production and circulating concentrations of cytokines and their 
antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 
(in press) 
85. Segal R, Yaron M, Tartakowski B. Methotrexate: mechanism of action in rheumatoid 
arthritis. Semin Arthritis Rheum 3:190-199, 1990 
86. Segal R, Mozes E, Yaron M, Tartakowski B. The effects of methotrexate on the 
production and activity of interleukin-1. Arthritis Rheum 32:370-377, 1989 
87. Segal R, Yaron M, Tartakowski B. Rescue of interleukin-1 activity by leucovorin 
following inhibition by methotrexate in a murine in vitro system. Arthritis Rheum 33:1745-
1749, 1990 
88. Meyer FA, Yaron I, Mashiah V, Yaron M. Methotrexate inhibits proliferation but not 
interleukin-1 stimulated secretory activities of cultured human synovial fibroblasts. J 
Rheumatol 20:238-242, 1993 
89. Firestein GS, Paine MM, Boyle DL. Mechanisms of methotrexate action in rheumatoid 
arthritis. Selective decrease in collagenase gene expression. Arthritis Rheum 37:193-200, 
1994 
90. Miller LC, Cohen ЕЕ, Orencole SF, Schaller JG, Savage N, Dinarello CA. Interleukin-lß 
(ТЫ β) is structurally related to dihydrofolatc reductase: effects of methotrexate (MTX) on 
ILI. Cytokine Res 7:1.49, 1988 
91. Johnson WJ, DiMartino MJ, Meunier PC, Muirhead KA, Hanna N. Methotrexate inhibits 
macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant 
induced arthritis. J Rheumatol 15:745-749, 1988 
92. Hu SK, Mitcho YL, Oronsky AL, Kerwar SS. Studies on the effect of methotrexate on 
macrophage function. J Rheumatol 15:206-209, 1988 
93. Kerwar SS, Oronsky L. Methotrexate in rheumatoid arthritis: studies with animal models. 
Adv Enzyme Regul 29:247-265, 1989 
94. Barrera Ρ, Boerbooms AMTh, Demacker PNM, van de Putte LBA, Gallati Η, van der 
Meer JWM. Circulating concentrations and production of cytokines and soluble receptors 
in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol 
33:1017-1024. 1994 
95. Chang DM, Weinblatt ME, Schur PH. The effects of methotrexate on interleukin-1 in 
patients with rheumatoid arthritis. J Rheumatol 19:1678-1682, 1992 
96. Kremer JM, Petrillo GF, Lawrence DA. Methotrexate (MTX) induces significant changes 
in IX-1, IL-2, IL-6 and IL-8 but not lymphocyte markers in patients with rheumatoid 
arthritis (RA). Arthritis Rheum 36:S77, 1993 
97. Thomas R, Carroll GJ. Reduction of leukocyte and interleukin-1 В concentrations in the 
synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 
36:9:1244-1252, 1993 
32 
Antirheumatic agents and cytokines 
98 Barrera Ρ, Boerbooms AMTh, Janssen EM, Sauerwein RW, Gallati Η, Mulder J, de Boo 
Τ, Demacker PNM, van de Putte LBA, van der Meer JWM Circulating soluble tumor 
necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor a, and interleukin 6 
levels in rheumatoid arthritis Longitudinal evaluation during methotrexate and azalhiopnne 
therapy Arthritis Rheum 36 1070-1079, 1993 
99 Cnlly A, Mclnness, McDonald AG, Watson J, Capell HA, Madhok R Intcrleukin-6 (IL-6) 
and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose 
oral methotrexate J Rheumatol 22 224-226, 1995 
100 Nakarai T, Ueno Y, Ueno Y, Koizumi Paradoxical enhancement of interleukin-2 mediated 
cytotoxicity against K562 cells by addition of a low dose of methotrexate Cancer Immunol 
Immunother 32 8-12, 1990 
101 Miller LC, Dempsey RD, Schaller JG. Dinarcllo CA Methotrexate (MTX) increases 
production of interleukin 2 (IL-2) Lymphokine Res 7 7 35, 1988 
102 Aaron SL Augmentation of IL 2 secretion by methotrexate therapy of rheumatoid arthritis 
Arthritis Rheum 32 S50, 1989 
103 Couret M, Combe B, Reme Τ, Sany J Production d'interleukine 2 et d'interferon-gamma 
dans la polyarthrite rhumatoide au cours d'une etude longitudinale chez des patients traites 
par methotrexate Revue Rhumatisme 57 641-645, 1990 
104 Kremer JM, Lawrence DA, Pelnllo GF, Litts LL, Mullaly PM Immune effects of 
stopping and restarting methotrexate (MTX) in patients with rheumatoid arthritis Arthritis 
Rheum 37 S252, 1994 (suppl 9) 
105 Flescher E, Bowhn TL, Ballester A, Houk R, Talal N Increased polyamines may down-
regulate interleukin 2 production in rheumatoid arthritis J Clin Invest 83 1356-1362, 1989 
106 Nesher G, Osborn T, Moore TL Lymphocyte polyamine depletion in rheumatoid arthritis 
patients treated with methotrexate Arthritis Rheum 37 S254, 1994 (suppl 9) 
107 Kremer JM The mechanism of action of methotrexate in rheumatoid arthritis The search 
continues J Rheumatol 21 1-5, 1994 
108 Polisson RP, Dooley MA, Dawson DV, Pisetsky DS Inlerleukin-2 receptor levels in the 
sera of rheumatoid arthritis patients treated with methotrexate Arthritis Rheum 37 50 56, 
1994 
109 Rose CD, Fawcett PT, Gibney K, Doughty RA, Singscn BH Serial measurements of 
soluble interleukin 2 receptor levels (sIL-2R) in children with juvenile rheumatoid arthritis 
treated with oral methotrexate Ann Rheum Dis 53 471-474, 1994 
110 Taylor R, Xie C, Beckenbaugh R, Goronzy J, Weyand С Disease specific lymphokine 
pattern in rheumatoid arthritis Selective modulation by methotrexate Arthritis Rheum 
37 S277, 1994 (suppl 9) 
111 Kerstens PJSM, Stolk JN, Boerbooms AMT, de Abreu RA, van de Putte LBA Purine 
enzymes in rheumatoid arthritis A clue to prediction of the response to azathiopnne7 
Review and hypothesis Clin Exp Rheumatol 13 107-111, 1995 
112 Dupont F, Schandene L, Denys C, Wybran J Differential in vitro actions of cyclosporin, 
methylpredmsolone, and 6-mercaptopunne implications for drugs' influence on 
lymphocyte activation mechanisms Clin Immunol Immunopalhol 40 422-428, 1986 
113 Szawlowski PW, Maddocks JL Effect of interleukin-2 on the inhibition of the human 
mixed lymphocyte reaction (MLR) by azathiopnnc Br J Clin Pharmacol 20 107-110, 1985 
114 Cnlly A, Mclnnes IB, Capell HA, Madhok R The effect of azalhiopnne on serum levels 
of interleukin 6 and soluble interleukin 2 receptor Scand J Rheumatol 23 87-91, 1994 
115 Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, Curran Τ, Rao 
A The T-cell transcription factor NFATp is a substrate for calcineunn and interacts with 
Fos and Jun Nature 365 352-355, 1993 
116 Russell RGG, Graveley R, Coxon F, Skjodt H, del Pozo E, Elford Ρ, Mackenzie A 
Cyclosporin A Mode of action and effects on bone and joint tissues Scand J Rheumatol 
21 9-18, 1992 (suppl 95) 
117 Goldfeld AE, Tsai E, Kmcaid R, Belshaw PJ, Schneber SL, Strominger JL, Rao A 
Calcineunn mediates human tumor necrosis factor alpha gene induction in stimulated Τ and 
В cells J Exp Med 180 763-768, 1994 
33 
Chapter 2 
118. Andersson J, Nagy S, Groth CG, Andersson U. Effects of FK506 and cyclosporin A on 
cytokine production studied in vitro at a single cell level. Immunology 75:136-142, 1992 
119. Yocum DE, Wilder RL, Dougherty S, Klippel JH, Pillemer S, Wahl S. Immunologic 
parameters of response in patients with rheumatoid arthritis treated with cyclosporin A. 
Arthritis Rheum 33:1310-1316, 1990 
120. Crilly A, Kolta S, Dougados M, Sturrock RD, Amor B, Capell HA, Madhok R. Effect of 
cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheuma­
toid arthritis. Ann Rheum Dis 54:137-139, 1995 
121. Falkenbach A, Wigand R, Unkelbach U, Jorgens К, Martinovic A, Scheuermann EH, 
Seiffert UB, Kaltwasser JP. Cyclosporin treatment in rheumatoid arthritis is associated with 
an increased serum activity of beta-glucuronidasc. Scand J Rheumatol 22:83-85, 1993 
122. Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in 
serum of patients with Crohn's disease. Effect of cyclosporin. Gut 31:795-799, 1990 
123. Clements PJ, Lanchenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, Paulus 
HE. Cyclosporin in systemic sclerosis. Results of a forty-eight-week open safety study in 
ten patients. Arthritis Rheum 36:75-83, 1993 
124. Schlagheke R, Beusner D, Kornely E, Specker С Effects of glucocorticoids in rheumatoid 
arthritis. Diminished glucocorticoid receptors do not result in glucocorticoid resistance. 
Arthritis Rheum 37:1127-1131, 1994 
125. Lee SW, Tsou AP, Chan H, Thomas J, Pelrie K, Eugui E, Allison AC. Glucocorticoids 
selectively inhibit the transcription of the interleukin IB gene and decrease the stability of 
interleukin IB mRNA. Proc Natl Acad Sci U S A 85:1204-1208, 1988 
126. Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of interleu-
kin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability. 
Mol Pharmacol 43:176-182, 1993 
127. Shaw G, Kamen R. A conserved sequence from the 3' untranslated region of GM-CSF 
mRNA mediates selective mRNA degradation. Cell 46:659-667, 1988 
128. Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC. Dexamethasone inhibition of 
interleukin 1 beta production by human monocytes. Postlranscriplional mechanisms. J Clin 
Invest 81:237-244, 1988 
129. Lee W, Oppenheim JJ, Matsushima K. Analysis of the suppression of IL-la and IL-16 
production on human peripheral mononuclear adherent cells by a glucocorticoid hormone. 
J Immunol 140:3034-3039, 1988 
130. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor 
necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232:977-980, 1986 
131. Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL6 from 
monocytes, endothelial cells and fibroblasts. Eur J Immunol 20:2439-2443, 1990 
132. Mukaida N, Zachariae CCO, Gusella GL, Matsushima K. Dexamethasone inhibits the 
induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis 
factor. J Immunol 146:1212-1215, 1991 
133. Reed SC, Abide AH, Alpers JD, Hoover RG, Robb RJ, Nowell PC. Effect of cyclosporin 
and dexamethasone on interleukin-2 receptor gene expression. J Immunol 137:150-154, 
1986 
134. Chikanza LC, Panayi GS. The effects of hydrocortisone on in vitro lymphocyte 
proliferation in corticosteroid sensitive and resistant subjects. Eur J Clin Invest 23:845-850, 
1993 
135. Akahoshi T, Oppenheim JJ, Matsushima K. Induction of high-affinity interleukin 1 
receptor on human peripheral blood lymphocytes by glucocorticoid hormones. J Exp Med 
167:924-936, 1988 
136. Butler JB, Huang X, Planck SR, Carter DB, Rosebaum JT. Discordant regulation of 
mRNA for IL-IB and its receptor by IL-la and dexamethasone in cultured synoviocytes. 
Arthritis Rheum 34:SI42, 1991 (suppl 9) 
137. Snyers L, Wit LD, Content J. Glucocorticoid upregulation of high affinity interleukin-6 
receptors on human epithelial cells. Proc Natl Acad Sci USA 87:2838-2842, 1990 
34 
Antirheumatic agents and cytokines 
138 Hart PH, Whitty GA, Burgess DR, Croatto M, Hamilton JA Augmentation of glucocorti­
coid action on human monocytes by interleukin-4 Lymph Res 9 147-153, 1990 
139 Bendrups A, Hilton A, Meager A, Hamilton JA Reduction of tumor necrosis factor α and 
interleukin-Iß levels in human synovial tissue by interleukin 4 and glucocorticoid Rheuma-
tol Int 12 217-220, 1993 
140 Vetto J Γ, Papa MZ, Lotze MT, Chang AC, Rosenberg SA Reduction of interleukin-2 and 
lymphokine-activated killer cells in humans by the administration of corticosteroids J Clin 
Oncol 5 496-503, 1987 
141 Chatenoud L, Legendre C, Ferran C, Bach JI\ Kreis II Corticosteroid inhibition of the 
ОКТЗ-induced cytokine-related syndrome Dosage and kinetics prerequisites Transplanted 
on 51 334-338, 1991 
142 Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y, Moldawer LL, 
Lowry ST Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in 
man J Immunol 150 1992-2006, 1993 
143 Robinson D, Hamid Q, Ying S, Bentley A, Assoufi B, Durham S, Kay AB Prednisolone 
treatment in asthma is associated with modulation of bronchoalveolar lavage cell ìnterleu-
kin-4, interleukin 5 and interferon-gamma cytokine gene expression Am Rev Respir Dis 
148 401-406, 1993 
144 Vecchiarelh A, Siracusa A, Cenci E, Puliti M, Abbrutì G Effect of corticosteroid 
treatment on interleukin-1 and tumor necrosis factor secretion by monocytes from subjects 
with asthma Clin Exp Allergy 22 365-370, 1992 
145 Roche NE, Tulbnght JW, Wagner AD, Hunder GG, Goron/y JJ, Weyand CM 
Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and 
giant cell arteritis Arthritis Rheum 36 1286-1294, 1993 
146 Van den Brink HR, van Wijk MJ, Geertzen RG, Bijlsma JW Influence of corticosteroid 
pulse therapy on the scrum levels of soluble interleukin 2 receptor, interleukin 6 and 
interleukin 8 in patients with rheumatoid arthritis J Rheumatol 21 430-434, 1994 
147 Moachon L, Weill BJ, Chereau C, Deslandre С, Renoux ML, Giroud JP, Menkes CJ 
Pulse methylprednisolone therapy reduces monocyte IL-1 production ex vivo (letter) J 
Rheumatol 16 1515-1516, 1989 
148 Wood NC, Symons JA, Dutz GW Serum interleukin 2 receptor in rheumatoid arthritis a 
prognostic indicator of disease activity7 J Autoimmun 1 353-361, 1988 
149 Espersen GT, Vestegaard M, Emst E, Grunnet N Tumor necrosis factor alpha and 
interleukin-2 in plasma from rheumatoid arthritis patients in relation with disease activity 
Clin Rheumatol 10 374-376, 1991 
150 Gutierrez-Rodriguez O, Starusta-Bacal P, Gutiérrez-Montes О Treatment of refractory 
rheumatoid arthritis The thalidomide experience J Rheumatol 16 158-163, 1989 
151 Anaya JM, Espinoza LR Phosphodiesterase inhibitor pentoxifylline an antunflammatory/-
lmmunomodulatory drug potentially useful in some rheumatic diseases J Rheumatol 
22 595-599, 1995 
152 Maksymowych WP, Avina Zubieta A, Luong MH, Russell AS An open study of pentoxi­
fylline in the treatment of severe refractory rheumatoid arthritis J Rheumatol 22 625-629, 
1995 
153 Dougados M, Combe B, Beveridge Τ, Bourdeix I, Lallemand, Amor B, Sany J Di 
207,887 in rheumatoid arthritis A double-blind placebo-controlled study Arthritis Rheum 
35 999-1006, 1992 
154 Sipe JD, Barile LM, Loose LD Modification of proinflammatory cytokine production by 
the antirheumatic agents tenidap and naproxen a possible correlate with clinical acute 
phase response J Immunol 148 480-484, 1992 
155 Martel-Pelletier J, Ounissi H, Cloutier JM, Pelletier JP Tenidap effectively reduces 
cytokine synthesis and expression by human rheumatoid arthritis synovium Arthritis 
Rheum 37 S309, 1994 (suppl 9) 
156 Miltenburg AMM, Dolham RJEM, de Kuiper R, Verweij CL, Dijkmans ВАС, Breedveld 
FC Tenidap inhibits Τ cell proliferation, cytokine production and the induction of mRNA 
encoding TNFa and IFN gamma Arthritis Rheum 37 S384, 1994 (suppl 9) 
35 
Chapter 2 
157 Pelletier JP, McCollum R, DiBattista J, Loose LD, Cloutier JM, Martel-Pelletier J 
Regulation of human normal and osteoarthntic chondrocyte interleukin-1 receptor by 
antirheumatic drugs Arthritis Rheum 36 1517-1527, 1993 
158 Abdulkanm M, Al-Humidan M, Reilly KM, Leeming MRG, Russell RG Tenidap inhibits 
bone resorption induced by PTH, 1,25 Vit D3, IL-1, TNF and PGE¡ in vitro by 
mechanisms independent of inhibition of prostaglandin synthesis Arthritis Rheum 
34D171, 1991 (suppl 9) 
159 Lindsley HB, Smith DD, Cohick CB Suppression by temdap of IFN-gamma-induced 
expression of HLA class Π antigens on cultured human synoviocytes (HSC) and reduction 
of PBMNC adhesion to rheumatoid HSC in vitro J Immunol 150 140A, 1993 
160 Littman BH, Drury CE, Zimmerer RO, Stack CB, Law G Rheumatoid arthritis treated 
with tenidap and Piroxicam Clinical associations with cytokine modulation by tenidap 
Arthritis Rheum 38 29-37, 1995 
161 Leeming MRG A double-blind randomised comparison of tenidap versus auranofin plus 
diclofenac in early rheumatoid arthritis Arthritis Rheum 36 A84, 1993 (suppl 9) 
162 Yocum DE The use of immunomodulators in early rheumatoid arthritis Semin Arthritis 
Rheum 23 44-49, 1994 (suppl 2) 
163 Pincus T, Callahan LF New therapeutic approaches in autoimmune rheumatic diseases, 
with special emphasis on rheumatoid arthritis Br J Rheumatol 34 193-199, 1995 
164 Cheung NT, Taylor D, Dawes PT, Mattey D In vitro effect of leflunomide on RA 
synovial fibroblasts proliferation and production of the matrix metallo-proteinase pro-
MMP3 Br J Rheumatol 34 113, 1995 (suppl 1) 
165 Mukaida N, Okamoto S, Ishikawa Y, Matsushima К Molecular mechanisms of 
mterleukin-8 gene expression J Leukoc Biol 56 554-558, 1994 
166 Seitz M, Franke M, Kirchner H Induction of antinuclear antibodies in patients with 
rheumatoid arthritis receiving treatment with human recombinant interferon gamma Ann 
Rheum Dis 47 642-644, 1988 
167 Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielmski CC, Smolen JS Induction 
of systemic lupus erythematosus by interfcron-γ in a patient with rheumatoid arthritis J 
Rheumatol 18 1621 1622, 1991 
168 Machold KP, Smolen JS Interferon-γ induced exacerbation of systemic lupus erythemalo 
sus J Rheumatol 17 831-832, 1990 
169 Kahan A, Amor B, Menkes CJ, Strauch G Recombinant interferon in the treatment of 
systemic sclerosis Am J Med 87 273-277, 1989 
170 Hem R, Behr J, Hündgen M, Hunzclmann N, Meurer M, Braun Falco О, Urbanski A, 
Krieg Τ 'treatment of systemic sclerosis with γ-interferon Br J Dermatol 126 496-501, 
1992 
171 Vreugdenhil G, Schattenberg A, Dompehng EC, Swaak AJG, de Witte Τ Haemopoielic 
growth factors in rheumatoid arthritis a critical approach to their use in view of possible 
adverse effects Am J Med 94 229-230, 1993 
172 Yasuda M, Kihara T, Wada T, Shiokawa S, Furuta E, Suenagu Y, Nonaka S, Nobunaga 
M Granulocyte colony-stimulating factor induction of improved leukocytopema with 
inflammatory flare in a Felty's syndrome patient Arthritis Rheum 37 145-146, 1994 
173 Wijdenes J, Racadot E, Wendhng D Interleukm-6 antibodies in rheumatoid arthritis J 
Interferon Res 14 297-298, 1994 
174 Kyle V, Coughlan RJ, Tighe H, Waldmann H, Hazleman BL Beneficial effect of 
monoclonal antibody to interleukin-2 receptor on activated Τ cells in rheumatoid arthritis 
Ann Rheum Dis 48 428-429, 1989 
175 Sewell KL Parker КС, Woodworm TG, Reuben J, Swartz W, Trenlham DE DAB„,6IL-2 
fusion toxin in refractory rheumatoid arthritis Arthritis Rheum 36 1223-1233, 1993 
176 Moreland LW, Sewell L, Sullivan WF, Shmerhng RH, Parker КС, Swartz WG, 
Woodworth TG, Trentham DE, Koopman WJ Double-blind placebo-controlled phase Π 
tnal of diphtena-interleukin-2 fusion toxin (DAB4S6rL-2) in patients with refractory 
rheumatoid arthritis (RA) Arthritis Rheum 36 S39, 1993 
36 
Antirheumatic agents and cytokines 
177. Kremer JM, Petrillo GF, Rigby WFC, Plehn SJ, Woodworth TG, Parker КС, Taintor GS. 
Phase I/II, open-label trial of DABM,IL-2 administered to patients with active rheumatoid 
arthritis (RA) receiving treatment with methotrexate (MTX) (astraci). Arthritis Rheum 
37:S341, 1994 
178. Sewell KL, Moreland LW, Fürst DE, Meehan RT, Kremer JM, Rigby WFC, Parker КС, 
Lynch AM, Woodworth TG. Phase П, open-label trial of DABM9IL-2 administered up to 
four times a year to patients with active rheumatoid arthritis (RA). Arthritis Rheum 
37:S341, 1994(suppl9) 
179. Lebsack ME, Paul CC, Bloedow DC, Burch FX, Sack MA, Chase W, Catalano MA. 
Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis 
Rheum 34:S45, 1991 
180. Lebsack ME, Paul CC, Martindale JJ, Catalano MA. A dose and regimen -ranging study 
of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 36:S39, 
1993 
181. Drevlow B, Lovis R, Haag MA, Sinacore J, Jacobs C, Blosch C, Beck C, Landray A, 
Moreland L, Pope RM. Phase I study of recombinant interleukin-1-receptor (rhu IL-1R) 
administered subcutaneously in patients with active rheumatoid arthritis. Arthritis Rheum 
37:339, 1994 (suppl 9) 
182. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles Ρ, Katsikis Ρ, Brennan FM, 
Walker J, Bijl H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric 
monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 36:1681-1690, 1993 
183. Elliott MJ, Maim' RN, Feldmann M, Long-Fox A, Charles Ρ, Bijl H, Woody JN. Repeated 
therapy with monoclonal antibody to tumor necrosis factor a (cA2) in patients with 
rheumatoid arthritis. Lancet 344:1125-1127, 1994 
184. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni С, Smolen JS, Leeb В, Breedveld 
FC, Macfarlane JD, Bijl H, Woody JN. Randomised double-blind comparison of chimeric 
monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid 
arthritis. Lancet 344:1105-1110, 1994 
185. Elliott MJ, Woo P, Charles P, Long-Fox A, Woody JN, Maini RN. Treatment of systemic 
juvenile chronic arthritis (JCA) with monoclonal anti-TNFa. Temporary control of 
systemic but not articular features of disease. Arthritis Rheum 37:S276, 1994 (suppl 9) 
186. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi 
GS. The therapeutic effects of an engineered human anti-tumor necrosis factor alpha 
antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34:334-342, 1995 
187. Moreland LW. Margolies GR, Heck LW, Saway PA, Jacobs C, Beck C, Blosch C, 
Koopman WJ. Soluble tumor necrosis factor receptor (sTNFR): Results of a phase I dose-
escalation study in patients with rheumatoid arthritis. Arthritis Rheum 37:S295, 1994 
(suppl 9) 
37 

Chapter 3 
METHOTREXATE VERSUS AZATHIOPRINE 
TREATMENT FOR RHEUMATOID 
ARTHRITIS. EFFECTS ON CYTOKINES 
Barrera Ρ, Boerbooms AMTh, Janssen EM, Sauerwein RW, Gallati Η, Mulder J, de 
Boo Τ, Demacker PNM, van de Putte LBA, van der Meer JWM. Circulating soluble 
tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor a, and 
interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during 
methotrexate and azathioprine therapy. Arthritis Rheum 36:1070-1079, 1993 
Crilly A, Madhok R. The effects of methotrexate on soluble interleukin-2 receptor 
levels in rheumatoid arthritis: comment on the article by Barrera et al (letter). 
Arthritis Rheum 37:597-598, 1994 
Barrera Ρ, Boerbooms AMTh, van de Putte LBA, van der Meer JWM. Reply to 
letter. Arthritis Rheum 37:598-599, 1994 

Cytokine levels in RA patients taking MTX or AZA 
Abstract 
Objective. To assess whether circulating concentrations of soluble tumor necrosis 
factor receptors (STNFR; p55 and p75), soluble interleukin 2 receptors (SIL-2R), 
tumor necrosis factor a (TNFa), and interleukin 6 (IL-6) reflect clinical response and 
whether changes are dependent on the drug used in rheumatoid arthritis (RA) 
patients taking methotrexate (MTX) or azathioprine (AZA). 
Methods. These cytokines and soluble receptors were assessed in 20 controls and 
serially for up to 48 weeks in 61 patients using a bioassay (IL-6), and immunoassays 
(sTNFR, SIL-2R, TNFa and IL-6). 
Results. Concentrations ofp55andp75, SIL-2R and TNFa (but not IL-6) were signi-
ficantly higher in RA than in controls. Significant decreases in SIL-2R and p55 con-
centrations were associated with clinical improvement and were observed in the 
group of patients treated with MTX, but not AZA. Both treatments induced decreases 
in IL-6 concentrations but circulating AZA (or its metabolites) appears to interfere 
with the measurements ofIL-6bioactivity. TNFa andp75 levels did not show signifi-
cant changes. 
Conclusion. Measurements of circulating SIL-2R, p55, and IL-6 may be useful in the 
evaluation of RA disease activity and response to therapy. Interference of circulating 
drugs must be ruled out when bioassays are used to evaluate cytokine levels. 
Introduction 
Accumulating evidence indicates that a number of cytokines are crucial in the 
pathogenesis of rheumatoid synovitis and other autoimmune diseases. Cytokines such 
as interleukin-1 (IL-1), tumor necrosis factor a (TNFa) and IL-6 have been detected 
in rheumatoid synovium (1-8) and elevated concentrations have been found in 
synovial fluid (SF) and serum of rheumaqtoid arthritis (RA) patients (9-10). Soluble 
receptor forms of several cytokines have been described. The soluble IL-2 receptor 
(sIL-2R) is a truncated form of the IL-2 receptor a chain (11). Levels of sIL-2R are 
markedly elevated in autoimmune diseases and are considered to be an activation 
marker of the immune system (12). Two types of TNF cell receptors have been 
identified (p55 and p75); both can be shed from the cell surface yielding soluble 
fragments (13,14). These soluble receptor forms (sTNFR) function as TNF antago-
nists in vitro, al tough they may also prolong TNF activity by protecting it against 
degradation (15). 
In RA, concentrations of IL-6 (16-18), sIL-2R (19), and sTNFR (20) are higher in 
SF than in serum, suggesting that the inflamed joint is the main production site of 
these mediators. However, specimens for measurement in the circulation are easily 
obtained and more suitable for longitudinal studies. The effects of different disease-
modifying anti-rheumatic drags (DMARDs) on circulating cytokines and their 
soluble receptors may be helpful in understanding their mechanism of action. So far, 
these effects have been evaluated mostly in cross-sectional or open studies but 
comparative studies with different DMARDs are sparse. 
In a recent randomized double-blind trial conducted in our center, methotrexate 
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(MTX) proved to be superior to azathioprine (AZA) in the treatment of active RA 
(21,22). In the present study, circulating concentrations of sTNFR, sIL-2R, TNFa 
and IL-6 were serially r-easured in patients included in the trial conducted by 
Jeurissen et al (21). The aim was to assess whether these concentrations (a) reflected 
differences in clinical response, (b) correlated with each other and with clinical and 
laboratory parameters of disease activity, and (c) were differentially influenced by 
the drugs used. 
Patients and methods 
Patients 
The details of the study have been extensively described (21,22). Briefly, 64 patients 
with active definite or classical RA entered a 48-week, prospective, randomized, 
double-blind trial of MTX versus AZA. 
Active RA was defined by the presence of at least 3 of the following 4 criteria: ^6 
joints tender or painful on motion, > 3 swollen joints, erythrocyte sedimentation rate 
(ESR) > 28 mm/hour, and morning stiffness > 45 minutes in duration. Patients were 
randomly allocated to receive either MTX (initial dosage 7,5 mg weekly) or AZA 
(initial dosage 100 mg daily). Dosages of non-steroidal anti-inflammatory drugs 
(NSAIDs) and prednisone (<10 mg/day) were stable for at least 4 weeks before 
study entry. At study entry 8 patients taking AZA and 2 taking MTX had been on 
a stable regimen of low-dose prednisone (< 10 mg/day). During the study period, 
the mean corticosteroid dosage did not change in any patient, but the NSAJD dosage 
was increased in 3 patients (2 taking AZA and 1 taking MTX). Control sera were 
obtained from 20 healthy laboratory personnel working in our center. 
Cytokine assays 
Sera had been collected for subsequent analysis, along with concomitantly obtained 
data from clinical and laboratory evaluations, as a part of this trial conducted by 
Jeurissen et al (21). 
Sera were kept frozen at -20°C until assay. Cytokine levels were measured before 
treatment at various intervals up to 48 weeks of treatment. To minimize interassay 
variations, all samples from each patient were measured in a single assay. 
Levels of sIL-2R were measured using a "sandwich" enzyme-linked immunosorbent 
assay (ELISA) (Cellfree; Τ Cell Sciences, Cambridge, MA), according to the 
manufacturer's instructions. Results are expressed in units/ml relative to a set of 
standards provided with the test kit. The sensitivity of this assay is 50-100 units/ml. 
TNFa was assessed by radioimmunoassay (RIA) as we previously described (23). 
This RIA measures total TNFa (both free and complexed to its receptors), as 
demonstrated by the lack of interference of the addition of up to 5 ng/ml recombi­
nant sTNFR (p55 and p75) to sera containing known amounts of TNFa (Barrera Ρ 
et al: unpublished observations). The sensitivity of this RIA is between 10 and 100 
pg/ml (average 70 pg/ml). 
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IL-6 was measured by bioassay and ELISA. The IL-6 bioassay was performed as 
previously described (24). Briefly, 5000 B9 cells were seeded in Iscove's modified 
Dulbecco's medium containing 5% fetal calf serum, penicillin (100 IU/ml), strepto-
mycin (100 /ig/ml) and ß-mercaptoethanol (5 χ 10'5M) in 96-well, flat-bottom 
microtiter plates (Costar, Badhoevedorp, The Netherlands) in the presence of serum 
samples or recombinant IL-6 standard (kind gift of Dr. L.A. Aarden, CLB 
Amsterdam, The Netherlands). Cell proliferation was measured by thymidine incor­
poration after 64 hours (7.4 kBq 3H-thymidine/well). Samples were heat inactivated 
for 30 min at 56°C, and tested in 2-fold dilutions. Half-maximal thymidine 
incorporation was was defined as 1 unit/ml IL-6. The sensitivity of this assay is 0.3 
units/ml. 
The IL-6 ELISA (materials were a gift from Dr. J. Wijdenes, Innotherapy, 
Besançon, France), was performed as follows. Flat-bottom microtiter plates were 
coated for 24 hours at 4°C with anti-IL-6 monoclonal antibody, (Mab) BE8 (7 μg/ml 
in phosphate buffered saline [PBS], ΙΟΟμΙ/well). The plates were washed, and serial 
dilutions of recombinant IL-6 and samples were added (100 μΐ/well) and incubated 
for 1 hour at 37°C. Plates were washed and incubated for 1 hour at room tempe­
rature with a second biotinylated anti-IL-6 Mab, BE4 (2 μg/ml in PBS with 0.25% 
bovine serum albumin [BSA], 100 μΐ/well). After washing, horseradish peroxidase-
streptavidin was added (4 μg/ml in PBS with 0.25% BSA, 100 μΐ/well), and plates 
were incubated for 45 minutes at room temperature. Plates were washed and 
developed with a solution of 47% OPD in 14 mM citric acid and 36 mM trisodium 
citrate (pH 5.2, 100 μΐ/well; Merck). The reaction was stopped by addition of 2.5 
M H2S04 (50 μΐ/well). Plates were read at 492 nm in a Titertek Multiskan reader. 
The sensitivity of this ELISA is 20 units/ml. 
Soluble TNF receptors (p55 and p75) were measured by enzyme-linked binding 
assay (Hoffmann-La Roche, Basel, Switzerland). This assay measures total (both 
free and bound) receptor concentrations, since addition of up to 10 ng/ml 
recombinant TNFa to serum containing known amounts of sTNFR does not 
influence the assay. The sensitivity of this assay is 100 pg/ml. 
Definition of clinical improvement 
The clinical outcome was evaluated by means of an overall index. This index was 
based on the same parameters used to define active RA for study inclusion: 1) 
patient's assessment of pain, using a visual analogue scale (0 mm = no pain, 
100 mm = very severe pain), 2) Ritchie articular index, 3) ESR, and 4) duration 
of morning stiffness. Improvement was defined as > 30 % reduction in at least 2 of 
these 4 values and no worsening of the other variables. Stable disease was defined 
as 0-29 % reduction in die 4 variables. Worsening was defined as an increase in the 
4 values compared with baseline (21-22). To simplify, we compared patients with 
improvement versus those with lack of effect (stable disease or worsening). 
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Statistical analysis 
Unless otherwise specified data are expressed as the median and range. Since the 
variables studied were not normally distributed, distribution-free methods were 
applied. Comparison of sTNFR, sIL-2R, TNFa, and IL-6 concentrations during 
therapy with pre-treatment concentrations were made by Wilcoxon signed rank test 
for paired samples. To utilize all data gathered during the followup, comparison 
between both therapies (MTX versus AZA) and between patients with clinical 
improvement versus those with lack of effect was analyzed by a distribution-free test 
for curve analysis (25). Comparison of therapy groups included only patients who 
completed 24 and 48 weeks of treatment with the originally assigned drug. The 
analysis according to clinical response included all patients randomized into the 
study, irrespective of therapy. Correlations were evaluated using Spearman's rank 
correlation coefficient for each data point during the followup. 
Results 
Clinical results 
The clinical and radiographic findings in this study have been published elsewhere 
(21,22). Comparison between treatment groups showed significantly more 
improvement in the MTX group, both in clinical and laboratory measurements of 
disease activity. Patients treated with MTX showed a more rapid clinical improve-
ment and less radiographic progression than did those treated with AZA. Switching 
to another therapy due to adverse reactions or lack of effect on the initial DM ARD 
was more often necessary in the AZA group. Irrespective of the therapy, a total of 
44 and 46 patients experienced clinical improvement after 24 and 48 weeks, respec-
tively. The course of treatment and the clinical outcome are sumarized in Table 1. 
Table 1. Course of treatment and clinical outcome in patients treated with 
azathioprine or methotrexate* 
Time of study Azathioprine Methotrexate 
No. of patients enrolled 
Week 24 
Continued therapy 
No. (%) improved 
Switched therapy 
Reason 
Week 48 
Continued therapy 
No. (%) improved 
Switched therapy 
Reason 
33 
20 
12 (60) 
13 
Side effects 
12 
9(75) 
8 
No effect 
31 
30 
23 (76) 
1 
Noncompliance 
25 
21 (84) 
5 
Side effects/no effect 
* Improvement determined according to the overall index (see Patients and methods for details) 
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Pretreatment cytokine concentrations 
Data on 3 patients (2 taking MTX and 1 taking AZA), 2 of whom showed clinical 
improvement, were excluded from analysis because no pretreatment sera were 
available. Baseline concentrations of sIL-2R (P < 0.0001), TNFa (P < 0.02), and 
the soluble TNF receptors p55 (P = 0.0001) and p75 (P < 0.04) were significantly 
higher in the RA patients than in the control group. In contrast, IL-6 bioactivity in 
the patients did not differ significantly from that in the controls (Table 2). TNFa 
was undetectable in 8 patients (1 MTX; 7 AZA) and in 10 controls; p75 was 
undetectable in 13 patients (6 MTX; 7 AZA). Pretreatment cytokine concentrations 
were similar in both treatment groups and in patients who showed clinical improve­
ment or a lack of effect at the end of the study. 
Table 2. Concentrations of sTNFRs (p55 and p75), TNFa, sIL-2R, and bioactive 
IL-6 in RA patients at baseline and in healthy controls* 
Group (n) 
Patients (61) 
Median 
Range 
Controls (20) 
Median 
Range 
sTNFR 
p55 p75 
(pg/ml) (pg/ml) 
3000t 2970t 
1650-7900t 0-15700t 
1310 2380 
0-1970 1360-3480 
ΤΝΓα 
(pg/ml) 
130* 
0-ЗЗОф 
55 
0-260 
SIL-2R 
units/ml 
1380t 
365-19800t 
300 
0-730 
IL-6 
units/ml 
11.6 
0.8-74.7 
8.5 
7-13.5 
* sTNFR = soluble tumor necrosis factor receptor; sIL-2R 
t Ρ < 0.0005 versus controls. 
t Ρ < 0.05 versus controls. 
Cytokine concentrations during followup 
soluble interleukin-2 receptor. 
The differences between patients with and widiout clinical improvement were 
examined. Since analysis after 24 and 48 weeks of treatment yielded similar results, 
only the data after 24 weeks are presented. At that time, 42 patients showed clinical 
improvement and 19 showed a lack of response. Significant decreases in p55 
concentrations (P < 0.005) were observed only in the patients with clinical 
improvement; in contrast, p75 concentrations did not change significantly in either 
group (Figure 1). 
A steady decrease in sIL-2R concentrations (P < 0.05 from week 8 onward) 
occurred in the patients with clinical improvement, but (except for week 16) no 
significant change was observed in the patients wiüi lack of response to therapy 
(Figure 2). Although TNFa concentrations did not decrease in either group over the 
followup period, lower levels were observed in the patients with clinical response 
compared to those with a lack of effect (P < 0.02) (Figure 3). IL-6 bioactivity 
decreased already after 4 weeks both in patients who improved (P < 0.05) and even 
more markedly in those with a lack of effect (P < 0.005); the differences between 
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Figure 1. Concentrations of p55 and p75 soluble tumor necrosis factor receptors in the serum of 
RA patients with clinical improvement (A) and with lack of response (B) to therapy after 24 
weeks. Horizontal bars show the median. ** - significant change from baseline {P < 0.005); 
t - concentration above the range on the у axis. 
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Figure 2. Concentrations of soluble interleukin-2 receptors in the serum of RA patients with 
clinical improvement (A) and with lack of response (B) to therapy after 24 weeks. Horizontal bars 
show the median. * * - / ' < 0.005 and *** - Ρ < 0.0005 versus baseline. 
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these 2 groups, however, were not significant (Figure 4). 
When data were analysed according to the therapy, significant decreases in p55 
(P = 0.01 after 24 weeks) and sIL-2R (P < 0.005 from week 8 onward) 
concentrations were observed only in patients treated with MTX (Table 3). 
Furthermore, sIL-2R levels in the AZA group were significantly higher than those 
in the MTX group over the followup period (P = 0.02). Concentrations of bioactive 
IL-6 decreased in both treatment groups. However, in contrast with the results 
obtained for sIL-2R and p55, this decrease was more marked and occurred earlier 
in patients treated with AZA (Ρ < 0.0001 by week 4) than in those treated with 
MTX (Ρ < 0.05 after 16 weeks of treatment) (Figure 5). Over the followup period, 
IL-6 bioactivity was significantly lower in the AZA group than in the MTX group 
(P < 0.02). The concentrations of TNFa and p75 did not show significant changes 
in any of the groups. 
Measurement of IL-6 levels by ELISA 
In contrast to the superiority of AZA over MTX in decreasing IL-6 bioactivity, 
MTX seemed slightly more effective at decreasing immunoreactive IL-6 concentra­
tions: After 24 and 48 weeks, immunoreactive IL-6 levels decreased beyond the 
detection limit in 60 % and 55 % of the patients treated with MTX and in 47 % and 
50% of those treated with AZA, respectively (Figure 6). Subsequent experiments 
showed that serum from patients treated with AZA (but not MTX) exerted an in­
hibitory effect on the IL-6 bioassay. (Barrera Ρ et al: unpublished observations). 
Interrelationships between cytokines and soluble receptors and correlation with 
disease activity parameters 
In the entire group of 61 patients, a significant correlation between sIL-2R and p55 
(r > 0.50; Ρ < 0.0005) was observed during the followup. In contrast, the 
correlation between sIL-2R and p75 was weaker (r = 0.37; Ρ < 0.005) and present 
only at baseline. Both sTNFR correlated significantly with each other (r > 0.50; 
Ρ < 0.0005). TNFa concentrations showed no significant correlations with either 
sTNFR or any of the parameters studied. The positive correlations between 
pretreatment IL-6 bioactivity and sIL-2R and sTNFR in the RA patients tended to 
decrease during the followup (data not shown); however, this was not the case when 
only the patients treated with MTX were analysed (correlation coefficient between 
IL-6 and SIL-2R, p55, and p75 respectively, were 0.65, 0.34 and 0.44). 
The parameters measured in this study showed no significant correlation with clinical 
(disease duration, Ritchie articular index, number of tender joints, duration of 
morning stiffness, and disease activity score [26]) or with radiologic (erosion score 
and total score [21]) measurements. On the oüier hand, positive correlations were 
found with some laboratory parameters of disease activity, such as the C-reactive 
protein (CRP) level, the ESR, and the platelet count (Table 4). 
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Table 4. Spearman correlation coefficient among pretreatment sTNFRs (p55, 
p75), sIL-2R, bioactive IL-6 levels and laboratory parameters of disease activity 
ESR CRP Platelets 
sTNFR 
P55 0.38t 
p75 0.19 
SIL-2R 0.38t 
IL-6 0.28§ 
ESR = erythrocyte sedimentation rate; CRP = C-reactive protein. 
t Ρ < 0.005; t Ρ < 0.0005; § Ρ < 0.05. 
Discussion 
In this study, circulating levels of sTNFR, sIL-2R, TNFa, and IL-6 were serially 
measured in patients with active RA randomized to receive treatment with MTX or 
AZA. A number of interesting findings emerged from these investigations. First, we 
found that concentrations of both of the sTNFR (p55 and p75), sIL-2R and TNFa 
are significantly elevated in patients with RA as compared to controls. Similar 
observations for sTNFR and sIL-2R have been reported by other investigators 
(19,20,27). With respect to TNFa, the results reported in literature are conflicting 
(see below). Despite active RA before treatment, elevated immunoactive and 
bioactive IL-6 concentrations were observed only in some of the patients, resulting 
in mean IL-6 concentrations that were not significantly higher than in controls. The 
relatively low serum IL-6 concentrations in this and other studies (16-18) and the 
thousandfold higher levels found in synovial fluid suggest a predominant intra­
articular production or a rapid clearance of the circulating IL-6. 
A second important finding in our study is that clinical improvement is accompanied 
by significant reductions in the concentrations of p55 and sIL-2R, the parameters 
which best correlated with laboratory indices of RA activity such as CRP, ESR, and 
platelet counts. Decreases in sIL-2R concentrations, together with clinical 
improvement, have been observed in RA (28-30), and associations between sTNFR 
levels and disease severity were recently reported in a cross-sectional study (27). 
However, to our knowledge, this is the first report of a long-term study of 
concomitant measurements of circulating levels of TNFa and sTNFR in RA. The 
following observations are probably relevant: (a) The concentrations of each type 
sTNFR individually exceeded by 20-30 fold those of TNFa, the p75 sTNFR levels 
being higher than those of p55; (b) The TNFa concentrations throughout the study 
period were higher in patients with lack of response to therapy than in those who 
improved; and (c) A decrease in p55 sTNFR concentrations occurred in patients with 
clinical improvement but no significant changes in TNFa or p75 concentrations were 
observed irrespective of response to therapy or the DMARD used. 
Elevated TNFa levels and correlations with disease severity have been found in 
various infectious and non-infectious diseases (31-33). Similar observations in RA 
(34-36) have not been confirmed in other studies which failed to detect circulating 
0.63Í 
0.40t 
0.50Φ 
0.41t 
0.36t 
0.261 
0.40t 
0.29§ 
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TNFa (27). Some of these discrepancies are probably due to the presence of sTNFR 
in biological fluids, which may interfere to a different extent in TNF bioassays and 
immunoassays (37). With the assays used in this study, such interference could be 
excluded; however the question is whether circulating TNFa retains its biological 
activity. Recently van Zee et al (38) showed that a great excess of sTNFR is requi­
red to block the bioactivity of high concentrations of TNFa, whereas lower TNFa 
concentrations (approximately 4 times higher than those in our study) can be 
efficiently inhibited by a 8-9-fold excess of p55. The ratio of sTNFRs to TNFa in 
this study, together with the unchanged TNFa concentrations even in patients with 
clinical improvement, suggest that circulating TNFa may not be biologically active. 
The different course of the p55 versus the p75 sTNFR and TNFa in the patients 
with clinical response is interesting. The expression and shedding of both sTNFR 
may be distinctly regulated (27,39,40), but the main source of the circulating forms 
is still unknown. Interestingly, in a recent study, pre-treatment with Ibuprofen in 
human experimental endotoxinemia increased and prolonged concentrations of TNFa 
and p75 sTNFR in the circulation without affecting p55 levels (41). It is therefore 
possible that concomitant NSAID therapy is also responsible for our findings. 
Perhaps the most interesting observation in this study is that MTX and AZA differ 
not only with respect to clinical efficacy but also in their capacity to induce changes 
in circulating cytokine and soluble receptor concentrations. Corroborating the clinical 
results, the decreases in concentrations of sIL-2R and p55 were significant in the 
patients treated with MTX (but not with AZA), and MTX was slightly more 
effective in decreasing immunoactive IL-6 levels. In view of the better clinical 
response obtained with MTX, it is possible that these differences are due to a more 
effective suppression of the inflammation by this drug, rather than to a specific 
effect of MTX. The early and pronounced decrease in IL-6 bioactivity in patients 
treated with AZA has to be explained by the inhibitory effects of circulating AZA 
or its metabolites in the bioassay (Barrera Ρ et al: unpublished observations). This 
bioassay is therefore not suitable for evaluating IL-6 concentrations in patients 
treated with this drug. 
Decreases in sIL-2R concentrations in RA have been observed during treatment with 
amiprilose HCl (Therafectin; Greenwich Pharmaceuticals, Fort Washington, PA) 
(28) and with corticosteroids (30) but not with intramuscular gold (42). Decreases 
in IL-6 concentrations have been reported with intramuscular (43) and oral gold 
(44), while for sulfasalazine the results are contradictory (44,45). Neither MTX nor 
AZA altered TNFa concentrations in this study, but decreases have been observed 
during therapy with corticosteroids (36) and sulfasalazine (45). 
Taken together, these results indicate that diverse DMARDs distinctly affect 
circulating cytokines and soluble receptors. The differences in cytokine patterns 
between patients with improvement versus those without, suggest that measurements 
of sIL-2R, p55 and IL-6 may be useful in the evaluation of therapeutic response. 
Further studies are needed to determine whether these effects are causally related to 
disease-modifying activity or merely reflect epiphenomena. 
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The effects of methotrexate on soluble interleukin-2 receptor levels 
in rheumatoid arthritis: comment on the article by Barrera et al. 
Letter 
We read with interest the article by Barrera et al (1) concerning cytokine levels in 
rheumatoid arthritis (RA) patients receiving methotrexate (MTX) and azathioprine 
(AZA) therapy (1). Those authors observed that MTX therapy caused a significant 
reduction in circulating levels of soluble interleukin-2 receptor (sIL-2R) and 
interleukin-6 (IL-6) that was associated with clinical improvement, while AZA did 
not affect sIL-2R levels but did reduce IL-6 levels. 
We have also measured circulating levels of sIL-2R, by enzyme-linked immuno­
sorbent assay (T Cell Sciences, Cambridge, MA), and IL-6, by B9 bioassay (2), in 
RA patients receiving MTX or AZA. Although we observed a decrease in 
circulating levels of sIL-2R between week 0 (1175 units/ml; interquartile range 
flQR] 692-1400; η = 16) and week 12 (880 units/ml; IQR 370-1135; η = 15) and 
week 24 (740 units/ml; IQR 440-1150, η = 11), in patients receiving MTX, this 
decrease was only statistically significant at week 12. There was also a decrease in 
circulating levels of IL-6 at 12 weeks of MTX therapy (n = 19), which was 
statistically significant, but the levels increased again at week 24 (Crilly et al: 
unpublished observations). In this same patient group, there was clinical improve­
ment as assessed by the Ritchie articular index (RAI), pain score (PS), and duration 
of morning stiffness (MS). Similarly, we found that AZA therapy did not 
significantly alter circulating levels of sIL-2R or IL-6 at either 12 or 24 weeks of 
therapy (n = 18 and 14, respectively), although there was clinical improvement as 
assessed by the RAI, PS, and MS (Crilly et al: unpublished observations). 
Based on our findings as well as those reported by Dooley et al (3), we believe that 
it is still not totally clear whether MTX has the ability to influence sIL-2R levels in 
RA patients. Dooley et al reported that not only MTX, but also placebo treatment 
caused a significant reduction in circulating levels of sIL-2R in patients with RA. 
When their patients were grouped as responders and nonresponders at completion 
of the study, the sIL-2R levels were similar regardless of the treatment given. 
Because a placebo treatment group was not included in Barrera's study, we would 
question their findings with regard to this. 
We believe the findings of Dooley et al (3), along with our own results, suggest that 
MTX does not influence lymphocyte activity in RA patients, as assessed by sIL-2R 
levels. This is perhaps not surprising since drugs like MTX and AZA suppress bone 
marrow function in vivo and it has been suggested that they work by reducing the 
number of mature monocytes available for recruitment to the joint (4). 
We have also observed that oüier second-line agents also thought to specifically 
target macrophage activity and function decrease IL-6 but not sIL-2R levels (5,6). 
In contrast, we have found that cyclosporin A, a drug which is known to specifically 
target Τ cell function, reduces circulating levels of sIL-2R as well as IL-6 (7). We 
believe, therefore, that the effect of MTX on sIL-2R levels is still open to debate. 
Crilly A, Madhok R. 
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Reply 
The comments by Crilly and Madhok are especially interesting in light of their 
recently published abstract about sIL-2R and interleukin-6 (IL-6) measurements in 
RA (1). In that study, sIL-2R and IL-6 were measured at 0, 12, and 24 weeks in 
patients treated with MTX or placebo. In patients treated with MTX, a significant 
reduction in sIL-2R (n = 16, Ρ = 0.0008) and IL-6 (n = 20, Ρ = 0.018) was 
observed after 12 weeks. The levels of sIL-2R (n = 11) and IL-6 (n = 14) 
remained low after 24 weeks, but this was not statistically significant. In patients 
treated with placebo, no significant changes in sIL-2R or IL-6 were observed after 
12 or 24 weeks. They concluded that: "the clinical benefits in patients receiving 
MTX may in part be due to modulation of cytokines such as IL-6 and sIL2-R." 
In their comment on our article, Crilly and Madhok show very similar data on 
MTX-treated patients compared, this time, with AZA-treated patients (where no 
changes in sIL-2R and IL-6 levels occurred). Inconsistent with Uieir previous 
statement, they now question the effects of MTX in sIL-2R levels. Some of the 
discrepancies between their findings and ours might be due to the different study 
structure. We conducted a double-blind, randomized study including a considerable 
number of patients with active RA, refractory to intramuscular gold and/or D-
penicillamine. Data concerning patient selection and study definition in the study by 
Crilly and Madhok are lacking and die non-significant decrease in sIL-2R levels 
after 24 weeks of MTX treatment may be due to the small numbers of patients at 
this time. For ethical reasons, a placebo group was not included in our study since 
MTX (2) and AZA (3) have demonstrated to be superior to placebo in clinical trials. 
Levels of sIL-2R in patients treated with placebo did not change during 24 weeks 
in the study by Crilly et al (1), while Dooley et al (4) found a significant decrease 
in sIL-2R levels both in patients treated with MTX or placebo for 18 weeks. 
Furthermore Dooley et al found no significant differences in sIL-2R levels among 
responders and non responders at study completion. Interpretation of the data in this 
abstract (4) is difficult since the data given concern die whole patient group (MTX 
and placebo) and no definition of outcome (responder or nonresponder) is provided. 
Comparing patient groups in a cross-sectional way at a given time (i.e., study 
completion) may underestimate differences, since interindividual variations in sIL-2R 
levels are marked, and exceed by more than 5-fold the variation in a given patient 
over a period of time (Barrera et al: unpublished results). Therefore, measurements 
at several time points or analysis of percentages of changes from baseline might be 
more adequate. 
Finally, the mechanism of action of MTX has yet to be elucidated. Besides an effect 
on lymphocyte activation (as measured by sIL2-R), effects in monocytes (5), 
polymorphonuclear cell Chemotaxis (6), proliferating synovial cells (7), and 
angiogenesis (8) have been suggested. The field open to debate is therefore broad 
enough, and more studies about the effects of antirheumatic drugs in the cytokine 
cascade are necessary. 
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Antirheumatic drugs and interleukin-6 bioassay 
Abstract 
Bioassays are currently used to measure the presence of functionally active 
cytokines in biological fluids. These assays may be influenced by the presence of 
other substances, either cytokine specific or not, in such fluids. In the present 
study, we analyzed whether some currently used disease modifying antirheumatic 
drugs (DMARDs) could interfere with the measurements of circulating interleukin-
6 (IL-6) bioactivity in the B9 hybridoma assay. When sera from healthy controls 
and patients treated with various DMARDs, such as azathioprine (AZA), 
methotrexate (MTX), intramuscular gold and sulphasalazine (SASP), were tested 
in the IL-6 bioassay, an inhibitory effect was only observed with sera from 
patients treated with AZA. Addition of exogenous AZA, 6-mercaptopurine (6-MP) 
and MTX to the IL-6 bioassay, resulted in a dose-dependent inhibition of the B9 
cell proliferation induced by IL-6, AZA being most potent on a molar basis. 
Concentrations of AZA and 6-MP compatible with serum concentrations achieved 
in RA patients were able to inhibit the bioassay, but this was not the case for 
MTX. Exogenous SASP and its metabolites did not modify the IL-6 induced B9 
cell proliferation. This study shows that circulating AZA (or its metabolites) exert 
an inhibitory effect in the IL-6 bioassay. This method is therefore not suitable to 
measure IL-6 concentrations in patients treated with AZA. Interference of drugs 
must be ruled out when bioassays are used to evaluate cytokine levels in 
biological fluids. 
Introduction 
The biological effects of interleukin-6 (IL-6) suggest a relevant role in the 
pathogenesis of rheumatoid diseases. IL-6 is the major inducer of acute phase 
protein synthesis, it is implicated in Τ lymphocyte proliferation, В lymphocyte 
differentiation, immunoglobulin production, and hemato- and thrombopoiesis (1). 
IL-6 shares pro-inflammatory effects with cytokines like interleukin-1 (IL-1) and 
tumor necrosis factor (TNF) which in turn induce its production (2-3). Further­
more, IL-6 possesses also anti-inflammatory properties like the induction of tissue 
inhibitor of metalloproteinases-1 (4,5) and the inhibitory effect on of IL-1 and 
TNF production (6). IL-6 is produced by rheumatoid synovium (7-9) and is 
found at high concentrations in synovial fluid (SF) of patients with rheumatoid 
arthritis (RA) (10-12) correlating with local (10,13) and systemic (13) parameters 
of disease activity. Circulating IL-6 concentrations in RA also correlate with 
acute phase parameters (10,11) and though it is probable that the inflamed joint is 
the main production site of IL-6 in RA, measurements of circulating IL-6 are 
more suitable for follow up studies. 
Some evidence suggests that treatment with different disease-modifying anti­
rheumatic drugs (DMARDs) affect circulating IL-6 concentrations in RA. 
Decreases in circulating IL-6 have been observed during treatment with intra­
muscular (14) and oral gold (15), methotrexate (16) and cyclosporin (17), while 
for sulphasalazine (SASP) contradictory results have been reported (15,18). 
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In a randomized, 48-week, double-blind trial conducted in our center (19), 
methotrexate (MTX) proved to be superior to azathioprine (AZA) in the treat-
ment of active rheumatoid arthritis (RA). In these patients, treatment with both 
DMARDs resulted in significant decreases of circulating concentrations of IL-6 
bioactivity, but, unexpectedly this decrease was much more marked and occurred 
earlier in patients treated with AZA and in the group of patients which did not 
experience clinical improvement (more often treated with this drug). MTX, in 
contrast, induced a more pronounced decrease than AZA when IL-6 was assessed 
by means of an immunoassay (20). Therefore, it seemed that a factor present in 
the circulation of patients treated with AZA, but not with MTX, exerted an 
inhibitory effect in the IL-6 bioassay. Since this factor might be the trial drug, we 
studied the effects of MTX, AZA and SASP, three currently used DMARDs in 
the measurements of IL-6 bioactivity. 
Methods 
IL-6 bioassay 
Iscove's modified Dulbecco's medium (IMDM) supplemented with 5% fetal calf 
serum (FCS), penicillin (100 IU/ml), streptomycin (100 /ig/ml) and ß-mercap-
toethanol (5 χ IO"5 M) constituted the B9 culture medium. The IL-6 bioassay was 
performed as previously described (21). Briefly, 5000 B9 cells in culture medium 
were seeded in 96-well flat bottom microtiter plates (Costar, 1170 AB Badhoeve-
dorp, The Netherlands) in the presence of known amounts of recombinant human 
IL-6 (rhu IL-6) (gift of Prof. L.A. Aarden, CLB Amsterdam, The Netherlands) 
or diluted samples (usual dilution range 1/20-1/160). Cell proliferation was 
measured by thymidine incorporation after 64 h (7.4 kBq [3H] thymidine/well). 
When indicated, a colorimetrie method which measures the conversion of MTT 
(3-[4,5,dimethyl,thiazol-2 yl]-2,5,diphenyl tetrazolium bromide, Sigma M-5655) 
to formazan by living cells (22) was additionally used. One unit/ml IL-6 was 
defined as the concentration that leads to half-maximal thymidine incorporation 
(or conversion from MTT to formazan). The sensitivity of this assay is 0.3 U/ml. 
Cell viability was judged by the trypan blue exclusion test. 
Effect of circulating DMARDs in the IL-6 bioassay 
Sera from healthy controls or RA patients treated with different DMARDs was 
added to B9 cells cultured in the presence of serial dilutions of rhu IL-6. 
Sera from patients treated with MTX (n=4), AZA (η = 4), salazopyrin (SASP) 
(n = 2), intramuscular gold (n = 2) or only nonsteroidal antiinflammatory drugs 
(NSAIDs) (n = 2) were tested. The sera were heat inactivated for 30 min at 
56°C, diluted in B9 culture medium and tested in 2-fold dilutions (final dilution 
range 1/20 - 1/1280). The control consisted of B9 cells cultured with rhu IL-6 in 
the absence of sera. Cell proliferation was measured by [3H] thymidine incorpo­
ration as indicated above. 
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Effect of exogenous AZA, MTX, sulfasalazine (SASP) and their metabolites 
in the IL-6 bioassay 
The drugs tested were MTX (Pharmachemie, Haarlem, The Netherlands) alone 
or in combination with folinic acid (Lederle, Etten-Leur, The Neüierlands), AZA 
(Wellcome, Weesp, The Netherlands) and its main metabolite 6-mercaptopurine 
(6-MP) (kind gift of Dr R.A. d'Abreu, Nijmegen, The Netherlands), and sulfa-
salazine (SASP) and its main metabolites sulfapyridine, acetyl-sulfapyridine, and 
S-aminosalicylic acid (5-ASA) (Pharmacia, Upsala, Sweden). For reference, the 
circulating concentrations of these drugs are shown in Table 1. 
The drugs were diluted in B9 culture medium (final concentration range 103 to 
10"12 M) and added to B9 cells cultured in the presence of 5 U/ml rhu IL-6. The 
control consisted of B9 cells cultured with 5 U/ml rhu IL-6 in culture medium. 
Cell proliferation was measured by [3H] thymidine incorporation and additionally 
by a colorimetrie method (22) when MTX was tested. 
Results 
Influence of circulating drugs in the IL-6 bioassay 
When sera from patients treated with AZA (η = 4) were added to B9 cells 
cultured with exogenous IL-6, an inhibition of the cell proliferation was obser­
ved. This inhibition was dose-dependent (Figure 1A) and still observed at serum 
dilutions of approximately 1/1300. 
Sera from healthy controls or patients treated with MTX, SASP, intramuscular 
gold or NSAIDs, enhanced the B9 cell proliferation induced by low IL-6 concen­
trations reflecting the presence of endogenous IL-6 in these sera (Figure IB). 
Effect of exogenous AZA, MTX, SASP and their metabolites in the IL-6 
bioassay 
Among the drugs tested, AZA, 6-MP and MTX (Figure 2A) resulted in a dose-
dependent inhibition the B9 proliferation induced by IL-6. This effect was not 
due to drug-induced cell toxicity (assessed by trypan blue exclusion). 
On a molar basis AZA and 6-MP were more potent than MTX since significant 
inhibition occurred with concentrations >10'12M for AZA, ^10"'°M for 6-MP 
and > 107M for MTX respectively. 
Low concentrations of MTX (10'M) resulted in an increased thymidine uptake by 
the B9 cells but had little or no effect when cell proliferation was assessed by a 
colorimetrie method. 
No effect on the cell proliferation was observed after addition of SASP or its 
metabolites (Table 1). 
Folinic acid alone did not affect cell proliferation, but when added together with 
MTX (at approximately lOOx molar excess) reversed the inhibition caused by this 
drug (Figure 2B). 
65 
Chapter 4 
* 
ел 
4 > ^ 
ce 
О. 
2 
е+н 
О 
а 
u 
αϊ 
1» 
4—» 
S5 
•с 
3 4 3 
CA 
U 
• ^н 
"о 
Л 
s i £ 
'Я 
Ξ 
тз 
s 
ел 
С 
1 
с 
8 
с 
s & 
Q 
А 
I 
в 
о. 
3 
с 
i I M α (Л 
S 
ε (Λ 
Ι a 4J 
ε 
1 
• κ 
>> 
sa 
о 
'.о 
о Ä 
.Й 
Он 
< 
ел 
X H 
'S 
О 
Q 
•α 
<я 
Η 
SS 
2 2 ζ ζ ζ z 
ΛΙ ΛΙ 
Ι
4 
ε ο 
5 « 
s 
α 
*s 
U"í ϋ 
t* Ф^ 
α -
sS 2 « 
^ 6 
t n 
00 —< 
«ri ö 
cd • c 
x: ^ 
vo 2 
S cu 
Β- , . 
zè 
2 χ 
x 8 
о —• 
*о _¿ 
ι О 
«Λ t N 
X¡ Sí 
J3 О -с 
ΓΛ «η 
г
 
2-
8 
г
 
10
-
г
 
И
-
О 1) 4) 
»tí Ctí <tì 
ÍÍÍ 
о ö <Ь 
00 00 чО 
ι-» 00 чо 
» 4 t 1 
ι —< v i 
» η « 
^ α, α, eu < 
Λ 5 И ел СЛ 
<< vo ел ел < ; « t 
Я .·= 
г - —с 
< 
N 
< 
О 
Он 
ел 
< 
ел 
ел Я < " 
ел 
υ 
υ 
с 'f. • 
•с ^ Ç 
t 8 2 
" l o S с« 4> m 
ε •" о 
чо II ~ 
Il < "S 
t . . . c/5 
« Î i C 
. . c o 
I -l's 
S i 8.g 
a 2 S S 
« нц xi 
χ о о 
S ë c 'S Ili s 
8 1 1 S 
и S •- S 
Ë il il " 
S - „ Q 
. и Ζ Ζ 
3 с 
С CU 
ce Ç 
s 
CU си u U A 
Он 0 H 
66 
Antirheumatic drugs and interleukin-6 bioassay 
Figure 1. Effect of serum from patients treated with different DMARDs on the B9 bioassay. 
Control: В cells cultured with IL-6 in B9 medium. 
(A) Serum from one patient treated with 100 mg/day AZA was added at different dilutions 
(range 1/20-1/1280) to B9 cells cultured with IL-6. 
(B) Serum from one healthy control (no drug) and patients treated with other DMARDs or 
NSAIDs were added to B9 cells cultured with IL-6 (dilution 1/20). 
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Figure 2. Effects of exogenous DMARDs on the B9 bioassay. 
The control consisted of B9 cells cultured without DMARDs and is set at 100%; 5 U/ml rhu IL 
6 was added to all cultures. 
(A) Effect of different concentrations of AZA, 6-MP, and MTX on the B9 cell proliferation 
measured by [3H] thymidine uptake. A colorimetrie method was additionally used for MTX (MTX 
М П ) . Results show the average of 3 experiments. Drug concentration (log molar) is on the χ 
axis; cell proliferation (as percentage of the control) on the у axis. 
(B) Rescue effect of folinic acid on the inhibition of B9 cell proliferation induced by MTX. 
Proliferation measured by a colorimetrie method (MTT). 
Results represent the average of 3 experiments. MTX concentration (log molar) is on the χ 
axis; folinic acid concentration (log molar) is on the ζ axis, cell proliferation (as percentage of 
the control) is on the у axis. 
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Discussion 
Bioassays are currently used to quantitate cytokines in a variety of diseases since 
they provide information not only about the presence but also about the functional 
activity of cytokines in biological fluids. These assays may be hampered by the 
presence of inhibitors, either cytokine-specific or not. The influence of drugs 
present in biological fluids on cytokine bioassays has been suggested by other 
authors (23), but this is, to our knowledge, the first report about interference of a 
circulating DMARD with measurements of IL-6 bioactivity. The interference of 
AZA was first observed in a clinical study (20) and corroborated herein by in-
vitro evidence. 
The effect of different sera in the IL-6 bioassay was first studied. Only sera from 
patients treated with AZA resulted in a dose-dependent inhibition of the B9 cell 
growth induced by IL-6. When different DMARDs and their metabolites were 
exogenously added to the bioassay, only the drugs with cytostatic properties 
(AZA, 6-MP and MTX) resulted in a dose-dependent inhibition of the B9 cell 
proliferation induced by IL-6. SASP and its metabolites did not alter the bio-
assay. Considering the serum levels of 6-MP, AZA, and MTX achieved in RA 
patients (Table 1) and the sample dilution in the bioassay (range 1/20-1/160), it is 
clear that samples from patients treated with AZA yield concentrations of this 
drug and its metabolite that will inhibit the B9 cell proliferation while this is not 
true for patients treated with MTX. The increased thymidine uptake observed 
with nanomolar concentrations of MTX is probably due to inhibition of thymi-
dilate synthetase by MTX (24). Caution with sample timing is advisable, since 
nanomolar MTX concentrations could be attained in the bioassay if samples taken 
shortly after MTX intake are used. 
Taken together, our results show that the B9 bioassay is not suitable to measure 
IL-6 in patients treated with AZA. Treatment with MTX, SASP, and intramuscu-
lar gold, did not seem to interfere with this assay. The general implication is that 
when cytokine bioassays are used in clinical studies, the effects of circulating 
drugs in the bioassays should first be tested. 
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Effect of a single MTX dose on cytokines in RA 
Abstract 
Methotrexate (MTX) is an effective treatment for rheumatoid arthritis (RA) and its 
effects may be partly due to cytokine modulation. Herein, we assessed the effects of 
a single MTX dose on the production and circulating concentrations of several 
cytokines and soluble receptors in 42 RA patients at three consecutive days. Three 
patient groups were studied: (a) 16 patients taking the first MTX dose, (b) 11 
patients on chronic MTX treatment and (c) a control group of 15 patients not treated 
with MTX. Cytokine production was studied in peripheral blood mononuclear cells 
(PBMNC) and in a whole-blood culture system (WBCS). Group (a) had a more 
active disease according to laboratory parameters as well as higher circulating 
interleukin-6 levels (P = 0.002). The secretion of IL-lß by stimulated PBMNC was 
higher in this group (P = 0.008) and decreased significantly (P = 0.03) after a 
single MTX dose. No significant change in any parameter was observed after MTX 
in group (b). In the total patient group, circulating concentrations of IL-lß and 
TNF-a were low but blood celh showed a high capacity of production for these 
cytokines. In contrast for sTNFRs, high circulating levels but a limited in-vitro 
production were observed. 
In conclusion, a single MTX dose may result in decreased production of IL-lß by 
PBMNC in patients with active RA. Furthermore, we observed an imbalance in the 
production of TNF-a and sTNFRs by peripheral blood cells of RA patients and 
propose that the WBCS is convenient for studying cytokine production in RA. 
Introduction 
There is a growing body of evidence suggesting that cytokines and their antagonists 
may play an important role in the pathophysiology of RA and, therefore, the effects 
of antirheumatic drugs on these mediators are of special interest. In RA, the efficacy 
and rapid therapeutic effect of low-weekly dose methotrexate (MTX) treatment have 
been demonstrated (1,2) but its mechanism of action has yet to be elucidated. MTX 
has antifolate effects (3,4) and may therefore alter DNA and RNA synthesis (5), 
transmethylation reactions (6) and adenosine release from cells (6-8). Inhibition of 
proliferating synovial cells (9-10), neutrophil Chemotaxis (11) and migration (7-8), 
superoxide production (12) and arachidonic acid metabolism (13-14) as well as anti-
inflammatory effects of this drug (15) have also been reported. Furthermore, some 
data suggest that MTX might result in modulation of cytokine production or activity. 
In-vitro studies have shown inhibition of IL-1 bioactivity by MTX (16-17). This 
might be due to either binding of the drug to IL-lß, which shares structural 
homology with the enzyme dihydrofolate reductase (16), or to the anti-folate effect 
of MTX (18). Inhibition of IL-6 but not TNF bioactivity, have been observed in 
vitro (18), whereas enhancement of IL-2 production or activity have been reported 
in animal models of arthritis during MTX treatment (19-20). 
Studies in RA patients are however scarce. Decreases in the production of IL-1 by 
peripheral blood mononuclear cells (PBMNC) have been reported after some weeks 
of treatment with MTX (21) but no changes were observed after a single dose (17). 
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Reduction of IL-Iß concentrations in synovial fluid (SF) (22), increased IL-2 
production by PBMNC (23-24) and decreases in circulating concentrations of soluble 
IL-2 receptor (sIL-2R), 55 kDa soluble TNF receptor (p55 sTNFR) and IL-6 (25) 
have also been reported during MTX therapy for RA. Even a single MTX dose may 
cause decreases in acute phase reactants (26), inhibition of neutrophil Chemotaxis 
(11) and leukotriene B4 production (13,14). Since these effects may be mediated by 
cytokines, we investigated the effects of a single MTX dose on circulating 
concentrations and production of several cytokines and soluble cytokine receptors 
in RA patients. 
Materials and methods 
Patients 
Forty-two patients who fulfilled the ARA criteria for RA (27) were studied (Table 
1). Patients were classified in three groups: (a) those starting MTX therapy (n = 16) 
at a dose of 7.5 mg/week; (b) those on chronic MTX therapy for at least 12 months 
(n = 11); [mean + SD dose 7.95 ± 2.5 mg/week] and (c) the control group 
consisting of 15 patients treated with other or no DMARDs for at least 12 months 
[sulphasalazine (n = 6), azathioprine (n = 1), intramuscular gold (n = 2), or no 
DM ARD (η = 6)]. AU patients received concomitant therapy with NSAIDs and 14 
received low dose corticosteroids (< 10 mg/day) for at least 1 yr before the study. 
The dosage of NSAIDs, steroids and DMARDs had not changed for at least 3 
months and was kept stable during the study. Blood samples were obtained on three 
consecutive days at 08.00 hours. No medication was allowed after 20.00 hours the 
previous day. MTX in a single oral dose was administered to patients in group (a) 
and (b) after the first venous sampling, whereas patients in group (c) were given 
their medication in the usual schedule. 
Blood collection 
Venous blood samples were collected aseptically in 4 ml Vacutainer tubes (Becton 
& Dickinson, Rutherford, NJ). Circulating and ex-vivo cytokine production in a 
whole-blood culture system (WBCS see below) were studied in all patients (n = 42). 
The spontaneous and stimulated cytokine production by peripheral blood mono­
nuclear cells (PBMNC) was studied in 35 patients (n = 12/8/15 in group a/b/c 
respectively). All samples were stored at -80°C until assay. 
Whole blood culture system (WBCS) (28) 
Two 4 ml Vacutainer tubes containing 48 μ\ EDTA-K, and 250 μ\ aprotinin (10000 
kallikrein inactivating units/ml, Bayer, Mijdrecht) were drawn. One tube was 
directly centrifuged 10 min at 2250 g and 5 min at 15000 g to remove the platelets 
and used to measure circulating cytokines. Stimulated cytokine production in whole 
blood (WBCS) was studied in the second tube by addition of 50 μϊ LPS (final 
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concentration 10 μg/ml; Escherichia coli serotype 055:B5 Sigma, St Louis). After 
24 h incubation at 37CC, this tube was centrifugated as indicated above. Aliquots 
were stored at -80°C until assay. 
Cytokine production by PBMNC (29) 
Peripheral blood mononuclear cells (PBMNC) were isolated from heparinized blood 
by Percoli (Pharmacia, Upsala, Sweden) centrifugation (δ = 1.075 g/ml) at 4°C and 
washed twice in saline. Differential cell counts were determined morphologically and 
cell viability (higher than 98 % in all cases) was assessed by tripan blue exclusion. 
PBMNC were suspended at a concentration of 5 χ IO6 cell/ml in RPMI complete 
medium [RPMI 1640 medium with 20 mM HEPES (Flow, UK) supplemented with 
2 mM L-glutamine (Gibco, New York), 1 mM pyruvic acid (Sigma, St Louis, MO), 
50 μg/ml gentamicin and 5 % heat-inactivated pooled human serum]. Aliquots of 100 
μΐ (5 χ IO5 cells) were added to 96-well round-bottomed microliter plates (Greiner, 
Feirickenhausen). An equal volume of RPMI complete medium with or without LPS 
(50 ng/ml final concentration) was added. The plates were incubated at 37°C in a 
humidified, 5% C02 atmosphere for 24 h. Thereafter, the supematants containing 
secreted cytokines, were centrifuged for 5 min at 13000 g. The remaining cell 
fractions were resuspended in 200 μΐ RPMI complete medium/well and exposed to 
three freeze-thaw cycles to lyse the cells and obtain material to measure cell-
associated cytokines. The samples were stored at -80°C. 
Cytokine assays 
IL-la, IL-lß and TNF-a were assessed by radioimmunoassay (RIA) as previously 
described (28-33). IL-la was measured exclusively in the cell fraction of PBMNC 
since this cytokine is primarily cell-associated (28). Plasma samples intended for the 
IL-lß assay were first extracted widi chloroform (31). The RIA for IL-la and ß are 
not influenced by the presence of IL-1 receptor antagonist (IL1-RA) since addition 
of up to 10 ng/ml IL-1RA to plasma containing known amounts of IL-la or β did 
not alter die results (34). The RIA for TNF-a measures total TNF (both free and 
complexed to its soluble receptors) as demonstrated by the lack of interference of 
the addition of up to 5 ng/ml recombinant sTNFR (p55 and p75) to plasma 
containing known amounts of TNF-a (unpublished observations). The average 
sensitivity of these RIA is 70 pg/ml. IL-6 was measured by B9 hybridoma bioassay 
as previously described (35). The sensitivity of this assay is 0.3 U/ml. STNFRs (p55 
and p75) were measured by means of an enzyme-linked binding assay (ELIBA) with 
a sensitivity of 100 pg/ml (Hoffmann la Roche, Basel). This assay measures total 
receptor concentrations (both free and bound to TNF) since addition of up to 10 
ng/ml recombinant TNFa to plasma containing known amounts of sTNFR does not 
influence the assay. SIL-2R was measured using a 'sandwich' ELISA (Cellfree, 
T-cell Sciences, Cambridge), according to the manufacturer. The sensitivity of this 
assay is between 50-100 U/ml. Exogenous MTX in concentrations up to ΙΟ"5 M did 
not affect any of these assays (data not shown). 
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Statistical analysis 
The Kruskall-Wallis and Wilcoxon rank sum test were used to analyse differences 
among therapy groups. Differences between values after 24 or 48 h and pre-
treatment levels were evaluated with the Wilcoxon signed rank test for paired 
samples. The Spearman's rank correlation coefficient was used to analyse 
correlations. In view of the explorative character of the study, the Ρ values were not 
corrected for multiple testing. 
Results 
Patients in group (a) had a shorter disease duration and higher ESR, CRP and 
platelet counts as well as lower haemoglobin concentrations than did those in the 
other two groups. This reflects a more active disease and probably explains the 
higher percentage of patients treated with steroids in this group (Table 1). PBMNC 
differential cell counts were similar in all treatment groups (Table 1) and were not 
altered by a single MTX dose. 
Table 1. Patient characteristics by treatment group 
Variable 
Age (yr) 
Mean ± SD 
Range 
Disease duration (yr) 
Mean ± SD 
Range 
Female / male 
RF positive 
No. of previous DMARDs 
Mean ± SD 
Range 
No. of patients on low-dose corticosteroids 
Laboratory parameters 
Mean ± SD 
ESR (mm/h) 
CRP (mg/1) 
Haemoglobin (mmol/1) 
Platelets (x 1071) 
PBMNC cell counts (%) 
Monocytes 
Lymphocytes 
Polymorphonuclear cells 
Group (a) 
Methotrexate 
first dose 
π = 16 
59.6 ± 14.7 
19- 83 
11.8 ± 9.02 
0.66 - 35 
1 3 / 3 
14 
2.9 ± 1 
1 - 4 
7 
64 ± 35 
50 ± 31 
6.9 ± 0.9 
401 ± 132 
27 ± 9 
60 ± 17 
13 ± 20 
Group (b) 
Methotrexate 
chronic 
η = 11 
61.6 ± 14.9 
2 8 - 8 3 
13.2 ± 9.1 
3 - 3 7 
7 / 4 
10 
3.2 ± 1.1 
1 - 5 
3 
46 ± 24 
31 ± 28 
7.0 ± 0.9 
295 ± 106 
25 ± 9 
65 ± 12 
10 ± 5 
Group (c) 
Other/No 
DMARD 
η = 15 
63.4 ± 11.8 
28-77 
16.5 ± 10.1 
2 - 38 
1 0 / 5 
14 
2.3 ± 1.6 
0 - 7 
4 
33 ± 26 
35 ± 25 
7.5 ± 0.6 
259 ± 68 
26 ± 10 
63 ± 14 
11 ± 15 
PBMNC = peripheral blood mononuclear cells. 
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Circulating cytokines and soluble receptors 
IL-lß was detected in 9 patients (group a/b/c η = 5/3/1; mean ± SD 174 ± 135 
pg/ml) while TNF-α was detected in 19 patients (group a/b/c η = 2/9/8; mean ± 
SD 88 ± 73 pg/ml) at least in one occasion. IL-6 and both types of sTNFRs and 
sIL-2R were detectable on three consecutive days in every patient (Table 2). 
Higher IL-6 concentrations were observed in group (a) than in group (b) and (c) 
(P = 0.002), but no significant differences between the groups were observed for 
sTNFRs. In the total group of 42 patients, p75 concentrations exceeded those of p55 
by a median of 2.55-fold. In the 19 patients with detectable TNF-a, the median 
sTNFR to TNF-a ratio was 53 and 150 respectively for p55 and p75. 
Marked inter-subject variability was observed for each cytokine although the intra-
subject variability over three consecutive days was less pronounced. Both inter- and 
intra-subject variability of sTNFRs and sIL-2R concentrations were much lower than 
those of IL-6 (Table 2). No significant change in circulating cytokines or receptors 
was observed after a single dose MTX. 
Production of cytokines and soluble receptors in WBCS 
Ex-vivo stimulation resulted in a marked production of IL-lß and, to a lesser extent, 
TNF-a in all patients (Table 2). In contrast, the concentrations of sTNFRs after 
stimulation were only slightly higher than those in the circulation (P < 0.05) (Table 
2) which resulted in a median sTNFR to TNF-a ratio of 2 and 5 respectively for 
p55 and p75. No significant differences in the WBCS production of IL-lß, TNF-a 
and sTNFRs were observed either between patient groups or after a single MTX 
dose in group (a) and (b). 
Production of cytokines by PBMNC 
Spontaneous production of secreted and cell-associated IL-lß was observed in all 
patients whereas spontaneous production of cell-associated IL-la and TNF-a and 
secreted TNF-a was not detected in three, 17 and two patients respectively. PBMNC 
stimulation resulted in a marked production of secreted IL-lß and TNF-a and cell-
associated IL-lß and IL-la in all patients but no cell-associated TNF-a was detected 
in 16 patients (Table 3). As shown in Figure 1, TNF-a was predominantly secreted, 
while for IL-lß, the secreted levels exceeded only slightly the cell-associated 
fraction. No sTNFRs production (either spontaneous or after stimulation) could be 
detected in any patient. 
Comparison between patient groups showed higher spontaneous and stimulated 
production of cell-bound IL-la and IL-lß and more secreted IL-lß (Ρ = 0.008) and 
TNF-α after stimulation in group (a) (Table 3). Interestingly in this group, a 
significant decrease in stimulated IL-lß secretion \P = 0.03, Figure 2A] and smaller 
decreases of cell-associated IL-lß and IL-la [Figure 2B and 2C] production were 
observed 48 h after MTX administration. MTX did not affect TNF-α production in 
group (a) [Figure 2D] or the production of any cytokine in group (b). 
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Figure 1. Whole-blood culture system (WBCS) and peripheral blood mononuclear cells (PBMNC) 
stimulated production of IL-1 (A) and TNF-σ (B) in 35 RA patients. 
Horizontal line shows the median. 
Correlations among cytokines 
A good correlation was observed between circulating concentrations of both sTNFR 
types (p55 and p75) (r = 0.7, Ρ = 0.006) and between IL-6 and sIL-2R levels 
(r = 0.53, Ρ = 0.05). Correlations among cytokine production by either WBCS or 
PBMNC are shown in Table 4. The same production pattern was observed in both 
systems (i.e IL-lß exceeded TNF-a) but no significant correlation was observed 
between concentrations measured in PBMNC and WBCS for any individual 
cytokine. 
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Table 4. Correlation among the production of different cytokines 
(Spearman correlation coefficient) 
Correlation among I and II 
Spontaneous Stimulated 
WDCS IL-lß 
p75 
PBMNC П.-la cell associated 
IL-lß cell-associated 
IL-Iß supernatant 
WBCS = whole blood culture system; PBMNC = peripheral blood mononuclear cells. 
* Ρ < 0.05; ** Ρ < 0.005; *** Ρ < 0.0005; NS = not significant. 
Discussion 
In the present study we analysed the effects of a single MTX dose on the production 
and circulating cytokine concentrations in RA patients. Since these effects could be 
dependent on treatment duration, patients receiving the first dose and on chronic 
MTX therapy were assessed together with a control group of patients on chronic 
treatment with other or no DM ARD. As expected, patients receiving the first MTX 
dose (group (a)) had a more active disease as reflected by laboratory parameters. 
In this group, circulating IL-6 levels (P = 0.002) and stimulated IL-lß production 
(P — 0.008) were higher and there was a tendency to increased production of IL-la 
and TNF-a by PBMNC. These results support previous findings of correlations of 
IL-6 with disease activity (25) and suggest an increased production of pro-
inflammatory cytokines, especially IL-lß, during active RA. 
Interestingly, the amount of IL-lß secreted by stimulated PBMNC decreased 
significantly after the first MTX dose [group (a)] and this was accompanied by 
smaller decreases in cell-associated IL-lß and IL-la. In patients chronically treated 
with MTX [group (b)l, IL-1 production was lower and apparently not affected by 
one MTX dose. This suggests that MTX modulates IL-lß production by PBMNC, 
especially when the latter is increased (i.e. during active disease), and that a steady 
phase with lower IL-lß production is reached during chronic MTX treatment. 
Our findings are sustained by previous observations by Chang et al (21) who 
reported a decrease in IL-1 production by PBMNC in 4 out of 8 RA patients after 
6 weeks of MTX therapy. Furthermore, reductions in synovial IL-lß concentrations 
have been observed during MTX treatment (22) and these might be due to inhibition 
of IL-lß production in the joint. In contrast, Segal et al (17) reported no changes in 
die production of IL-1 by PBMNC of 9 RA patients 48 hours after MTX. However, 
only four patients receiving the first MTX dose were included in the study by Segal 
et al (17), and among those, significant decreases in secreted (n = 1) and cell 
associated (n = 2) IL-1 production were observed. In contrast to IL-lß, TNF-a 
production was not affected by a single MTX dose. This is on line with our previous 
findings of unchanged circulating TNF-a concentrations during long-term MTX 
TNF-a 0.55** 
p55 0.60*** 
IL-1Ö cell-associated 0.80*** 0.79*** 
IL-lß supernatant 0.56** 0.59*** 
TNF-a supernatant 0.68*** NS 
IL-lß supernatant 0.55** 0.72*** 
TNF-a supernatant 0.56*** 0.57*** 
TNF-a supernatant 0.43** 0.50** 
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therapy (25) and the with the lack of inhibition of TNF-a by MTX observed in-vitro 
(18). 
Our results show that in RA patients, circulating concentrations of IL-Iß and TNFa 
are low, but blood cells have a high production capacity for these pro-inflammatory 
cytokines. This contrasts with the high circulating levels and the limited production 
of sTNFRs. The latter was only detectable in WBCS but not in PBMNC suggesting 
that neutrophils (36), present in whole blood may be responsible for some sTNFRs 
production. In RA, sTNFRs levels in synovial fluid are higher than in serum (37) 
and increased expression (38) and shedding of TNFRs (39) has been observed in 
synovial tissue. These observations, together with the low sTNFRs production by 
blood cells suggest that circulating sTNFRs levels may predominantly reflect their 
production in the joint. 
Consistently with previous findings (25), we observed a good correlation between 
circulating IL-6 and sIL-2R levels and between both types of sTNFRs, p75 
exceeding p55 by two- to three-fold both in the circulation and after in-vitro 
stimulation. In contrast, the sTNFRs/TNF-a ratio was high in the circulation (53 
and 150 for p55 and p75 respectively) but a switch in favour of TNF-a production 
was observed after in-vitro WBCS stimulation (sTNFRs/TNF = 2 and 5 for p55 and 
p75 respectively). If present in vivo, such imbalance in production of proinflamma-
tory TNF-a and its specific ligands would be deletereous. To date, there is evidence 
for an insufficient production of sTNFRs for complete suppression of TNFa activity 
in vivo (40) and clinical improvement has been reported during treatment with anti-
TNF-a monoclonal antibodies in RA (41). These observations warrant future studies 
using sTNFRs as anti-TNF therapy. 
In this study, a whole-blood culture system (WBCS) and isolated PBMNC were used 
to assess cytokine production. The first method is easy to perform, less time-con-
suming and may mimic physiological conditions more closely since it measures the 
response of all types of blood cells and does not require artificial cell-separating 
procedures. This WBCS has been used in several infectious diseases (42) and 
healthy controls (43) but only sporadically in rheumatic diseases (44). The lack of 
correlation in individual cytokine production by WBCS and PBMNC observed in this 
and other study (43) is not surprising: The first system assesses secreted but not cell-
associated cytokines, implicates more cell-cell interactions, and is subjected to the 
influence of factors present in plasma (i.e. cytokine antagonists, acute phase 
proteins, drugs, RF etc). The WBCS proved useful to study IL-lß and TNF-a 
production and may also be convenient to assess other cytokines (IL-6, IL-2, gamma 
interferon) (44) and cytokine antagonists [sTNFRs and IL-1 receptor antagonist 
(43)]. Taken together our results suggest that, in patients with active RA, a single 
MTX dose may decrease IL-lß but not TNF-a production by PBMNC. In RA, 
clinical improvement has been observed after inhibition of the pro-inflammatory 
cytokines IL-1 and TNF-a with the IL-1 receptor antagonist (45) and anti-TNFa 
antibodies (41) respectively. It is therefore possible' that modulation of IL-lß 
production by MTX may be implicated in the therapeutic effect of this drug and this 
hypothesis should be elucidated in long-term studies. 
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METHOTREXATE ALONE OR COMBINED 
WITH SULFASALAZINE FOR RA. 
EFFECTS ON CYTOKINE MEASUREMENTS 
Barrera Ρ, Haagsma CJ, Boerbooms AMTh, van Riel PLCM, Borm GF, van de 
Putte LBA, van der Meer JWM. Effect of methotrexate alone or in combination 
with sulphasalazine on the production and circulating concentrations of cytokines 
and their antagonists. Longitudinal evaluation in patients with rheumatoid 
arthritis. Br J Rheumatol 34:747-755, 1995 

Cytokine modulation by methotrexate alone or with sulphasalazine in RA 
Abstract 
In a recent study from our group, the combination of methotrexate and 
sulphasalazine (MTX + SASP) seemed superior to MTX alone in the treatment of 
rheumatoid arthritis. To assess the impact of these therapies on the cytokine 
cascade, the in-vitro production and circulating concentrations of several 
cytokines and endogenous cytokine antagonists were measured in 30 healthy 
controls and longitudinally in a subset of 26 patients enrolled in this study. 
Compared to controls, RA patients had significantly higher circulating 
concentrations of interleukin-6 (IL-6), soluble receptors for tumor necrosis factor 
(sTNFR), soluble receptors for interleukin-2 (slL-2R) and interleukin-1 receptor 
antagonist (IL-1RA), and their peripheral blood mononuclear cells (PBMNC) 
showed a higher spontaneous production of interleukin-Iß (IL-lß), tumor necrosis 
factor a (TNFa) and IL-1RA (both secreted and cell-associated) and a higher 
stimulated production of cell-associated TNFa, IL-1RA and (to a lesser extent), 
IL-lß. Treatment with MTX alone (n = 12) or combined with SASP (n = 14), 
resulted in significant reductions of circulating IL-6 and slL-2R but did not alter 
IL-lß, TNFa or IL-1RA concentrations. Decreases in circulating levels of sTNFR 
and in the in-vitro production of cell-associated IL-lß and IL-1RA after 
stimulation were only observed in patients treated with MTX + SASP. 
The concentrations of TL-1RA and sTNFR in the circulation exceeded moderately 
those of IL-lß and TNFa but this is probably insufficient to block IL-1 and TNFa 
activity. 
In conclusion, therapy with MTX alone or with SASP modulates IL-6 and sIL-2R 
concentrations in RA. Decreased production of IL-lß and IL-IRA and circulating 
sTNFR levels were only observed during therapy with MTX + SASP. Whether this 
relates to the better clinical effect observed with the combination therapy remains 
to be investigated. Circulating levels of IL-6, sIL-2R and sTNFR seem useful 
markers of disease activity in RA. 
Introduction 
The involvement of cytokine networks in the pathogenesis of rheumatoid arthritis 
(RA) is proved beyond discussion (1-2). Proinflammatory cytokines such as 
interleukin-1 (IL-1) and tumor necrosis factor α (TNFa) (3-4) are present in the 
rheumatoid synovial membrane and implicated in cell proliferation, synthesis of 
prostaglandins, metalloproteinases and interleukin-6 (IL-6) (5), proteoglycan 
breakdown and bone resorption (1). Intra-articular injection of IL-1 (6) and TNF 
(7) result in joint inflammation and blocking IL-1 and TNF ameliorates several 
animal models of arthritis (8-9). IL-6, the major inducer of acute-phase response 
(10), is also present in RA synovial tissue (2) and may amplify the inflammatory 
process by its action on B- and T-cells (1). However, in contrast to IL-1 and 
TNF, IL-6 does not enhance prostaglandins or collagenase production and may 
counteract inflammation by enhancing the synthesis of tissue inhibitor of metallo-
proteinase-1 (11) and reducing IL-1 and TNF production (12). The role of these 
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cytokines in human arthritis is supported by preliminary studies showing impro-
vement during IL-1 (13), TNF (14), and IL-6 (15) blockade in RA patients. 
The activity of cytokines in biological fluids is subject to modulation by natural 
inhibitors and soluble cytokine receptors. The IL-1 receptor antagonist (IL-1RA), 
a competitive inhibitor of IL-1 which binds to the IL-1 receptors without inducing 
a biological response (16), is present in the rheumatoid synovial membrane (17). 
High concentrations of soluble receptors for IL-2 (sIL-2R) (18-20) and TNF 
(sTNFR) (19,21) have been detected in plasma and synovial fluid of RA patients. 
The sIL-2R, a soluble form of the a chain IL-2 receptor, is a marker of 
lymphocyte activation in vivo (22) and may be useful to monitor disease activity 
in RA (18). The two types of sTNFR (p55 and p75) are shed from the cellular 
membrane and bind to TNF in solution acting as endogenous TNF antagonists 
(23). 
Methotrexate (MTX) and sulphasalazine (SASP) are currently used anti-rheumatic 
drugs. Although their mechanism of action remains unclear, several reports 
suggest that these drugs may differ in their effects on circulating cytokines and 
cytokine production. In vitro studies with MTX have shown inhibitory effects on 
IL-1 (24) and IL-6 but not TNF bioactivity (25) while SASP has been reported to 
decrease IL-1 (26-27) and TNF (27) production and to inhibit the binding of 
TNFa to its receptor (28). Furthermore in RA patients, decreases in synovial 
levels of IL-lß (29), in the production of IL-1 by peripheral blood mononuclear 
cells (PBMNC) (30-31) and in circulating concentrations of IL-6, p55 sTNFR 
(19) and sIL-2R (19-20) have been reported during MTX, whereas treatment widi 
SASP has been associated with reductions in IL-la, IL-lß and TNFa (32), but 
not in sIL-2R (33) or IL-6 (32) concentrations, though die latter was not corro-
borated in other study (34). 
To date, the effect of combination therapy with MTX and SASP on cytokines has 
not been assessed. Therefore, after a recent study in our centre showed that the 
combination of MTX and SASP was superior to MTX alone in the treatment of 
active RA (35), we analysed the effects of these therapies on circulating levels 
and on the in-vitro production of several cytokines and their endogenous anta-
gonists. 
Patients and methods 
Patients 
Twenty-six patients with active RA enrolled in a 24-week, randomised, open trial 
of MTX versus MTX in combination with SASP (35) and 30 healthy controls 
(laboratory staff) were studied. Cytokine concentrations were assessed at baseline 
and after 4, 8, and 24 weeks. Fourteen additional patients enrolled in the original 
clinical study (35) were excluded from cytokine measurements since they were 
controlled in other centre. Active RA was defined as a disease activity score 
(DAS) > 3. The DAS is a validated score composed of the Ritchie Articular 
Index, number of swollen joints, erythrocyte sedimentation rate (ESR) and patient 
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wellbeing on a visual analogue scale (36). Twelve patients were allocated to 
therapy with MTX alone (7,5 mg weekly in a single dose) and 14 patients to the 
combination MTX + SASP (2000 mg daily in two doses). If no clinical improve-
ment was observed after 16 weeks, the MTX dose was increased to 15 mg/week. 
Non-steroidal anti-inflammatory drugs (NSAIDs) were kept at stable dose and no 
corticosteroids were administered either at study entry or during the study. 
Circulating cytokine concentrations 
Blood samples used to assess circulating cytokines (IL-lß, TNFa, IL-1RA) and 
soluble receptors (sIL-2R, sTNFR) were drawn in Vacutainer tubes (Becton & 
Dickinson, Rutherford, NJ), containing 48 μΐ EDTA-K3 and 250 μ\ aprotinin 
(10000 kallikrein inactivating units/ml, Bayer, Mijdrecht, the Netherlands). 
IL-6 was measured in serum from a Vacutainer tube without additives. Samples 
were centrifuged 10 min at 2250 g and 5 min at 15000 g to remove the platelets 
and frozen at -80°C until assay. 
Cytokine production by PBMNC 
The production of IL-lß, TNFa and IL-1RA was assessed. sTNFR production 
was not measured since PBMNC do not seem to release these receptors either 
spontaneously or after LPS stimulation (31). PBMNC were isolated from hepari-
nized blood by Percoli (Pharmacia, Upsala Sweden) centrifugation (6=1.075 
g/ml) at 4°C and washed twice in saline. PBMNC were suspended at a concen-
tration of 5 χ 106 cells/ml in RPMI complete medium (RPMI 1640 medium with 
20 mM HEPES (Flow, UK) supplemented with 2 mM L-glutamine (Gibco, New 
York), 1 mM pyruvic acid (Sigma, St Louis, MO), 50 μg/τa\ gentamicin and 5% 
heat-inactivated pooled human serum). Aliquots of 100 μί (5 χ 10' cells) were 
added to 96-well round-bottomed microtiter plates (Greiner, Feirickenhausen, 
Germany). An equal volume of RPMI complete medium with or without LPS (50 
ng/ml final concentration) was added. The plates were incubated at 37°C in a 
humidified, 5% C02 atmosphere for 24 h. Thereafter, the supernatants containing 
secreted cytokines, were centrifuged for 5 min at 13000 g. The remaining cell 
fractions were resuspended in 200 μ\ RPMI complete medium/well and exposed 
to 3 freeze-thaw cycles to lyse the cells and obtain material to measure cell-
associated cytokines. The samples were stored at -80°C. The RPMI culture 
medium, Percoli and saline used in this study were sterile and pyrogen-free. 
Cytokine assays 
IL-lß, TNFa (31) and IL-1RA (37) were assessed by radioimmunoassays (RIA) 
with an average sensitivity of 40, 60 and 150 pg/ml respectively. The RIAs for 
IL-lß and IL-1RA are specific, i.e. the coexistence of IL-lß and IL-1RA in a 
given sample does not alter the results [unpublished results and (37)]. 
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IL-6 was measured by a B9 hybridoma bioassay with a sensitivity of 0.3 U/ml. 
As previously reported, this assay is not influenced by treatment with MTX or 
SASP (38). sTNFR (p55 and p75) were measured by enzyme-linked binding 
assay (ELIBA) (gift of Dr H. Gallati, Hoffmann la Roche, Basel, Switzerland) 
with a sensitivity of 100 pg/ml. The assays for TNFa and sTNFR measure total 
concentrations (both free levels and complexes of TNF and sTNFR) as previously 
reported (31). sIL-2R was measured using an enzyme linked immunosorbent 
assay (ELISA) (Innotest hIL-2Rs, Innogenetics, В 2000 Antwerp, Belgium), 
according to the manufacturer's instructions. The average sensitivity of this 
ELISA is 390 pg/ml. To minimize interassay variations, all samples were 
measured in a single assay. 
Statistical analysis 
Baseline variables were compared using the Student West or Wilcoxon rank sum 
test. Closed testing procedures (39) were used to compare cytokine measurements 
during the study with pretreatment values. Differences in cytokine concentrations 
between groups during the 24 week follow-up were analyzed by a distribution-
free test for curve analysis (40). Spearman's rank correlation coefficient was used 
to evaluate correlations between variables at study entry, and between changes in 
variables after 24 weeks. A two-sided Ρ value of 0.05 was considered to be 
significant. The clinical trial was an open study (35), but cytokine measurements 
were performed in a modified single-blind fashion. 
Results 
Clinical results 
No significant differences in pretreatment characteristics were observed between 
both treatment groups except for the number of painful joints which was higher 
in the group treated with combination therapy (Table 1). 
After 24 weeks of treatment, improvement was observed in both treatment 
groups. However, the combination therapy proved to be superior to MTX alone 
as reflected by the more pronounced changes in clinical variables including the 
Ritchie Articular Index, DAS, number of swollen and painful joints, general 
wellbeing, pain score, grip strength (Table 1) and the number of patients where 
the MTX dose was increased after 16 weeks because of lack of improvement 
(n = 8, all but one in the MTX group). 
Toxicities occurred with similar frequency in both treatment groups and were 
observed in seven patients treated with MTX alone (gastrointestinal η = 5, 
increase in transaminases η = 2, headache η = 1, stomatitis η = 1) and in six 
patients treated with MTX + SASP (gastrointestinal η = 2, increase in transami­
nases η = 5). One patient in the combination group dropped out at week 4 
because of the development of an 'overlap syndrome' with leucopenia, lung 
abnormalities, skin lesions and anti-ds DNA antibodies. 
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The results of this small open study suggest that the combination MTX + SASP 
is clinically superior and not more toxic than MTX alone (35). This is currently 
being evaluated in large double-blind trials comparing MTX + SASP versus the 
individual components. 
Table 2. Circulating cytokines and cytokine production by PBMNC in healthy 
controls and RA patients at baseline. Median and (25, 75 percentile). 
Variable Controls (n = 30) Patients (n = 26) 
Circulating Concentrations 
IL-Iß (pg/mJ) 
TNFa (pg/ml) 
IL-6 (U/m!) 
p55 (pg/ml) 
p75 (pg/ml) 
SIL-2R (pg/ml) 
IL-IRA (pg/ml) 
Production by PBMNC 
65 
105 
1 6 
950 
3035 
1825 
220 
Secreted without stimulation 
IL-Iß (pg/ml) 
TNFa (pg/ml) 
IL-1RA (pg/ml) 
100 
72 5 
2880 
(ND-90) 
(85-115) 
(1 2-2 2) 
(630-1100) 
(2710-3290) 
(1300-2838) 
(205-285) 
(65-165) 
(ND-150) 
(2420-4070) 
Cell-associated without stimulation 
IL Iß (pg/ml) 
TNF« (pg/ml) 
IL-IRA (pg/ml) 
Secreted after stimulation 
IL-IB (pg/ml) 
TNF(i (pg/ml) 
IL IRA (pg/ml) 
257 
ND 
1690 
10650 
2535 
7745 
Cell-associated after stimulation 
IL-Iß (pg/ml) 
TNFa (pg/ml) 
IL-1RA (pg/ml) 
4985 
195 
4860 
(185-510) 
ND 
(1250-2200) 
(6970-14100) 
(1930-3590) 
(5360-10600) 
(3080-6470) 
(120-230) 
(2750-6780) 
77 5 
92 5 
29 4 
2110 
4785 
4625 
312 
375 
152 5 
5305 
743 
72 5 
4810 
10500 
3445 
8990 
7690 
290 
7895 
(70-85) 
(75-105) 
(11 5-38 9) 
(1730-2700) 
(3720-7150) 
(3150-7200) 
(230-520) 
(155-1940) 
(65-565) 
(2480-7200) 
(485-1840) 
(35-135) 
(1270-6690) 
(4080-15400) 
(1570-5500) 
(5760-13200) 
(3520-13200) 
(185-390) 
(3430-14000) 
NS 
NS 
< 0 001 
< 0 001 
< 0 001 
< 0 001 
0 005 
< 0 001 
0 01 
0 02 
< 0 001 
< 0 001 
0 005 
NS 
NS 
NS 
NS 
0 02 
0 02 
PBMNC = peripheral blood mononuclear cells, ND = not detectable, NS = not significant 
Baseline comparisons in cytokine concentrations 
Compared to healthy controls, the circulating concentrations of IL-6, soluble 
TNF and IL-2 receptors and IL-IRA and the spontaneous production of secreted 
and cell-associated IL-lß, TNFa and IL-1RA by PBMNC were significantly 
higher in RA patients (Table 2). The production of cell-associated cytokines after 
in- vitro stimulation was also higher in RA patients and this difference was 
significant for TNFa and IL-1RA. In contrast, the concentrations of IL-lß and 
TNFa in the circulation and the secreted amount of IL-lß, TNFa and IL-1RA 
98 
Cytokine modulation by methotrexate alone or with sulphasalazine in RA 
after PBMNC stimulation were similar in patients and controls (Table 2). No 
differences in pretreatment levels of circulating cytokines or cytokine production 
by PBMNC were observed between treatment groups (data not shown). 
In RA patients, circulating IL-IRA concentrations were higher (median 4-fold) 
than those of IL-lß and the ratio sTNFR to TNFa was 20-30 and 40-70 respec-
tively for p55 and p75. The spontaneous production of IL-IRA in-vitro exceeded 
that of IL-lß by 10-20-fold in the secreted fraction and 3-6-fold in the cell-
associated fraction respectively. In contrast, the median concentrations of IL-1RA 
and IL-lß produced after PBMNC stimulation were similar (Table 2). 
Effects of treatment in cytokine concentrations 
Significant decreases in IL-6 and sIL-2R (Figure 1A and B) occurred in both 
treatment groups. The baseline concentrations of sTNFR in the circulation 
(Figure 1С and D) and the production of cell-associated IL-lß and IL-1RA 
(Figure 2A and B) after PBMNC stimulation tended to be higher (not significant) 
in patients treated with MTX + SASP, and significant decreases during follow-
up were only observed in this treatment group. The secreted amount of IL-lß 
after PBMNC stimulation decreased after 4 weeks, specially in the group treated 
with MTX alone, however, the median values at week 24 were not significantly 
different from baseline (Figure 2C). Neither the circulating levels of IL-1RA 
(Figure IE), IL-lß, and TNFa nor the spontaneous production or the secretion of 
these cytokines after PBMNC stimulation (data not shown) showed significant 
changes during the study. Longitudinal comparison of circulating cytokines and 
cytokine production, corrected for pretreatment values, did not show significant 
differences between treatment groups. 
Table 3. Correlation between circulating concentrations of sTNFR and sIL-2R 
and several cytokines and clinical and laboratory parameters. Spearman correla-
tion coefficient between absolute values at entry and between changes versus 
baseline after 24 weeks. 
DAS 
Swollen joints 
CRP 
Haemoglobin 
p75 
S1L-2R 
IL-6 
П.-IRA 
Entry 
0 . 6 1 " 
0.67**» 
0.45* 
-0.46* 
0.81*** 
0.65*** 
0.53** 
0.61** 
p55 
24 weeks 
0.66*** 
0.64** 
0.59** 
-0.44* 
0.68*** 
0.63** 
0.52* 
0.63·· 
Entry 
0.48* 
0.56** 
0.35 
-0.40* 
SIL-2R 
24 weeks 
0.45* 
0.56** 
0.52* 
-0.47* 
0.67*** 0.68*** 
Entry 
0.61** 
0.59** 
p75 
24 weeks 
0.43· 
0.44· 
DAS = disease activity score; CRP = C-reactive protein. 
* · * Ρ < 0.001, ** Ρ < 0.005, * Ρ < 0.05. 
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Figure 1. Circulating concentrations of IL 6 (A), sIL2R (B), sTNFR (C.D), and IL IRA (E) in 
patients treated with MTX alone (dotted boies) or with MTX + SASP (hatched boxes). 
Cytokine concentrations on the γ axis, time in weeks on the χ axis. 
Horizontal line - median; Vertical line - range; Box = p75 and p25 values, 
t = value above the у axis range; * - Ρ < 0.05 (closed testing) (39). 
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Figure 2. In vitro production of cell-associated IL-1 ß (A), cell-associated IL-1 RA (В), and 
secreted IL-1 В (С) after stimulation of PBMNC in patients treated with MTX alone (dotted 
boxes) or with MTX + SASP (hatched boxes). 
Cytokine concentrations on the γ axis, time in weeks on the x axis. 
Horizontal line - median; Vertical line = range; Box - p75 and p25 values. 
t - value above the γ axis range; * - Ρ < 0.05 (closed testing) (39). 
Interrelationships between cytokines and other parameters 
sTNFR and sIL-2R showed positive correlations with the DAS, number of 
swollen joints, C-reactive protein (CRP) and IL-6 and negative correlations with 
haemoglobin concentrations (Table 3). IL-6 measurements also correlated with 
baseline CRP (r = 0.49, Ρ < 0.05) and ESR (r = 0.58, Ρ < 0.005). The 
production of IL-lß, TNFa and IL-1RA by PBMNC showed significant inter-
relationships but no correlation with circulating cytokine levels and clinical or 
laboratory measurements of disease activity (data not shown). 
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Discussion 
In the present study circulating cytokines (IL-lß, TNFa, IL-6, IL-1RA), soluble 
receptors (sIL-2R and sTNFR) and the production of IL-lß, TNFa and IL-1RA 
by PBMNC were longitudinally assessed in patients with active RA enrolled in a 
randomized open trial of MTX combined with SASP versus MTX alone (35). 
Potential different effects of combination (MTX + SASP) and single drug 
(MTX) therapy on the cytokine network could be relevant since: (a) MTX 4-
SASP seemed superior and not more toxic than MTX alone in the clinical study 
(35) and (b) previous reports had suggested that MTX and SASP may differ in 
their modulation of circulating cytokines and cytokine production (24-33). 
Several of the parameters studied showed important changes during Üierapy and 
there were some differences between both therapy groups. 
Significant decreases in the circulating sTNFR levels and in the production of 
cell-associated IL-lß and IL-IRA after stimulation were only observed in patients 
treated with MTX + SASP but not in the MTX group (Figures 1 and 2). This 
difference may reflect the fact that baseline levels of these parameters were 
higher (not significant) in the group treated with MTX + SASP, and that 
decreases are more likely to occur in tliis case. On the other hand, it might result 
from an additional or specific effect of SASP on the release of TNF receptors 
and on the production of IL-1 and its antagonist. 
Early decreases in IL-6 and sIL-2R concentrations occurred in both therapy 
groups, being also more marked in the group with higher pretreatment levels 
whereas the levels of IL-lß, TNFa and IL-1RA in die circulation remained 
unchanged. 
We have previously demonstrated that MTX therapy does not alter TNFa but 
reduces IL-6 and sIL-2R concentrations (19) and this has been corroborated by 
other authors (20,41). However, our findings in patients receiving combination 
therapy do not support that SASP reduces circulating levels of IL-lß and TNFa 
as reported by Danis et al. (32). 
In patients with active RA, we have observed reductions in the secretion of IL-lß 
by stimulated PBMNC after die first MTX dose (31). Similar effects were 
observed in the present study after 4 weeks of MTX therapy. This effect was not 
progressive over the time, and also not observed in the group treated with 
combination therapy which had lower IL-lß secretion at baseline. Therefore, 
Üiough MTX may decrease IL-lß secretion in some patients in the short term, it 
is unlikely that this explains the sustained therapeutic effect of this drug. 
Our results show that, compared to healdiy controls, RA patients have signifi-
cantly higher: (a) circulating levels of IL-6, sIL2R, sTNFR and IL-1RA, (b) 
spontaneous production of secreted and cell-associated IL-lß, TNFa and IL-1RA, 
and (c) stimulated production of cell-associated TNFa, IL-1RA and IL-lß (not 
significant) by PBMNC (Table 2). 
Elevated concentrations of IL-6 (42-43), sIL-2R (18-20) and sTNFR (19,21) have 
been previously reported in RA. These parameters are interrelated and show 
positive correlations with some measures of disease activity (Table 3). Therefore, 
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a decrease in their circulating levels during therapy probably reflects clinical 
improvement. Although it is not likely that these parameters will supersede 
current disease activity assessments, they may have some value as disease activity 
markers. 
In contrast, the concentrations of IL-lß (44,45) and TNFa in plasma are low and 
similar in RA patients and healthy controls. The increased serum TNFa concen-
trations reported in some studies (19,42,46) might have been due to production of 
TNFa in the blood sample during clotting or to endotoxin contamination (47,48). 
Our results corroborate former findings of an increased spontaneous production 
(49-52) and a normal IL-lß secretion after LPS stimulation (49) in RA. 
With regard to the production of TNFa in RA, previous reports have yielded 
contradictory results (51,53). The higher spontaneous in-vitro production of 
cytokines in RA may well reflect an activation of PBMNC in-vivo. 
When the ratio of endogenous antagonists (IL-IRA and sTNFR) to agonists (IL-1 
and TNF, respectively) was analysed, a moderate excess of the antagonists was 
observed in the circulation. The spontaneous production of IL-1RA by PBMNC 
was also somewhat higher than the IL-lß production but this was not the case 
after LPS stimulation. Furthermore, we have previously shown that PBMNC 
from RA patients do not release sTNFR either spontaneously or after stimulation 
(31). Since 10-500- and 30-300-fold higher levels of IL-1RA (16,17) and sTNFR 
(54) respectively are required for 50% suppression of IL-1 and TNF bioactivity, 
the concentrations of antagonists measured in this study may not be adequate to 
block completely the effects of IL-1 and TNF. An imbalance between IL-1 and 
IL-1 RA has already been suggested to play a role in the pathogenesis of RA 
(17,55) and Lyme arthritis (56) and this might also be the case for TNFa and its 
soluble receptors. This hypothesis, sustained by the promising results of clinical 
studies with IL-1RA (13) and anti-TNFa monoclonal antibodies (14) in RA, 
encourages further research in the field of anticytokine strategies. 
Taken together, our results show that circulating concentrations of IL-6, sIL-2R, 
sTNFR and IL-IRA, the spontaneous production of IL-lß, TNFa and IL-1RA 
and die cell-associated production of these cytokines after PBMNC stimulation 
are elevated in patients with active RA. In this open study, the combination MTX 
+ SASP seemed clinically superior to MTX alone. Reductions of circulating IL-6 
and sIL-2R levels were observed in both treatment groups, whereas decreases in 
sTNFR concentrations and the in-vitro production of cell-associated IL-lß and 
IL-IRA after stimulation occurred only with the combination therapy. Whether 
this relates to the better clinical effect in this patient group or is an specific effect 
of SASP remains to be investigated. Furthermore, the circulating levels and 
production of endogenous antagonists for IL-1 and TNF in RA may not be 
sufficient to suppress the activity of these pro-inflammatory cytokines. 
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CIRCULATING CYTOKINE 
MEASUREMENTS IN PATIENTS WITH 
SYSTEMIC SCLEROSIS TREATED WITH 
METHOTREXATE OR PLACEBO 
Barrera Ρ, van den Hoogen FHJ, Boerbooms AMTh, van Lier HJJ, van de Putte 
LBA, van der Meer JWM. Circulating cytokines, interleukin-1 receptor antagonist 
and soluble cytokine receptors in systemic sclerosis. Longitudinal measurements 
during a methotrexate-placebo controlled trial. (Submitted) 

Cytokine levels in SSc patients taking MTX or placebo 
Abstract 
Objective. To compare circulating concentrations of several cytokines, soluble 
cytokine receptors and/or antagonists between patients with systemic sclerosis and 
healthy controls. To determine the effects of methotrexate (MTX) therapy on these 
parameters and to assess their relationship to disease duration and extension of 
skin and organ involvement. 
Design. Randomized, single observer, double-blind, placebo- controlled study. 
Setting. University hospital. 
Patients. 26 patients with systemic sclerosis and 10 healthy controls were studied. 
Intervention. Patients were randomly allocated to receive either MTX (η = 16; 
15 mg/week) or placebo (η = 10) for up to 24 weeks. 
Measurements. Interleukin-lß (IL-lß), tumor necrosis factor a (TNFa), 1L-6, IL-1 
receptor antagonist (IL-1 RA) and soluble receptors for TNFa (sTNFRs = p55 and 
p75) and IL-2 (sIL-2R) were measured at baseline and at 4-weekly intervals. 
Results. Circulating concentrations of both types of sTNFRs, sIL-2R and IL-6 
were significantly higher in SSc patients than in controls. Markedly elevated 
sTNFRs and sIL-2R levels were present in patients with: (a) short disease 
duration, (b) muscular, (c) oesophageal involvement, and (d) in one patient who 
developed renal failure. After 24 weeks, 9 patients, all but one treated with MTX, 
showed clinical improvement, but no alterations in any of the cytokines studied 
were observed. 
Conclusions. Circulating concentrations of sTNFRs, sIL-2R and IL-6 are elevated 
in SSc. The high levels of sTNFRs and sIL-2R in patients with a short disease 
duration and muscular or oesophageal involvement, suggest an increased 
production during the early inflammatory phase of the disease and in certain 
patient subsets. In this study, MTX therapy appeared to be effective in SSc but did 
not result in modulation of circulating cytokine concentrations. 
Introduction 
Systemic sclerosis (SSc) is a multisystemic disease characterized by cutaneous 
and visceral fibrosis and vascular damage. The pathogenesis of SSc remains 
unknown but several cytokines are probably involved in the lymphocyte activation 
(1-4), fibrosis (5-7) and inflammation (8) observed in this disease. 
Many immunosuppressive drugs have been used in the treatment of SSc (9-11) 
but, so far, none has proven unequivocally its efficacy in controlled studies. 
Methotrexate (MTX) is an effective treatment for rheumatoid arthritis (RA) and 
we recently observed decreases in circulating soluble tumor necrosis factor and 
interleukin-2 receptors ( p55 sTNFR and sIL-2R) and IL-6 concentrations during 
such therapy in RA (12). After an open study had suggested the efficacy of MTX 
in the treatment of SSc (13), a 24-week, randomized, double-blind trial of MTX 
versus placebo followed by an additional 24-week observational study was 
conducted in our centre (14). Herein, we report the results of longitudinal 
measurements of cytokines (IL-lß, TNFa and IL-6), soluble cytokine receptors 
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(sTNFRs and sIL-2R) and the IL-1 receptor antagonist (IL-IRA) during the first 
24 weeks of this trial. 
Patients and methods 
Patients 
The details of the clinical study will be described elsewhere (14). Briefly, 29 
patients meeting the preliminary criteria for the classification of SSc (15) entered 
a 24-week, prospective, randomized trial of MTX versus placebo. Patients were 
randomly allocated to receive weekly doses of 15 mg either MTX (η = 17) or 
placebo (n = 12) administered as an intramuscular injection. Drugs with potential 
disease-modifying effects were discontinued at least three months prior to study 
entry. Allowed concurrent treatment (including prednisone ( < 10 mg/day) and 
non-steroidal anti-inflammatory drugs) was kept at stable dose during the trial. 
The clinical outcome was evaluated after 24 weeks. Good response was defined 
as > 30% improvement in either total skin score (16) or patient's global 
assessment expressed in a visual analogue scale (0 mm = bad, 100 mm = good 
general well-being) or > 15% improvement in diffusion capacity for carbon 
monoxide (DLC0) whenever not accompanied by persistent digital ulcerations or 
> 15% worsening in DLC0. 
Methods 
Plasma samples were collected in Vacutainer EDTA tubes (Becton & Dickinson, 
Rutherford, NJ) during die trial, and frozen at - 80°C until assay. Cytokine 
concentrations were measured at 4-weekly intervals for up to 24 weeks. Week 24 
to 48 consisted of an observational study, wherein cytokines were not assessed 
since most of the patients initially receiving placebo had been switched to MTX 
because of poor clinical response (14). Control samples (n = 10) were obtained 
from healtìiy laboratory personnel. To minimize interassay variations, all samples 
were measured in a single assay. 
IL-lß, TNFa and IL-1RA were assessed by radioimmunoassay (RIA) (17-18) 
with an average sensitivity of 40, 60 and 150 pg/ml respectively and both types 
of sTNFRs (p55 and p75) were measured by enzyme-linked binding assay 
(ELIBA) (kind gift of Dr H. Gallati, Hoffmann la Roche, Basel, Switzerland) 
with a sensitivity of 100 pg/ml. As previously reported, the RIAs for IL-lß and 
IL-1RA are specific, i.e. not altered by the coexistence of IL-lß and IL-1RA in a 
given sample, and the assays for TNFa and sTNFR detect total concentrations 
(both free levels and complexes) of TNFa and sTNFR (12,18). 
IL-6 was measured by B9 hybridoma bioassay (19) with a sensitivity of 0.3 
unit/ml and sIL-2R were assessed using an enzyme linked immunosorbent assay 
(ELISA) (Innotest hIL-2Rs, Innogenetics, В 2000 Antwerp, Belgium), according 
to the prescriptions of the manufacturer. The average sensitivity of this ELISA is 
390 pg/ml. 
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Statistical analysis 
Baseline variables were compared using the Wilcoxon rank sum test and the 
Wilcoxon signed rank test for paired data was used to compare data at 24 weeks 
with pretreatment values. Differences between groups during the 24 week follow-
up were analyzed by a distribution-free test for curve analysis (20). Correlations 
were evaluated using the Spearman's rank correlation coefficient both at study 
entry and after 24 weeks. 
Results 
Clinical results 
The clinical results of this trial will be published elsewhere (14). Baseline 
comparisons of clinical and laboratory parameters and the course of treatment are 
summarized in Table 1. Three patients (MTX/placebo = 1/2) were excluded 
from cytokine assessments since no pretreatment plasma was available. Two 
patients did not complete the first 24 weeks of the study, one because of renal 
failure (placebo group) and the other because of side effects (MTX group). 
Table 1. Course of treatment and clinical response in patients with systemic 
sclerosis (SSc) treated with methotrexate (MTX) or placebo 
Time of study 
WeckO 
No. of patients enrolled 
Disease duration > 1 yr / < 1 yr 
Diffuse / limited SSc t 
Presence of organ involvement φ 
Renal 
Oesophageal 
Pulmonary 
Cardiac 
Muscular 
Anti-topoisomerase autoantibodies 
Week 24 
Continued therapy 
Withdrawals 
Kesponder 
MTX 
16 
1 0 / 6 
4/ 12 
0 
14 
8 
3 
4 
8 
IS 
1 (side effects) 
8 
Placebo 
10 
7 / 3 
4 / 6 
0 
8 
6 
4 
0 
7 
9 
1 (renal crisis) 
1 
Diffuse / limited SSc = sclerotic skin changes proximal to the elbows or knees / distal to the 
elbows or perioral only. 
Definition of organ involvement: 
Renal = serum creatinine > 130 /¿mol/l or creatinine clearance < 50 ml/min. 
Oesophageal = diminished motility of the barium swallow. 
Pulmonary = vital and total lung capacity < 80% or DLÇQ <. 70% of predicted normal 
values or interstitial changes on chest X rays. 
Cardiac = conduction disturbances on ECG or cardiomegaly on chest X rays. 
Muscular = creatine Phosphokinase > twice the upper normal limit without proximal 
weakness or specific changes on electromyogram. 
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After 24 weeks, 8 (53%) of the 15 patients treated with MTX, and 1 (11%) of 
the 9 patients treated with placebo showed a good clinical response according to 
predefined response criteria. This difference was statistically significant 
(P = 0.03). 
Differences between patients and controls 
Baseline circulating concentrations of IL-6 (P = 0.002), both types of sTNFR 
p55 (P = 0.0001) and p75 (P = 0.0002) and the levels of sIL-2R (/» = 0.0001) 
were significantly higher in SSc patients than in the control group. In contrast, 
similar concentrations of IL-lß, TNFa and IL-1RA were observed in patients and 
healthy controls (Table 2). 
Table 2. Pretreatment cytokine concentrations in patients with systemic sclerosis 
and healthy controls. Median and (25, 75 percentile). 
IL-lß 
TNFa 
IL-6 
p55 
p75 
SIL-2R 
IL-IRA 
(pg/ml) 
(pg/ml) 
(U/ml) 
(pg/ml) 
(pg/ml) 
(pg/ml) 
(pg/ml) 
Controls (n = 10) 
50 
105 
1.7 
630 
1630 
1838 
220 
(50 - 85) t 
(85 -115) 
(1.4-2.5) 
(500 - 900) 
(2560 - 2860) 
(1300-2825) 
(205 - 285) 
Patients (n = 26) 
60 
87.5 
4.6 
1940 
5110 
4000 
237.5 
(50 - 65) 
(70 - 100) 
(2 - 29.4) 
(1610-2350) 
(3620 - 6660) 
3500 - 5625) 
(170-345) 
Ρ 
0.002 
0.0001 
0.0002 
0.0001 
t not detectable in 5 controls. 
Analysis according to therapy, skin and organ involvement 
IL-6 (NS) and p55 concentrations (P = 0.005) in the MTX group were higher 
than in the placebo group at entry but this difference did not persist during the 
study. With this exception, cytokine concentrations at baseline and during the 
follow-up were similar in: (a) both treatment groups, and (b) patients who 
showed a good clinical response and those without improvement after 24 weeks 
of treatment. No significant changes in the cytokines studied were observed in 
either treatment group or in patients with good or without clinical response after 
24 weeks follow-up (Table 3). 
Interestingly, patients with disease duration shorter than 1 year (n = 9) presented 
higher concentrations of p55 and p75 sTNFR (P < 0.02, and Ρ < 0.002 respec­
tively) and higher sIL-2R levels (P < 0.05) than those with long-standing disease 
(n = 17) (Figure 1 A, B, C). Levels of IL-1RA and IL-6 were also higher in the 
former group, though this did not reach statistical significance (Figure 1 D, E). 
Patients with muscular involvement (defined as creatine Phosphokinase > twice 
the upper normal limit, η = 4) showed higher p55 (P < 0.02), p75 (P = 0.02), 
SIL-2R (P < 0.02) and IL-6 (P < 0.05) concentrations and a tendency for 
higher IL-1RA levels (P = 0.06) than those without (Figure 2). 
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Figure 1. Circulating concentrations of sTNFR (A,B), sIL 2R (0, IL-1RA (D), and IL 6 (E) in SSc 
patients with short (dotted boxes) and long (hatched boxes) disease duration. 
Cytokine concentrations on the / axis, time in weeks on the / axis. 
Vertical line - range. Horizontal line - median; Box - p75 and p25 values. 
Τ - value above the y axis; Ρ values for differences between groups during the follow-up. 
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Figura 2. Circulating concentrations of sTNFR (A,B), slL-2R (C), IL-1 RA (D), and IL-6 (E) in SSc 
patients with (dotted boxes) and without (hatched boxes) muscular involvement. 
Cytokine concentrations on the γ axis, time in weeks on the ж axis. 
Vertical line - range, Horizontal line - median; Box - p75 and p25 values. 
t - value above the у axis; Ρ values for differences between groups during the follow-up. 
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Figure 3. Circulating concentrations of sTNFR (A,B), sIL 2R (C), IL IRA (D), and IL 6 (E) in 
SSc patients with (dotted boxes) and without! hatched boxes) oesophageal dysfunction. 
Cytokine concentrations on the y axis, time in weeks on the χ axis. 
Vertical line - range. Horizontal line - median; Box - p75 and p25 values. 
t - value above the / axis; Ρ values for differences between groups during the follow-up. 
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Oesophageal dysfunction (defined as diminished motility of barium swallow) was 
present in 22 patients. In this group, concentrations of the soluble TNF receptors 
p55 (P < 0.02) and p75 (P = 0.03) and the levels of sIL-2R (/> = 0.05) were 
higher than in patients with normal oesophageal motility (Figure 3). 
In contrast, neither the extension of skin involvement nor the presence or absence 
of cardio-pulmonary involvement or antitopoisomerase I antibodies were associ­
ated with differences in cytokine concentrations (data not shown). 
One patient treated with 
placebo developed renal 
failure and scleroderma 
renal crisis. This was 
accompanied by increa­
ses in p55, p75, and 
sIL-2R concentrations 
(Figure 4) 
Figure 4. 
Concentrations of sTNFRs 
and slL-2R (// axis) in one 
patient who developed renal 
failure. Serum creatinine and 
creatinine clearance on the 
yl axis, time in weeks on 
the χ axis. 
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Interrelationships between cytokines and correlations with clinical and 
laboratory parameters 
No significant correlations were observed between IL-lß and other parameters 
studied. TNFa concentrations were positively correlated with both types of 
soluble TNF receptors, sIL-2R and ESR at study entry but not after 24 weeks. 
Variables showing significant correlations are presented in Table 4. Cytokines 
levels showed no correlations with clinical (disease duration, total skin score) or 
laboratory parameters (C-reactive protein, antitopoisomerase I antibody titers, 
creatinine clearance (21). 
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Table 4. Correlations between cytokines, soluble receptors and ESR. 
Spearman correlation coefficient at entry and after 24 weeks. 
p55 
Entry 24 wlc 
TNFa 0.67§ 0.45 
p55 
p75 
SIL-2R 
IL-1RA 
IL-6 
p75 
Entry 24 wk 
0.45t NS 
0.66§ 0.79§ 
SIL-2R 
Entry 24 wk 
0.44t NS 
0.43t 0.46t 
0.69§ 0.82§ 
IL-IRA 
Entry 24 wk 
О.бОф 0.58Φ 
0.44t 0.63t 
NS NS 
NS NS 
IL-6 
Entry 24 wk 
0.46t NS 
0.41t 0.53t 
NS NS 
NS NS 
0.50t 0.53Φ 
ESR 
Entry 24 wk 
0.52Φ NS 
0.47t 0.55t 
0.40t 0.73§ 
0.54t 0.70§ 
0.43t NS 
0.5Ц 0.41 
NS = not significant; ESR = erythrocyte sedimentation rate. 
t Ρ < 0.05 
t Ρ < 0.005 
§ Ρ < 0.0005 
Discussion 
This is the first longitudinal report on circulating cytokines, cytokine soluble 
receptors and/or antagonists in SSc and the first study assessing the effects of 
MTX on these parameters. Our results show that concentrations of IL-6, both 
types of sTNFRs and sIL-2R are elevated in SSc patients. In contrast IL-lß, 
TNFa and IL-1RA levels are similar in patients and healthy controls. 
Previous studies have shown either normal (1,22-24) or increased circulating 
levels of TNFa (8,25), IL-lß (25) and IL-6 (1) in SSc patients, in contrast, 
elevated sIL-2R concentrations (8,9,11,25-27) have been uniformly reported. 
Increased sTNFRs levels have been observed in RA (both in the circulation and 
synovial fluid) (12,28-30), systemic lupus erythematosus (31-32), osteoarthritis 
(28) and chronic osteomyelitis (30) and high levels of IL-IRA have been found in 
synovial fluid from patients with RA, infectious or inflammatory arthropathies 
(33) and lyme arthritis (34). To our knowledge, there has been only one previous 
report on sTNFRs concentrations in SSc patients (32), and IL-1RA measurements 
have not been reported yet in this disorder. Our results concerning sTNFRs 
concentrations corroborate those of Heilig et al (32) and are, to some extent, 
similar to previous findings in RA (12): patients have increased levels when 
compared to healthy controls, p75 levels exceed those of p55 and both sTNFRs 
are present in the circulation in much higher concentrations than TNFa and 
correlate positively with sIL-2R and ESR measurements. Interestingly, higher 
levels of both types of sTNFRs were found in patients with a short disease 
duration and muscular or oesophageal involvement. IL-IRA concentrations, in 
contrast, were similar in patients and controls but also exceeded those of IL-lß 
and tended to be higher in patients with short disease duration or muscular 
involvement. Furthermore IL-1 RA concentrations showed positive correlations 
were observed with TNFa, IL-6 and p55 levels and with pretreatment ESR 
measurements. 
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The excess of the natural inhibitors sTNFRs (35) and IL-1RA (36) compared to 
TNFa and IL-1 respectively, the correlations of sTNFRs and IL-1RA with acute 
phase response (as measured by ESR and IL-6) and the higher levels of these 
parameters in early SSc suggest an increased production of endogenous cytokine 
inhibitors, specially early in the disease, when inflammation is a prominent 
feature. Some data suggest that this "anti-inflammatory" response might not be 
sufficient to suppress the effects of IL-1 and TNF completely. Firstly, a large 
excess of sTNFRs and IL-1RA is necessary to block the activity of TNF (35) and 
IL-1 (37) in vitro. Secondly, the enhanced or aberrant expression of IL-1 (38-39) 
and TNFa receptors (40) reported in SSc fibroblasts may reflect an increased 
sensitivity for these cytokines. An imbalance between cytokines and their 
antagonists has been suggested to play a role in the pathogenesis of RA (36,41) 
and lyme arthritis (34) and may also be implicated in SSc. The promising results 
obtained with anti-TNF (anti-TNFa antibodies (42) and anti IL-1 (IL-1RA 
(43,44) therapies for RA may encourage their future use in the treatment of SSc. 
SIL-2R levels are considered to be a marker of lymphocyte activation (45) and 
high sIL-2R concentrations may be associated with a poor outcome in SSc 
(26,46). Consistently with previous studies (8,9,11,25-27), we found elevated 
sIL-2R levels in SSc, specially in early stages of the disease (8,9). Association 
between sIL-2R and extent of skin involvement has been suggested in some 
studies (8) but was not confirmed in this and another (9) study. 
The high concentrations of sTNFRs and sIL-2R in patients with early disease and 
the correlations between sTNFRs, sIL-2R, IL-IRA and acute phase reaction 
(ESR and IL-6) together with the decreases in ESR observed after 48 weeks in 
the clinical study (14), suggest that these parameters reflect inflammation and 
lymphocyte activation, which is more marked in the early stages of the disease. 
The lack of correlations between the parameters studied and extension of skin 
involvement may not be surprising since uninvolved skin of SSc patients also 
displays pathological features (5,47). 
High levels of sTNFRs and sIL-2R were observed in patients with muscular or 
oesophageal involvement and in one patient who developed renal failure. 
Although the latter may partly be due to decreased renal clearance (48,49), these 
data suggest that increased production of these soluble receptors may be present 
in certain patient subsets. In view of the limited number of patients in this study, 
these results need confirmation in larger patient series. 
MTX therapy for 24 weeks resulted in clinical improvement in a number of 
patients (14) but was not reflected in changes of any of the cytokines studied. 
This contrasts with our previous findings in RA where decreases in IL-6, p55 and 
sIL-2R were observed within some weeks of MTX treatment (12). It should be 
noted that clinical improvement in RA is reflected in a decrease of the acute 
phase reaction (i.e ESR and CRP which correlate with IL-6, p55 and sIL-2R). In 
contrast, the parameters used to define response in this study (skin score, 
patient's global assessment or DLC0) did not correlate with any of the cytokines 
studied and decreases in ESR were only observed after 48 weeks of treatment 
with MTX (14). Previous studies in SSc patients, have shown improvement in 
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skin scores without changes in IL-2, sIL-2R or IL-6 levels after treatment with 
cyclosporin (11) or gamma-interferon (50) respectively for 48 weeks, and similar 
concentrations of IL-Iß, TNFa and IL-2 have been observed in patients receiving 
chlorambucil or not (9). These observations suggest that the parameters measured 
in this study are not useful to monitor response to therapy in SSc. 
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slL-2R measurements in RA 
To the Editor 
We read with interest the article of Ward and colleagues who measured serially 
circulating interleukin-2 receptor (sIL-2R) levels in rheumatoid arthritis (RA) (1). 
The authors found no significant partial correlations between changes in sIL-2R 
concentrations (assessed every 2 weeks for up to 60 weeks in 24 patients with RA) 
and changes in seven other measures of disease activity. Those consisted of tender 
and swollen joint count, physician and patient global assessment, patient pain score, 
Health Assessment Questionnaire Disability Index, and the erythrocyte sedimentation 
rate and were, with one exception, considered the most accurate measures of disease 
activity in a previous study (2). In view of the lack of correlations the authors 
suggest that RA exacerbations are either not accompanied by Τ cell activation or that 
the latter is not reflected by changes in sIL-2R levels. 
The role of the Τ cells in the pathogenesis of RA is still unclear but they are likely 
involved in early phases of the disease. Chronic synovitis and its exacerbations 
however may be sustained by other cells such as macrophages and synovial cells (3). 
Herein we would like to comment on some aspects of the study by Ward et al. (1). 
Previous reports have uniformly shown that sIL-2R concentrations are elevated in 
patients with active RA and other autoimmune diseases and this is considered to 
reflect activation of the immune system, especially the Τ cells (4-6). Decreases in 
sIL-2R levels have been observed during treatment with corticosteroids (7-9), 
methotrexate (10-12), cyclosporin (13-14), and amiprilose HCl (Therafectin) (6) but 
not with intramuscular gold (8,15), oral gold, sulfasalazine (15), azathioprine 
(10,16), or NSAIDs (17). Despite the different design and follow-up times of these 
studies, their results suggest that antirheumatic drugs differ in their effects on 
immune activation as represented by sIL-2R levels. In their study, Ward et al (1) did 
not prescribe a standard treatment. Though the regression models used by the 
authors may have adjusted for initial therapy, treatment was changed in 15 patients 
(65%) during the study. This may have introduced bias due to switching from one 
second line drug to another (n = 7), increasing the dosage (n = 5), and prescription 
of additional antirheumatic drugs (n = 3) (2). 
In patients with active RA, decreases in circulating sIL-2R levels whether significant 
(6,10,18) or not (11,17) have been reported to coincide or precede (7,19) clinical 
improvement. Ward et al (1) used a broad definition of active RA based exclusively 
on the presence of at least six swollen or tender joints and not in other usually 
required additional measures of disease activity, such as an elevated erythrocyte 
sedimentation rate (ESR) or morning stiffness. The study included patients with 
"mildly or moderately" active arthritis (2) but there was no clear definition of 
disease exacerbation or improvement. The authors showed that changes in sIL-2R 
levels did not occur simultaneously (or within 2 to 4 weeks) with other, mostly 
clinical, parameters of disease activity but did not examine the correlations with an 
outcome (either clinical or radiological) after a longer follow-up. 
In light of previous studies showing only moderate (7,18-21 ) or absent (3,10,11,15, 
22) correlations between sIL-2R and clinical parameters of disease activity, the 
results reported by Ward et al. are not surprising. However several laboratory 
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measurements including С reactive protein, ESR (6,7,10,11,15,16,19,21), anemia 
(23), platelet counts (7), interleukin-6, soluble tumor necrosis factor receptors (10), 
and granulocyte-macrophage colony stimulating factor (24) have been reported to 
correlate with sIL-2R levels and most of these were not examined by Ward et al (1). 
We propose that the role of measuring sIL-2R levels in the short and long-term 
management of RA should be clarified in further longitudinal studies which include 
a clear definition of disease activity, avoid changes in antirheumatic therapy, and, 
whenever possible, standardize for other factors which may influence sIL-2R 
measurements such as disease duration, stress, mood disturbances (20), and the 
circadian rhythm (25). 
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Removal of 1MB and TNF from human plasma 
Abstract 
We studied the suitability of in vitro dialysis with pofyacrylonitrile (PAN) membranes 
to remove small amounts of interleukin-lß (IL-lß) and tumor necrosis factor (TNF) 
from plasma to be used as diluent for the standards in radio-immunoassays (RIA). 
Incubation of PAN membrane fragments with radiolabeled IL-lß or TNF yielded a 
significant binding of both cytokines to the membrane (percentage of membrane-
bound cytokine after incubation in saline or plasma was 14-17% and 23-46%, 
respectively). Dialysis of plasma (containing radiolabeled cytokine) against plasma 
(initially devoid of cytokine) resulted in a binding percentage of IL-lß and TNF to 
the PAN membranes of 44% and 28%, respectively. When plasma was dialysed 
against saline the percentage of membrane-bound IL-lß and TNF was 63% and 
37%, respectively. After dialysis of plasma against either plasma or saline the 
percentage IL-lß recovered from the dialysate was approximately 16% in contrast 
with 1-2% TNF. The results confirm the capacity of in vitro dialysis with PAN 
membranes to remove IL-lß and to a lesser extent TNF from plasma. Removal is 
most marked in the first minutes of dialysis (suggesting saturation of the membrane) 
and less effective for TNF due to its low diffusion across the membrane. 
Introduction 
In radioimmunoassays, the selection of an appropriate diluent for the standards is 
essential. To avoid loss of parallelism and to improve sensitivity, the diluent should 
posses a matrix similar to the sample. In the assay of circulating cytokines as 
interleukin-lß (IL-lß) and tumor necrosis factor (TNF), cytokine-free plasma should 
preferably be used as diluent. As normal pooled plasma usually contains variable 
amounts of these cytokines, its purification before use as diluent for the standards 
is indicated. 
Previous studies by Lonnemann et al. (1,2) have shown that in vitro dialysis with 
polyacrylonitrile (PAN) membranes can remove IL-1 and TNF from protein-free 
tissue culture medium or whole blood. This prompted us to evaluate the suitability 
of in vitro dialysis for the depletion of cytokines from plasma to be used as diluent 
in cytokine radioimmunoassays. Whether dialysis procedures are able to effectively 
remove circulating IL-lß and TNF or not could also be important in clinical 
situations such as renal failure, septic shock, and adult respiratory distress syndrome 
(ARDS) where dialysis or continuous arteriovenous hemo-filtration (CAVH) is often 
used as therapeutic measure. 
Materials and methods 
Iodination of human IL-lß and TNF 
Recombinant human IL-lß (kindly provided by Glaxo, Geneva, Switzerland) and 
TNF (kindly provided by Dr G.R. Adolf, Boehringer, Vienna, Austria) were labeled 
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with a modification of the chloramine-T method as described elsewhere (5 μg of 
protein was labeled with 0.5 mCi 125I) (3). Free iodine was removed by Sephadex 
G-25 filtration (Pharmacia, Upsala, Sweden) and the labeled cytokines were stored 
at 4° С for up to 2 months. 
Prior to use, any remaining free iodine was again removed by Sephadex G-25 M 
column chromatography. Fractions were collected and two peaks of I25I activity were 
found. Fractions in the first peak containing 125I-bound cytokine were used. 
SDS-PAGE 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out to screen the radiolabeled cytokines for presence of polymers or decay products. 
Samples containing 20000 cpm of radiolabeled IL-lß, TNF, and calibration markers 
(14, 24 and 60 kDa) were diluted with buffer containing sodium dodecyl sulfate 
(SDS). A discontinuous 9-13% separation gel and a 4.5% stacking gel were used. 
The gel was stained with Coomassie Brilliant Blue to estimate the molecular weight 
of the samples by comparison with the molecular weight calibration markers. Dried 
gels were subjected to autoradiography using Kodak films (Kodak X-OMAT™ AR). 
The relative amount of radioactivity in each lane was estimated by densitometric 
scanning (Ultroscan XL laser densitometer, Pharmacia, Upsala, Sweden). 
Incubation of PAN membrane fragments with radiolabeled IL-lß or TNF 
PAN membranes removed from a new 
dialyzer were cut in fragments and 
rinsed with saline. Incubation was 
performed in polystyrene Petri dishes 
(50 mm diameter; Nunc, Denmark) 
and in chambers previously described 
as the Teflon film dish (Figure 1). 
This film dish consists of a reusable 
aluminium holder with a Teflon ring 
(inner diameter 35 mm) in which a 
membrane can be mounted (4). 
In the Petri dishes, PAN membrane 
fragments of 13.5 cm2 were immersed 
in the fluid phase. In the film dish only 
one surface of the membrane fragment 
(9.62 cm2) was in contact with the 
fluid phase. Each Petri dish and film 
dish was filled with 4 ml human 
plasma or saline to which l2iI-labeled 
IL-Hi or TNF was added (approxi-
mately 1000 to 200000 cpm). 
After 6 h shaking incubation at room 
temperature, radioactivity in the fluid Figure 1. Teflon film dish chamber (4). 
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phase and adhered to the membrane was determined. Results are expressed as per­
centage of radioactivity recovered after incubation. The sum of radioactivity recove­
red in the fluid phase and membrane, after correction for blanks, was set at 100%. 
In vitro dialysis 
A plate dialyzer with polyacrylonitrile (PAN) membrane (AN 69s; Biospal 
SCU/CAVH Al-U Kit, Hospal NL 5400 AC Uden, The Netherlands) was used. 
Dialysis was performed in a closed-loop dialysis circuit as shown in Figure 2. 
Both blood and dialysate compartments were rinsed with 2 liters of pyrogen-ftee 
saline and flushed with air before filling. To avoid gradients across the membrane, 
dialysis of plasma against plasma was performed in six experiments: frozen plasma 
from the blood bank was thawed and used to fill both compartments. The blood 
compartment contained ,25I-labeled recombinant human IL-1 β or TNF (approximately 
IO4 cpm/ml plasma equivalent to less than 30 ng per dialysis), while the plasma in 
the dialysate compartment did not contain radiolabeled cytokine. 
Dialysis of plasma against saline was performed in two experiments: the blood 
compartment contained plasma with radiolabeled ILI-β or TNF and the dialysate 
compartment was filled with saline free of radiolabeled cytokine. The solutions in 
both compartments were circulated for 1 h in a countercurrent manner at a flow rate 
of 100 ml/min. The dialysis was performed under sterile conditions at room 
temperature. 
To determine time-dependent removal of the cytokines, serial samples (0.5 ml) were 
drawn every 5 min from both compartments. After dilution with 2 ml saline, the 
samples were treated with an equal volume of 20% trichloroacetic acid (TCA), cen-
trifuged, and the precipitates measured in a gamma counter. 
Figure 2. Diagram of in vitro dialysis circuit. 
QB and QD - flow in blood and dialysate compartment. 
Mean fill volumes of the blood and dialysate compartment were 117 and 100 ml, respectively. 
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In all experiments the non-TCA precipitable radioactivity during the dialysis 
procedure was negligible (<5%). The percentage of TCA precipitable radioactivity 
in the samples after correction for blank, represents cytokine bound '25I. (Radio­
activity in the sample from the blood compartment before dialysis was set at 100%). 
Recovery of radiolabeled cytokine from dialyzer compartments and PAN 
membranes after dialysis 
After 1 h of circulation as described above, the dialyzer was emptied by flushing air. 
The void volumes from both compartments were collected separately and the 
radiolabeled cytokine present in each compartment was calculated. 
After rinsing the system with saline, the PAN membranes were mechanically 
removed and the membrane-bound radioactivity was determined before and after a 
washing step with 0.1 % Triton X-100. Results are expressed as percentage of radio­
activity recovered from dialyzer and membranes. The total radioactivity initially 
added to the blood compartment was set at 100%. Results are corrected for blanks. 
Results 
Incubation of PAN membrane fragments with radiolabeled IL-1 and TNF 
Results of incubation of PAN membrane fragments in Petri dishes are shown in 
Figure ЗА. The recovery of radiolabeled IL-lß in the fluid phase was 85.8% 
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Figure 3. Recovery of radiolabeled IL-lß and TNF after incubation with PAN membrane fragments. 
Results are expressed in percentage of radiolabeled cytokine recovered from the fluid phase 
(plasma or saline) and membrane fragment after incubation. Each bar represents 8 experiments 
(mean ± SD). The sum of cpm in fluid phase and membrane fragment after blank subtraction was 
set at 100%. (A) Incubation in Petri dishes. (B) Incubation in film dishes. 
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(SD ± 14.2) after incubation in plasma (n = 8) and 67.4% (SD ± 3.2) after 
incubation in saline (n = 8). Consequently the membrane-bound radioactivity was 
14.1% and 32.6%, respectively. Similar experiments with TNF yielded a recovery 
in the fluid phase of 84.6% (SD ± 1.1) (n = 8) and 73.3% (SD ± 9.7) (n = 8) 
after incubation with plasma o r saline, respectively. The remaining membrane-bound 
activity was 15.4% and 2 6 . 7 % for plasma and saline incubation, respectively. 
When incubation was performed in the film dishes (Figure 3B), the percentage of 
IL-lß recovered in the fluid phase was 83% (SD ± 3.7) for plasma (n = 8) and 
76.7% (SD ± 4.3) for saline (n = 8) incubation. The percentage of membrane-
bound IL-lß was 16.9% and 2 3 . 2 % , respectively. Similar experiments with TNF 
yielded a recovery in the fluid phase of 83.5% (SD ± 7.1) for plasma (n = 8) and 
54.3% (SD ± 11.3) for saline (n = 8) incubation while the percentage of 
membrane-bound TNF was 1 6 . 5 % and 45.7% after incubation in plasma and saline, 
respectively. 
After incubation, the Petri dishes and film dishes did not contain radioactivity above 
the background levels. The membrane-bound radioactivity measured both before and 
after washing twice with saline and 0 . 1 % Triton X-100 respectively, was essentially 
unchanged. 
Time-dependent removal of radiolabeled IL-lß and TNF during in vitro dialysis 
The distribution of 125I-labeled I L - l ß over both compartments during 1 h of in vitro 
dialysis is shown in Figure 4 . When dialysis of plasma against plasma was 
performed (n = 3), the amount of 125I-IL-lß in the blood compartment fell rather 
abruptly to 54.8% in the first minutes and decreased further gradually to 36.6% of 
the initial value after 1 h. In the dialysate, which initially did not contain radiolabe-
led cytokine, 125I-labeled IL - lß gradually reached a plateau. After 1 h, 14.3% of'25I-
labeled IL-lß had crossed the hemodialysis membrane and was present in the 
dialysate compartment (Figure 4A) . Dialysis of plasma against saline (n = 1) 
yielded an even more pronounced decrease in radioactive IL-lß content of the blood 
compartment in the first minutes with a concentration of 19.5% and 9.1 % in blood 
compartment and dialysate, respectively, after 1 h dialysis (Figure 4B). 
The results of similar experiments performed with '25I-labeled TNF are shown in 
Figure 5. The amount of ,25I-labeled T N F in the blood compartment decreased to 
67.6% and 64.2% after 10 m i n dialysis with a final concentration of 60.5% and 
69.5% after 1 h dialysis of p lasma against plasma (Figure 5A) and saline (Figure 
5B), respectively. In contrast wi th I L - l ß , less than 2% radiolabeled TNF was found 
in the dialysate after 1 h dialysis either against plasma or saline. 
Recovery of radiolabeled cytokine from dialyzer compartments and PAN 
membranes after dialysis 
From the initial amount of 125I-labeled IL-lß present in the blood compartment an 
average of 84.5% was recovered after 1 h dialysis of plasma against plasma (n= 3) 
24.7% was found in the blood compartment, 15.3 % in the dialysate, and 44.5% was 
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membrane-bound. Dialysis of plasma against saline (n = 1) yielded a total recovery 
of 95.8% radiolabeled IL-lß distributed as follows: 16.6% was recovered from 
blood compartment, 16.1 % from dialysate and 63.1 % from membranes (Figure 6). 
In similar experiments with 125I-labeled T N F an average of 84% was recovered after 
1 h dialysis of plasma against plasma (n = 3): 54.2% was found in the blood 
compartment, 1.7% in the dialysate, and 2 8 . 1 % was membrane-bound. Dialysis of 
plasma against saline (n = 1) yielded a total recovery of 87.9% TNF with the 
following distribution: 47.6%, from blood compartment, 2.6% from dialysate and 
37.7% from membranes (Figure 6). 
The radioactivity not recovered in these experiments is partly due to loss in sampling 
(mean 5%); the rest probably remained bound to the nonmembrane parts of the 
dialyzer and the tubing. 
Figures 4 and 5. Time dependent distribution of '2Sl-labeled IL-1B (Figure 4) and TNF (Figure 5) 
during in vitro dialysis with PAN membranes. Horizontal axis: minutes of dialysis. Percentage 
radiolabeled cytokine in the samples of the blood compartment (open symbols), or dialysate (closed 
symbols). Dialysis of plasma against plasma (n - 3) (A), and of plasma against saline (n - 1) (B). 
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Figure 6. Recovery of '25l-labeled cytokine from the blood and dialysate compartments and 
membranes of the PAN dialyzer after 1 h of in vitro dialysis. The total amount of radiolabeled 
cytokine present in the blood compartment before dialysis was set at 100 %. Horizontal labels 
indicate dialysis of plasma against either plasma or saline. The six bars on the left represent 
recovery of '25l-labeled IL-1ß, the six bars on the right recovery of '2Sl-labeled TNF. 
In all experiments the saline used to rinse the dialyzer after dialysis contained no 
radioactivity above blank levels. The membranes recovered from the dialyzer were 
washed with Triton X-lOO; only 1.4% and 1.9% (respectively, for IL-lß and TNF) 
of the membrane-bound radioactivity was released after the washing step. 
SDS-PAGE 
Results of autoradiography after SDS-
PAGE of radiolabeled TNF and IL-lß 
are shown in Figure 7. 
For both TNF and IL-lß several weak 
bands were observed in the molecular 
weight range of 65-90 kDa. More than 
95% of IL-lß and 80% of TNF was 
present in a molecular weight range 
under 20 kDa. Two strong bands with 
molecular weights around 40 and 55 
kDa were present only in the TNF 
sample and comprised 19% of the total 
radioactivity as revealed by densito-
metric scanning. These probably repre-
sent TNF oligomers or complexes of 
TNF and other plasma proteins. Figure 7. Autoradiogram of a Polyacrylamide gel. 
Numbers on the right show the molecular weight. 
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Samples from the dialysate compartment were not analysed in view of the low 
recovery TNF in the dialysate compartment. 
Discussion 
In the present study we confirmed previous findings of a significant binding of IL-lß 
to PAN membranes (1,2) and extended these observations to TNF, using small 
amounts of these cytokines such as are likely to be found in pooled plasma. The 
removal of IL-la was not studied since this cytokine is known to be mostly bound 
to cell membrane and not circulating (5). 
Incubation of PAN membrane fragments either in Petri dishes or film dishes resulted 
in a 14-17% of membrane-bound IL-lß or TNF when diese cytokines were diluted 
with plasma. When diluted with saline, binding increased almost 2-fold independent 
of the cytokine studied. This suggests that cytokine binding to the membrane is not 
specific and probably has to compete with other plasma proteins. In general, 
experiments with membrane fragments yielded a lower percentage of membrane-
bound radioactivity than in vitro dialysis. This can be explained by the differences 
in surface exposed, the stationary versus recirculatory incubation, and the diffusive 
clearance (in addition to adsorption) that takes place during dialysis. In view of these 
results, in-vitro incubation of plasma with PAN membranes seems less suitable than 
in-vitro dialysis to remove IL-lß and TNF from plasma. 
The results of die in-vitro dialysis with PAN membranes demonstrate effective 
removal from plasma of a significant amount of IL-lß; the removal of TNF is less 
pronounced. When die time-dependent distribution of cytokine during dialysis is 
examined, the decrease of radiolabeled cytokine content in the blood compartment 
is most marked during the first minutes of dialysis and more pronounced for IL-lß 
than for TNF. The plateau reached thereafter suggests saturation of the PAN 
membrane either by cytokines themselves or, more probably, by adsorption of odier 
plasma proteins. In die dialysate compartment IL-lß appears gradually, in contrast 
with TNF which hardly diffuses through the membranes. After 1 h dialysis, the 
amount of TNF remaining in die blood compartment is more than 2-fold higher than 
for IL-lß while the amount recovered from the dialysate is 6-fold higher for IL-lß 
than for TNF. This underscores die low capacity of TNF to cross the PAN 
membranes. 
Dialysis of plasma against saline yields a higher cytokine binding to the membrane 
(specially for IL-lß) dian dialysis of plasma against plasma. This suggests that the 
presence of saline in the dialysate compartment leads to an increase in the passage 
of the cytokines through the membrane and in the binding to the dialysate side of the 
membrane, which is not in contact plasma proteins. 
Taken together the results show diat removal of IL-lß from the blood compartment 
is due to adsorption to the membrane and filtration to the dialysate compartment, 
while removal of TN F is less effective and mostly due to adsorption. Similar results 
have been recently reported by Lonnemann et al. (6). The low degree of diffusion 
of TNF through the PAN membrane was not unexpected. The PAN membrane has 
a high transmittance coefficient for molecular sizes between 1,3 and 44 kDa (7), 
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which should allow filtration of both cytokines in monomeric form (17 kDa), 
however active human natural and recombinant TNF is known to consist of trimers 
(8) and dimers (9). Our data on SDS-PAGE of samples containing recombinant 
radiolabeled TNF confirmed the presence of TNF aggregates. Besides by molecular 
size exclusion, other factors such as unspecific adsorption of plasma proteins to the 
membrane which could complex with TNF, die tertiary structure of the TNF 
molecule and the negative surface charge of the PAN membrane, may also play a 
role in the low filtration of TNF dirough the membrane. 
The proportion of cytokine which remains membrane-bound after 1 h dialysis is 
lower for TNF than for IL-lß. These results contrast with the similar membrane 
binding observed for both cytokines after incubation with membrane fragments in 
plasma. An explanation could be that due to the low TNF fraction present in the 
dialysate compartment, the PAN membrane is mainly exposed to TNF in the blood 
compartment while exposure to IL-lß (which crosses the membrane readily) takes 
place at both compartments. 
This lower membrane-binding of TNF is also in contrast with a recent study by Lon-
nemann et al. (6). In that study human blood with recombinant or natural TNF or 
IL-1 was circulated against saline and a higher membrane binding was found for 
TNF than for IL-1. In that study, the amount of membrane-bound cytokine was 
calculated from the difference between the amount added and recovered from both 
dialyzer compartments, while our data show a direct measurement of the membrane-
bound cytokine; furthermore it is possible that a greater TNF load in the blood 
compartment or a greater proportion of monomeric TNF could explain the 
differences. 
Although we did not investigate removal of larger quantities of radiolabeled 
cytokine, the early saturation of the membrane (suggested by the plateau invariably 
present in the blood compartment after some minutes dialysis) with the relative low 
cytokine load, which we investigated, could imply decreasing efficiency of the 
cytokine removal with increasing amounts of cytokine. Lonnemann et al. (6), 
however, found similar percentage of cytokine absorbed to the PAN membrane 
during in vitro dialysis with increasing cytokine load (75 ng and 1.5 μg). Together 
with our data, this suggests that after some minutes of dialysis, an equilibration 
between the circulating cytokine and the fraction which is adsorbed to the membrane 
has taken place, and to reduce further the circulating load die use of a new dialyzer 
would be necessary. 
The mechanism of binding IL-lß and TNF by PAN is not elucidated here; binding 
curves similar to ours have been reported for complement components and 
cytochrome с (10), and therefore we do not believe that the binding is cytokine-
specific. Washing the PAN membranes with saline and 0.1 % Triton X did not lead 
to significant release of membrane-bound cytokine. 
In vitro dialysis with PAN membranes seems to be a useful method to remove IL-lß 
from plasma (specially with dialysis of plasma against saline) to be used for 
standards in immunoassays. Removal of TNF is less effective and other methods 
such as affinity chromatography (11) may prove more suitable. 
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Our results may also have implications for clinical settings where these dialyzers are 
used. Continuous arteriovenous hemofiltration (CAVH) used as adjunctive therapy 
in septic shock and ARDS, is aimed to remove deleterious exogenous and 
endogenous mediators (such as TNF and IL-1). These cytokines are probably asso-
ciated with acute and chronic complications of in vivo hemodialysis (12,13). The 
presumed rapid saturation of these membranes, the low filtration of TNF, and the 
induction of cytokine production that may occur during in vivo dialysis (14-20) casts 
doubts on the usefulness of such membranes for removal of these cytokines in vivo. 
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Summary and conclusions 
Low-dose methotrexate (MTX) therapy is widely used in rheumatoid arthritis (RA), 
and increasingly for other autoimmune diseases. Double-blind trials of MTX versus 
placebo and other antirheumatic drugs and long-term follow-up studies have 
unequivocally proven the clinical efficacy of this drug and shown that this can be 
sustained for long periods of time (1,2). This has led to the more frequent and 
earlier use of this agent in RA, but in spite of this broad clinical experience, the 
mode of action of MTX remains poorly understood. 
Cytokines are a large family of low-weight peptides which regulate intercellular 
communication both in health and disease. Within the past few years it has become 
apparent that certain cytokines play a critical role in the pathology of inflammation 
and the hypothesis that MTX could interfere with these cytokines has attracted the 
interest of several investigators. Numerous in-vitro studies have been performed on 
this item, but only few reports have addressed the effect of MTX therapy in RA. 
These have mostly consisted of uncontrolled observations in small patient samples 
with short follow-up periods. These shortcomings led to the work presented in this 
thesis which will be summarized in this chapter. 
Chapter 1 is a general introduction to this thesis. The link between cytokines, RA 
and antirheumatic therapy and the aim of the present studies are briefly summarized. 
Chapter 2 is a review of the literature concerning the effects of slow-acting 
antirheumatic drugs (SAARDs) on cytokine modulation. This chapter addresses some 
aspects of the cytokine network relevant for RA and other autoimmune diseases, and 
summarizes in-vitro, animal, and human studies on the action of several SAARDs 
in this network. Our knowledge in this area is fragmentary, and more investigations, 
especially longitudinal studies during SAARD therapy in RA, will be helpful not 
only in understanding the mode of action of these agents, but also in providing a 
rationale for future combination therapies and for the development of new drugs. 
The effect of some other agents with potentially specific effects on cytokines and of 
the cytokine and anti-cytokine approaches already used in RA are commented upon 
briefly. Promising results are being obtained with anti-tumor necrosis factor (TNF) 
and anti-interleukin-1 (IL-1) therapies and trials using combinations of these 
therapies with MTX have been already envisaged. 
Chapter 3 describes longitudinal measurements of circulating cytokines in a 
double-blind, randomized trial of MTX versus azathioprine (AZA). Serum 
concentrations of TNFa, interleukin-6 (IL-6), soluble receptors for IL-2 and TNFa 
(sIL-2R and sTNFR) were assessed in 20 healthy controls and in 61 patients treated 
with low-dose MTX (n=30) or AZA (n=31) for up to 24 weeks. According to 
predetermined criteria of clinical improvement, a total of 42 patients had a good 
clinical response and 19 were considered non-responders at study completion. Most 
importantly, the trial demonstrated that MTX was clinically superior and resulted in 
less radiologic progression than did AZA (3,4). 
The aims of this study were to compare circulating cytokine concentrations 
between: a) patients with RA and healthy controls, b) patients treated with MTX and 
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AZA, and с) patients who responded and those who failed to show clinical 
improvement during therapy. 
Compared with normal controls, pretreatment concentrations of TNFa, sIL-2R and 
both forms of sTNFR (p55 and p75) were significantly higher in RA patients 
whereas elevated IL-6 levels were observed only in some patients yielding similar 
mean concentrations in RA patients and controls. 
Analysis of the differences between both treatment groups and between responders 
and non-responders yielded some interesting observations. First, significant 
decreases in sIL-2R and p55 sTNFR concentrations occurred only in patients treated 
with MTX and in the group of responders whereas no changes were apparent among 
those receiving AZA, or in patients who failed to improve during therapy. 
Moreover, sIL-2R and p55 sTNFR concentrations showed a positive correlation with 
laboratory measures of disease activity such as C-reactive protein, ESR and platelet 
counts. These observations strongly suggest that the immune-activation markers 
sIL-2R and p55 sTNFR are susceptible to change during therapy with MTX and that 
these changes reflect clinical improvement in RA. 
A second important finding was the lack of changes in p75 sTNFR levels during the 
study which shows that the two forms of sTNFR are differentially regulated. The 
concentrations of each sTNFR exceeded those of TNFa by 20-30 fold. Both sTNFR 
behave as endogenous TNF antagonists and, since we could not detect any bioactive 
TNFa in serum (unpublished data), this sTNFR to TNFa ratio seems sufficient to 
block TNFa in the circulation, though larger excesses sTNFR may be necessary to 
block TNFa in the joint. 
IL-6 is the main inducer of the acute phase reaction and decreases in IL-6 
concentrations could be expected to occur together with clinical improvement. IL-6 
bioactivity levels fell indeed with both treatments, though such effect was most 
pronounced and rapid after initiation of AZA therapy. This was surprising in view 
of the worse clinical outcome observed with AZA. Moreover, IL-6 measurements 
by means of an immunoassay did not confirm a more potent effect of AZA on IL-6 
inhibition. We therefore postulated that treatment with AZA could interfere with the 
measurements of IL-6 bioactivity and this was confirmed in the study described in 
chapter 4. 
In conclusion, measurements of circulating sIL-2R and p55 sTNFR concentrations 
in patients with RA appear to be useful in the evaluation of disease activity and 
response to therapy and are subjected to modulation by MTX but not by AZA. 
Therapy with the later drug seemed to interfere with measurements of IL-6 
bioactivity. 
As mentioned, Chapter 4 deals with methodological pitfalls in cytokine detection. 
The bio- and immuno-assays currently used to quantify cytokines in biological fluids 
have each advantages and drawbacks. Bioassays measure functional activity of 
cytokines but are time-consuming and not always specific, whereas immunoassays 
can be highly specific but do not distinguish between biological active and inactive 
substances. Among the bioassays for IL-6, those based on proliferation of В cell 
lines, such as the B9 hybridoma, are most specific and sensitive. The widely used 
B9 bioassay was chosen for our studies since it can detect picogram amounts of IL-6 
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and is not affected by the presence of other cytokines (5). However, several factors, 
including drugs, may interfere with cytokine detection in biological fluids, and the 
effects of SAARDs in this particular assay had not been previously assessed. 
Therefore, the aim of this study was to analyze: a) the effects of several SAARDs 
on IL-6 bioactivity in-vitro and b) whether the presence of these agents in the 
circulation of patients receiving S AARD therapy could interfere with IL-6 detection. 
Our results show that AZA, its main metabolite 6-mercaptopurine (6-MP), and MTX 
inhibit IL-6 bioactivity whereas sulfasalazine (SASP) and its metabolites do not. The 
proliferation of B9 cells in the presence of IL-6 was suppressed by addition of 
exogenous AZA, 6-MP and MTX. These effects were dose-dependent, not due to 
cytotoxicity, and occurred at therapeutic concentrations of AZA and 6-MP. In 
contrast, MTX was inhibitory only at higher concentrations than can be achieved in 
RA patients, and SASP and its metabolites did not alter IL-6 bioactivity at any 
concentration. 
These results were confirmed by a set of experiments where sera from RA patients 
treated with several SAARDs were added to B9 cells cultured in the presence of 
IL-6. Only the sera from patients receiving AZA suppressed IL-6 bioactivity. 
We conclude that the IL-6 bioassay should not be used in patients treated with AZA 
since this drug interferes with the detection of IL-6 bioactivity. This is not the case 
for patients receiving MTX or SASP therapy. The general conclusion of this study 
is that interference of drugs must be ruled out when bioassays are used to evaluate 
cytokine levels in biological fluids. 
An intriguing difference between MTX and other SAARDs is the fast onset of 
therapeutic effects after therapy initiation and the disease flares occurring shortly 
after withholding the drug. Moreover in patients with RA, decreases in acute phase 
reactants, neutrophil Chemotaxis and leukotriene B4 production have been observed 
even after a single dose of MTX suggesting that the drug has anti-inflammatory 
rather than immunosuppressive effects. Whether these rapid "anti-inflammatory" 
action of MTX could be mediated by cytokine modulation has not been properly 
assessed in previous literature. In 9 patients with RA, Segal et al. observed no 
changes in the production of IL-1 by peripheral blood mononuclear cells after a 
single dose of MTX (6), whereas Chang et al. reported a decreased IL-1 production 
in 4 out of 8 patients receiving MTX for up to 6 weeks (7). The small patient 
samples and the variable treatment duration in these studies preclude firm 
conclusions 
Therefore in Chapter 5, the effects of a single dose of MTX on circulating 
cytokines and cytokine production were investigated. The study enrolled 42 patients 
with RA which were classified in three groups: A) those starting MTX therapy 
(n=16), B) diose on chronic (> 1 year) MTX therapy (n=ll), and C) a control 
group on chronic treatment with other or no SAARD (n=15). Blood samples were 
obtained on diree consecutive days and the weekly MTX dose was administered just 
after the first sampling to groups A and B. Circulating concentrations of IL-lß, 
TNFa, IL-6, SÍL-2R and sTNFR and the production of IL-la and ß, and TNFa 
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Cytokine production was assessed using isolated peripheral blood mononuclear cells 
(PBMNC) and a whole blood culture system (WBCS). 
The observatioas in this study can be summarized as follows: Comparison between 
patient groups showed that group A had a more active disease, higher circulating 
IL-6 concentrations and increased PBMNC cytokine production after in-vitro 
stimulation. The amount of IL-lß released by stimulated PBMNC decreased 
significantly after a single MTX dose in group A whereas no such changes occurred 
in group B. 
Circulating concentrations of the proinflammatory cytokines IL-lß and TNFa were 
low in the group as a whole, but stimulated blood cells (PBMNC and WBCS) had 
a high production capacity for these cytokines. The concentrations of sTNFR in the 
circulation exceeded those of TNFa moderately but die production of these natural 
TNF antagonists by blood cells was very limited (WBCS) or absent (PBMNC). This 
suggests that the production of TNF antagonists may be insufficient to block TNFa 
in vivo. In the meantime, trials widi anti-TNFa monoclonal antibodies have 
confirmed this hypothesis and ongoing studies with sTNFR will indicate whether 
these endogenous TNFa antagonists have a place in the therapy of RA. 
Consistent with previous findings (chapter 3), IL-6, sIL-2R and both types of 
sTNFR were readily detectable in the circulation and showed positive 
intercorrelations and associations with other acute phase measures. The WBCS 
proved useful for studying cytokine production in RA, diough the results in this 
system were not correlated to those obtained using PBMNC. Finally, we observed 
a high inter-individual variation in cytokine measurements, which underscores the 
need of longitudinal studies to evaluate the effects of drugs in RA. 
In conclusion, significant decreases in the production of IL-lß were observed in 
patients with active RA receiving their first dose of MTX. No such effect was 
observed in patients on chronic MTX therapy who had a lower "pre-dose" IL-lß 
production and less active disease. 
Combiuatioas of SAARDs are currently used in patients with RA refractory to 
therapy with single agents, and recent insights advocate their use in early stages of 
the disease in order to prevent radiological damage and functional disability in 
patients with severe RA. 
Up till now, SAARDs combinations have been based on the efficacy and, to some 
extent, the toxicities of the individual drugs, though in most cases the choice of 
agents has been arbitrary. Knowledge of the kinetics and the effect of SAARDs on 
mediators of inflammation will be helpful in constructing SAARDs combinations on 
a rationale basis. Moreover, understanding the effects of SAARDs on cytokines may 
result in synergistic combinations of SAARDs with anti-cytokine therapies in die 
future. Chapter 6 deals with die effects of SAARDs combinations on cytokines. 
These were addressed in a randomized, 24-week, open study performed in our 
centre, where the combination of MTX and sulfasalazine (SASP) proved superior 
to MTX alone in patients refractory to previous SASP therapy (7). To assess 
wheüier this was reflected in different cytokine modulation, longitudinal 
measurements of circulating cytokines and cytokine production by PBMNC were 
performed in 26 patients enrolled in this study and in 30 healthy controls. Therapy 
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had consisted of MTX alone (n=12) or combined with SASP (MTX+SASP, n=14) 
and in addition to the cytokines mentioned in chapter 5, circulating concentrations 
and production of the endogenous IL-1 antagonist (IL-IRa) were assessed. 
This study showed that therapy with MTX alone or in combination with SASP 
resulted in significant decreases of circulating IL-6 and sIL-2R concentrations. The 
circulating levels of both sTNFR and the production of cell-bound IL-lß and IL-IRa 
by stimulated PBMNC tended to be higher at baseline in the group receiving 
MTX+SASP and decreased significantly only in this group. MTX therapy did not 
result in progressive reductions of the amount of IL-lß secreted by PBMNC. 
Compared to healthy controls, RA patients had significantly higher circulating 
concentrations of IL-6, sTNFRs, sIL-2R and IL-IRa and their PBMNC showed 
higher spontaneous production of IL-lß, TNFa, and IL-IRa. Again the excesses of 
endogenous antagonists seemed too low to counteract the effects of IL-1 and TNFa 
in vivo. Moreover, this study confirmed the correlations between soluble cytokine 
receptors, IL-6 and several parameters of disease activity. 
It can be concluded that MTX therapy decreases circulating IL-6 and sIL-2R levels 
in RA. Further studies are needed to elucidate whether the additional effects 
observed with MTX + SASP relate to the better clinical response in this therapy 
group or to a specific effect of SASP. Though MTX may decrease PBMNC 
production of IL-lß on the short term, this effect is not sustained and offers no 
insights into the mode of action of this drug in RA. 
Chapter 7 Cytokines have been implicated in the pathogenesis of systemic sclerosis 
(SSc), a multisystemic disease characterized by cutaneous and visceral fibrosis and 
vascular damage. Many immunosuppressive drugs have been used in this disorder 
but none has proven efficacious in controlled trials. After a small open study 
suggested that MTX could be of benefit in this disorder (9), a larger trial was 
conducted in our centre (10). Longitudinal cytokine measurements were performed 
during the double-blind phase of this study where patients were randomized to 
receive either MTX (n=16) or placebo (n=10) for up to 24 weeks. At this time 9 
patients, all but one treated with MTX, showed clinical improvement according to 
predetermined criteria. Circulating concentrations of IL-lß, TNFa, IL-6, IL-IRa, 
sTNFR, and sIL-2R were assessed, and compared with a control group of 10 healthy 
individuals. This study showed that SSc patients present with higher concentrations 
of IL-6, SIL-2R and sTNFR than do controls. Markedly high levels of sTNFR and 
sIL-2R were observed in patients with a short disease duration (< 1 year), and in 
those with muscular or oesophageal involvement. Cytokine concentrations did not 
correlate with the extension of skin involvement. Moreover, irrespective of therapy 
or clinical response, no significant changes in cytokine concentrations occurred 
during the study. 
These results suggest that an increased production or release of soluble cytokine 
receptors takes place during the early inflammatory phase of SSc, as well as in 
certain subsets of patients with organ involvement. The cytokines measurements in 
this study do not reflect improvement in skin scores and wellbeing observed in a 
number of patients receiving MTX therapy. 
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Chapter 8 is a reaction to a previous article by Ward et al. (11). These authors 
reported no significant correlation between measures of disease activity and sIL-2R 
concentrations in patients with RA and questioned the relationship between sIL-2R 
and Τ cell activation and between the latter and clinical exacerbations in RA. Our 
concern with some aspects of this study and our view on the value of longitudinal 
assessments of sIL-2R levels in RA is put forward in this paper. The sIL-2R is a 
truncated form of the IL-2 receptor released mainly by activated Τ cells and 
considered to reflect immunoactivation in several autoimmune diseases. We observed 
decreases in sIL-2R concentrations during MTX therapy for RA and, Üiough this 
effect may not be shared by all SAARDs, decreases have been reported during 
cyclosporin and corticosteroid therapy as well. Moreover sIL-2R concentrations 
correlate with several acute phase parameters and may have some value as markers 
of disease activity. 
Chapter 9 describes the use of in-vitro dialysis with polyacrilonitrile membranes to 
remove small amounts of IL-Iß and TNFa from plasma. This method was used to 
obtain cytokine-depleted plasma which was used as diluent for the standards in 
radioimmunoassays. 
Our studies focused on the effects of MTX therapy on systemic cytokine 
concentrations and cytokine production by peripheral blood cells. This choice was 
justified by two reasons. First, blood specimens are easily obtained and very suitable 
for longitudinal studies, and second, such studies are needed to identify systemic 
parameters that are susceptible to therapeutic modulation and might function as 
markers of disease activity. This does not obviate the need to know what is 
happening in the joint. Though this compartment is less accessible than peripheral 
blood, synovial biopsies can be obtained percutaneously without requiring surgery 
or arthroscopy. This sampling method is easy to perform and very well tolerated by 
patients. Percutaneous synovial biopsies are being used to study the effects of anti-
TNF and anti-T cell therapies on cytokine expression in the joint but reports 
considering the effects of SAARDs in this aspect are very scarce. Future studies in 
this field are needed to understand what "older" agents do to the joint and may help 
in selecting synergistic combinations of novel and "older" therapies. 
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Samenvatting (voor halfgevorderden) 
Medicamenteuze therapie is de hoeksteen van de behandeling van reumatische 
aandoeningen en in het bijzonder van reumatoide artritis (RA). In het algemeen 
worden combinaties van niet steroidale anti-inflammatoire (NSAIDs) en langzaam-
werkende antireumatische middelen (slow-acting antirheumatic drugs ofwel 
SAARDs) al dan niet met corticosteroïden toegepast. NSAIDs en corticosteroïden 
remmen snel de ontstekingsverschijnselen, maar hebben geen effect op het ziekte-
beloop. SAARDs daarentegen hebben een tragere werking en zijn bedoeld om 
blijvende gewrichtschade en functieverlies te voorkomen. Tot de SAARDs behoren 
antimalariamiddelen, sulfasalazine, goud en andere thiolderivaten als penicillamine, 
en een aantal middelen die celgroei kunnen remmen als methotrexaat (MTX), aza-
thioprine, cyclofosfamide en cyclosporine. 
Van deze middelen wordt MTX, dankzij de relatief snelle werking, steeds vaker 
toegepast bij reumatische aandoeningen. 
MTX is een foliumzuurantagonist. Dit verklaart het celgroei remmende effect van 
hoge doseringen toegepast bij kwaadaardige aandoeningen. Het werkingsmechanisme 
van lage doseringen MTX, toegepast bij reumatische ziekten, blijft helaas 
onduidelijk. 
Cytokines zijn "boodschap eiwitten" geproduceerd door allerlei lichaamscellen en 
betrokken bij hun communicatie. Ze beïnvloeden elkaar door ingewikkelde 
interacties (cytokinenetwerk of cascade genoemd). Deze cascade kent een hiërarchie 
waarbij "hooggeplaatste cytokines" de produktie van andere kunnen stimuleren, en 
vertoont regulatiemechanismen die de aanmaak of het effect van cytokines kunnen 
blokkeren. Ondanks overlap in hun activiteiten kunnen cytokines worden ingedeeld 
op grond van hun effect op ontsteking, weefsel en celgroei (bijvoorbeeld litteken-
vorming en bloedaanmaak) en afweer. Een dysbalans tussen ontstekingsbevorderende 
cytokines als interleukine-1 (IL-1) en tumor necrosis factor (TNF) en hun controle-
mechanismen lijkt een kritische rol te spelen bij reumatische ziekten. Dit heeft reeds 
geleid tot toepassing van zogenaamde anticytokinetherapieën in RA en tot het zoeken 
van geneesmiddelen met meer specifieke effecten op cytokines. 
Enkele studies in vitro (met cellen gekweekt in het laboratorium) suggereren dat 
MTX kan interfereren met cytokines. Zulke effecten in vivo (in patiënten) zouden 
kunnen bijdragen aan het werkingsmechanisme van MTX. Helaas waren er tot op 
heden weinig cytokinemetingen verricht tijdens behandeling met MTX (en andere 
SAARDs) bij reumatische aandoeningen. Dit vormde de aanzet voor dit proefschrift. 
Hierin wordt het effect van MTX behandeling op de volgende cytokines beschreven: 
IL-1 en TNF, de belangrijkste ontstekingsbevorderende cytokines; 
hun specifieke antagonisten, te weten de IL-1 receptor antagonist (IL-IRa) 
en de twee types oplosbare TNF receptoren (sTNFR) p55 en p75; 
Interleukine-6 (IL-6), voornamelijk betrokken bij de acute fase reactie, 
waarvan de produktie gestimuleerd wordt door IL-1 en TNF; 
de oplosbare interleukine-2 receptoren (sIL-2R), product van geactiveerde 
lymfocyten die de mate van activatie van het immuunsyteem weerspiegelen. 
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Hoofdstuk 2 geeft een literatuuroverzicht van de invloed van SAARDs op het 
cytokinenetwerk en van de recente ontwikkelingen omtrent behandelingen met 
cytokines en anticytokines in RA. De aspecten van de cytokinecascade, relevant voor 
reumatische aandoeningen, worden in het kort besproken. 
Hoofdstuk 3 beschrijft de effecten van behandeling met MTX en azathioprine 
(AZA) op circulerende cytokines in patiënten met RA. Deze werden gemeten in 61 
patiënten die deelnamen aan een studie van 24 weken, waaruit bleek dat MTX 
effectiever was en minder aanleiding tot bijwerkingen gaf dan AZA. 
De concentraties van sIL-2R en sTNFR bleken verhoogd te zijn bij RA. Deze 
daalden tijdens MTX-behandeling en, onafhankelijk van behandeling, ook bij 
patiënten met goede klinische respons maar niet in de groep die AZA kreeg en niet 
reageerde op therapie. 
De concentraties van bioactief IL-6 waren matig verhoogd en namen af tijdens beide 
behandelingen. Deze daling was, onverwacht, meer uitgesproken en sneller in de 
groep behandeld met AZA. Dit deed vermoeden dat AZA kan interfereren met de 
meting van IL-6, hetgeen werd bevestigd in de studie beschreven in hoofdstuk 4. 
We vonden correlaties tussen sIL-2R, p55 sTNFR en IL-6 en andere parameters van 
ziekteactiviteit en een onafhankelijke regulatie van de twee sTNFR types. De 
concentraties van elke sTNFR waren 20-30 maal hoger dan die van TNFa, maar 
gezien de gegevens uit literatuur lijkt deze verhouding niet voldoende om het effect 
van TNFa in het gewricht volledig te blokkeren. 
Op grond van deze gegevens concluderen we dat MTX behandeling leidt tot afname 
van de circulerende concentraties van sIL-2R, p55 sTNFR en IL-6 bij patiënten met 
RA. Deze cytokines bleken bruikbaar om de ziekteactiviteit en de respons op 
therapie te evalueren. 
De bepalingsmethoden die heden ten dage gebruikt worden om cytokines te 
kwantificeren, hebben voor- en nadelen. Biologische methoden of bioassays meten 
de activiteit van cytokines maar zijn tijdrovend en niet altijd specifiek. Daarentegen 
zijn immunologische methoden specifiek maar onderscheiden niet tussen biologisch 
actieve en inactieve stoffen. De IL-6 bioassay gebruikt in onze studies, is gebaseerd 
op de groei van В cellen in de aanwezigheid van IL-6. Deze B9-bioassay kan zeer 
kleine hoeveelheden IL-6 detecteren en wordt niet gestoord door de aanwezigheid 
van andere cytokines. Desalniettemin zouden andere factoren, onder andere 
geneesmiddelen aanwezig in patiëntenmonsters, deze IL-6 metingen kunnen storen. 
Daarom worden in Hoofdstuk 4 de effecten van verschillende SAARDs op de 
biologische activiteit van IL-6 gemeten en wordt nagegaan of kleine hoeveelheden 
SAARDs, aanwezig in patiëntenbloed, zouden kunnen interfereren met de detectie 
van IL-6. Onze bevindingen tonen aan dat AZA, zijn belangrijkste metaboliet 6-
mercaptopurine (6-MP) en MTX de bioactiviteit van IL-6 onderdrukken. Deze 
effecten waren dosisafhankelijk en werden waargenomen bij therapeutische 
concentraties van AZA en 6-MP. MTX daarentegen remde de IL-6 bioactiviteit 
alleen in concentraties hoger dan die bereikt bij patiënten met RA. Sulfasalazine 
(SASP) had geen effect op de IL-6 bioactiviteit. 
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Deze resultaten werden bevestigd door sera van patiënten behandeld met 
verschillende SAARDs toe te voegen aan B9 cellen gekweekt in de aanwezigheid van 
IL-6. Alleen de sera van patiënten behandeld met AZA konden de bioactiviteit van 
IL-6 onderdrukken. 
Onze conclusie is dat de B9-bioassay niet geschikt is om IL-6 te meten in patiënten 
behandeld met AZA, omdat dit SAARD interfereert met de bioactiviteit van IL-6. 
Dit is niet het geval bij patiënten behandeld met MTX of SASP. De algemene 
conclusie van deze studie is dat, indien bioassays worden gebruikt om cytokine-
concentraties te meten, de interferentie van medicatie eerst uitgesloten moet worden. 
Een interessant verschil tussen MTX en andere SAARDs is het snel optredende 
effect en de eveneens snelle opvlamming van de ziekte na het staken van de therapie. 
Afname van de acute fase reactie en bepaalde functies van witte bloedcellen zijn 
gerapporteerd zelfs na één dosis MTX. Deze snelle effecten suggereren een anti-
inflammatoire werking van MTX. Of dit berust op cytokinemodulatie is niet 
voldoende bestudeerd. Daarom worden in Hoofdstuk 5 de effecten van één dosis 
MTX op circulerende cytokines en cytokineproduktie onderzocht. De studie omvat 
42 patiënten met RA onderverdeeld in drie groepen: Groep A kreeg voor het eerst 
een dosis MTX, groep В was behandeld met MTX langer dan 1 jaar en groep С was 
een controlegroep behandeld met andere of geen SAARD. Bloedmonsters werden 
afgenomen op drie achtereenvolgende dagen, waarbij patiënten in groepen A en B, 
net na de eerste bloedafname, de wekelijkse dosis MTX kregen. Om de cytokine-
produktie te onderzoeken werd gebruik gemaakt van uit perifeer bloed geïsoleerde 
mononucléaire cellen (PBMNC) en van het vol bloed (whole blood culture system 
ofwel WBCS). 
De observaties in deze studie kunnen als volgt samengevat worden: patiënten in 
groep A hadden een actievere RA, hogere concentraties van IL-6 in de circulatie en 
een hogere produktie van cytokines na in-vitro stimulatie van PBMNC. In deze 
groep vonden we een significante afname van de produktie van IL-lß na de eerste 
dosis MTX. Dit effect werd niet waargenomen bij patiënten behandeld met MTX 
voor langere periodes, maar die patiënten hadden al een lagere IL-lß produktie en 
een minder actieve RA. 
In de hele patiëntengroep waren de circulerende concentraties van de 
proinflammatoire cytokines IL-lß en TNFa laag, maar na stimulatie vertoonden de 
bloedcellen eeu hoge produktiecapaciteit voor deze cytokines. De concentraties van 
sTNFR in de circulatie waren hoger dan die van TNFa, maar de produktie van deze 
natuurlijke TNF-antagonisten door bloedcellen was heel laag (WBCS) of afwezig 
(PBMNC). Dit suggereert, samen met de positieve resultaten verkregen in trials met 
anti-TNF therapieën in RA, dat de produktie van TNF-antagonisten onvoldoende is 
om TNF in vivo te blokkeren. Studies met oplosbare receptoren voor TNF zijn 
gestart om na te gaan of deze natuurlijke TNF-antagonisten bruikbaar zijn in de 
therapie voor RA. 
Conform hoofdstuk 3, waren IL-6, sIL-2R en beide vormen van sTNFR makkelijk 
te detecteren in de circulatie. Zij toonden positieve onderlinge correlaties en 
correlaties met andere acute fase parameters. De WBCS bleek bruikbaar om 
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cytokineproduktie in patiënten met RA te bestuderen. Tenslotte waren er grote 
interindividuele variaties in cytokinemetingen, hetgeen het belang benadrukt van 
longitudinale studies om de effecten van therapie in RA te evalueren. 
Combinaties van SAARDs worden tegenwoordig gebruikt bij patiënten met RA ,die 
onvoldoende reageren op behandeling met één middel alleen. Recente overzichten 
pleiten ook voor het gebruik van SAARD combinaties in vroege stadia om 
gewrichtsbeschadiging en functieverlies te voorkomen. 
Tot op heden worden SAARD combinaties gekozen op basis van de effectiviteit en 
de toxiciteit van de individuele middelen. In veel gevallen blijft deze keuze arbitrair. 
Kennis over de effecten van SAARDs op cytokines en andere mediatoren van 
ontsteking kan helpen om SAARDs op een rationele basis te combineren en om 
synergistische combinaties van SAARDs met anticytokine therapieën te ontwerpen 
in de toekomst. In Hoofdstuk 6 worden de effecten op cytokines van MTX 
behandeling vergeleken met die van de combinatie MTX en sulfasalazine 
(MTX + SASP). 26 Patienten met RA namen deel aan deze studie, waarbij de 
combinatie MTX + SASP effectiever bleek dan MTX alleen. Wat betreft de 
cytokinemetingen vonden wij een afname van de concentraties van IL-6 en sIL-2R 
in de circulatie in beide behandelingsgroepen. Dalingen in de circulerende 
concentraties van beide sTNFRs en van de produktie van celgebonden IL-lß en 
IL-IRa door bloedcellen traden alleen op bij patiënten die behandeld werden met 
combinatietherapie. Deze additionele effecten zouden kunnen berusten op de betere 
klinische werking van MTX+SASP, of specifiek kunnen zijn voor SASP. De 
secretie van IL-lß door bloedcellen nam iets af kort na het starten van MTX therapie 
(zie hoofdstuk 5). Dit effect bleek niet progressief en houdt waarschijnlijk geen 
verband met het werkingsmechanisme van MTX op de lange termijn. 
Vergeleken met gezonde controles, hadden RA patiënten hogere concentraties van 
IL-6, sTNFRs, sIL-2R en IL-IRa in de circulatie en ook een hogere spontane 
produktie van IL-lß, TNF en IL-IRa. Opnieuw leek de geringe overmaat van 
natuurlijke IL-1 en TNF antagonisten onvoldoende om de effecten van IL-1 en TNF 
volledig te blokkeren. Daarnaast bevestigden de resultaten van deze studie de al 
genoemde correlaties tussen sTNFR, sIL-2R, IL-6 en verschillende parameters van 
ziekteactiviteit. 
Systemische sclerose (SSc) is een bindweefselaandoening gekenmerkt door fibro-
sering van huid en organen en aantasting van bloedvaten. Hoewel de oorzaak van 
deze ziekte onbekend is, lijken cytokines betrokken te zijn bij de ontsteking, fibrose 
en weefselschade die bij SSc voorkomen. 
Thans bestaat er geen onbetwiste behandeling voor deze ziekte maar gunstige 
effecten zijn beschreven tijdens MTX therapie in enkele studies. De invloed van 
MTX behandeling op cytokines in Ssc werd onderzocht in Hoofdstuk 7. Deze studie 
betrof 26 patiënten met SSc bij wie MTX effectiever bleek dan placebo. Onze 
resultaten tonen aan dat de circulerende concentraties van IL-6, sIL-2R en sTNFR 
verhoogd zijn bij SSc, in het bijzonder bij patiënten met een korte ziekteduur en 
spier- of slokdarmaantasting. In tegenstelling tot de bevindingen bij RA, leidde MTX 
behandeling bij SSc patiënten met tot afname van cytokineconcentraties. 
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Op grond van deze resultaten concluderen we dat de vroege fases van SSc 
(gekarakteriseerd door ontsteking), en bepaalde subgroepen patiënten hoge 
concentraties van IL-6 en cytokinereceptoren in de circulatie vertonen. Deze 
weerspiegelen niet de verbetering van huidscores of algemeen welbevinden zoals 
waargenomen in een aantal patiënten behandeld met MTX. 
Hoofdstuk 8 is een commentaar op een artikel door Ward et al. Onze visie over de 
waarde van de metingen van sIL-2R in de circulatie van patiënten met RA wordt in 
het kort besproken. 
In Hoofdstuk 9 worden experimenten met in-vitro dialyse beschreven. Door 
dialyseren van plasma in een kunstnier met bepaalde membranen kunnen kleine 
hoeveelheden IL-1 en TNF verwijderd worden. Deze methode werd gebruikt om 
"cytokinevrij" plasma te verkrijgen voor de verschillende cytokinemetingen hier 
beschreven. 
Dit proefschrift richt zich op de invloed van MTX op cytokines in de circulatie en 
op de produktie van cytokines door bloedcellen van patiënten met reumatische 
aandoeningen, in het bijzonder RA. De keuze om metingen te verrichten in perifeer 
bloed werd bepaald door twee redenen. Ten eerste zijn bloedmonsters gemakkelijk 
verkrijgbaar en lenen zij zich voor longitudinale studies. Ten tweede zijn deze 
studies nodig om te identificeren welke cytokines veranderen tijdens behandeling en 
welke kunnen fungeren als parameters van ziekteactiviteit. Desalniettemin is 
informatie over wat zich in het gewricht afspeelt van essentieel belang. Hoewel het 
gewricht minder toegankelijk is dan bloed kunnen, door middel van gewrichts-
punctie, synoviumbiopten relatief gemakkelijk verkregen worden. Op deze wijze 
verkregen biopten worden al gebruikt om de effecten van nieuwe therapieën op de 
cytokine-expressie in het gewricht te bestuderen. Vergelijkbare studies over het 
effect van SAARDs zijn nog schaars. Meer onderzoek op dit gebied is nodig om te 
begrijpen hoe "oudere" middelen werken en om optimale combinaties van nieuwe 
en "oudere" behandelingen te identificeren. 
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La terapia medicamentosa de las enfermedades reumáticas consiste en general en 
combinaciones de antiinflamatorios no esteroideos (NSAIDs) y antireumáticos de 
acción lenta (slow-acting antirheumatic drugs o bien SAARDs) con о sin corticos-
teroides. Los NSAIDs y corticosteroides tienen un rápido efecto pero no influyen 
en el decurso de la enfermedad, mientras que los SAARDs actúan de forma mas 
lenta pero pueden retardar la destrucción y perdida de función articular. Entre los 
SAARDs se cuentan medicamentos contra la malaria, la sulfasalazina, las sales de 
oro y derivados del tiol como la penicilamina, y un grupo de de drogas que frenali 
el crecimiento celular como el metotrexato (MTX), la azatioprina, la ciclofosfamida 
y la ciclosporina. 
El MTX es uno de los SAARDs mas usados debido a su rápido efecto clínico. Este 
medicamento es un antagonista del ácido fólico lo que explica su efecto citotóxicc 
a dosis altas. El mecanismo de acción del MTX a las bajas dosis, usadas ec 
enfermedades reumáticas, permanece sin clarificar. 
Las citoquinas son una familia de proteínas producidas por todo tipo de células que 
actúan como mensajeros entre ellas. La producción y acción de las citoquinas está 
controlada por complejas interacciones: ciertas citoquinas pueden estimular o inhibit 
la producción de otras. Estos mecanismos regúlatenos en conjunto se denominas 
network o cascada. A pesar de cierta redundancia se puede clasificar a las citoquinas 
según sus efectos en procesos como la inflamación, el crecimiento de tejidos, la 
producción de células sanguíneas y la immunidad. Hoy en dia se considera que un 
disbalance entre citoquinas proinílamatorias, como la interleuquina 1 y el factor de 
necrosis tumoral (IL-1, TNF), y sus mecanismos de control esta implicado en la 
patogénesis de las enfermadades reumáticas, especialmente de la artritis reumatoidea 
(AR). Esto ha resultado en la introducción de tratamientos "anti-citoquina" y en la 
búsqueda de medicamentos que reduzcan la producción de citoquinas de forma 
específica. 
Algunos estudios in vitro (con cultivos celulares) sugieren que el MTX puede 
interferir con ciertas citoquinas. Similares efectos in vivo (en pacientes) podrían 
contribuir al mecanismo de acción de esta droga. Los escasos estudios al respecto 
fueron el principal estímulo de esta tesis donde se describe el efecto del tratamiento 
con MTX en las siguientes citoquinas: 
IL-1 y TNF, citoquinas con efectos proinflamatorios; 
sus antagonistas específicos, el IL-1 receptor antagonista (IL-IRa) y los dos 
tipos de receptores solubles para TNF (sTNFRs) denominados p55 y p75; 
La interleuquina-6 (IL-6), principal motor de la reacción de fase aguda y 
cuya producción es estimulada por IL-1 y TNF; 
los receptores solubles de la interleuquina-2 (sIL-2R), producidos poi 
limfocitos cuyas concentraciones reflejan la activación del sistema imune; 
El Capítulo 2 es un resumen de lo hasta hoy descrito sobre la influencia de los 
SAARDs en la cascada de citoquinas y del uso de citoquinas y anti-citoquinas como 
terapia de la artritis reumatoidea (AR). 
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En el Capítulo 3 se describen los efectos del tratamiento con MTX y azatioprina 
(AZA) en las concentraciones de citoquinas en pacientes con AR. El estudio incluye 
61 pacientes tratados con estas drogas durante 24 semanas, donde el MTX demostró 
ser mas efectivo y menos tóxico que AZA. En este estudio encontramos que los 
niveles de sIL-2R y sTNFR, elevados en pacientes con AR, disminuyen durante el 
tratamiento on MTX y en pacientes con buena respuesta clínica pero no en aquellos 
que recibieron AZA. Las concentraciones de IL-6 con actividad biológica estaban 
algo elevadas en pacientes con AR y disminuyeron con ambos tratamientos. De 
forma inesperada este efecto era mas pronunciado y rápido en pacientes tratados con 
AZA. Esto sugiere que AZA interfiere con el ensayo usado para medir IL-6, lo que 
fue confirmado en el capítulo 4. 
Hallamos correlaciones entre los niveles de sIL-2R, p55 sTNFR y IL-6 y otros 
parámetros de actividad de la AR. Las concentraciones de sTNFRs excedían 20-30 
veces las de TNF lo que, en vista de previos estudios, parece insuficiente para 
bloquear completamente los efectos del TNF. 
De este estudio se concluye que el tratamiento con MTX induce un descenso de los 
niveles circulantes de sIL-2R, p55 sTNFR y IL-6 en pacienten con AR. Estas 
citoquinas pueden ser útiles para medir la actividad de la AR y la respuesta al 
tratamiento con MTX. 
Todos los métodos usados hoy en dia para medir citoquinas tienen ventajas e 
inconvenientes. Los bioensayos miden la actividad biológica pero son laboriosos y 
no siempre específicos. Los immunoensayos son específicos pero no distinguen entre 
substancias activas e inertes. El bioensayo usado para medir IL-6 en nuestros 
estudios esta basado en la proliferación de los limfocitos В en presencia de IL-6. 
Este método detecta mínimas cantidades de IL-6 y no es alterado por la presencia 
de otras citoquinas. Sin embargo otros factores, por ejemplo medicamentos presentes 
en la sangre, podrían alterar los resultados de este ensayo. En el Capítulo 4 se 
analizan los efectos de diversos SAARDs en la actividad biológica de IL-6 y la 
posible interferencia de estos medicamentos en la circulación con la detección de 
esta citoquina. Los resultados demuestran que AZA, su metabolito principal la 6-
mercaptopurina (6-MP) y el MTX pueden inhibir la actividad biológica de IL-6. 
Esto ocurre a concentraciones terapéuticas de AZA mientras que el efecto de MTX 
solo es aparente a concentraciones mayores que las halladas en pacientes con AR. 
La sulfasalazina (SASP) no altera la acción de IL-6. De esto se concluye que este 
bioensayo no es adecuado para medir IL-6 en pacientes tratados con AZA, pero si 
en los que reciben MTX o SASP. El colorarlo de este estudio es que si se planea 
el uso de cualquier tipo de bioensayo para medir citoquinas en pacientes, primero 
se ha de descartar la interferencia de la medicación usada. 
El MTX se diferencia de otros SAARDs por su rápido efecto y el asimismo rápido 
empeoramiento de los simtomas tras cesar la terapia. Un descenso de la reacción de 
fase aguda y de ciertas funciones de las células blancas se ha detectado incluso 
después de administrar una sola dosis de MTX. Esto sugiere un efecto antiinflama-
torio que podría ser resultado de una acción en citoquinas. El Capítulo 5 esta 
dedicado al análisis del efecto de una sola dosis MTX en las concentraciones 
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circulantes y la producción de citoquinas por células sanguíneas. Estas fueron 
medidas en 42 pacientes con AR clasificables en tres grupos: A) pacientes que 
recibían la primera dosis de MTX, В) pacientes tratados con MTX de forma crónica 
y C) un grupo de control, tratado con otros SAARDs. Las mediciones, efectuadas 
en tres dias consecutivos, fueron hechas justo antes y tras 24 y 48 horas de la 
ingesta de MTX en el grupo A y B. La producción de citoquinas se midió tanto en 
células mononucleares aisladas de la sangre periférica (PBMNC) como en muestras 
sangre completa (WBCS). Los resultados de este estudio se pueden resumir como 
sigue: Los pacientes del grupo A presentaban una artritis mas activa y también mas 
altas concentraciones de IL-6 y una mayor producción de citoquinas por PBMNC 
estimuladas. La producción de IL-1 descendió tras una dosis de MTX en este grupo 
de pacientes pero no en aquellos que recibían MTX de forma crónica (grupo В) y 
tenían ya una producción de IL-1 mas baja. 
Considerando a todos los pacientes en conjunto, las bajas concentraciones circulantes 
de IL-1 y TNF contrastan con la gran capacidad de producción de estas citoquinas 
por células sanguíneas. Los niveles circulantes de sTNFR exceden a los de TNF, 
pero la producción de estos antagonistas del TNF por células sanguíneas es muy 
escasa o ausente. Estas observaciones junto con la mejora clínica observada con 
terapias anti-TNF sugieren que la producción de sTNFR es insuficiente en pacientes 
con AR y ya se han iniciado estudios para determinar la utilidad terapéutica de estos 
anta-gonistas naturales del TNF. 
Conforme con los resultados descritos en el capítulo 3, los niveles de IL-6, sIL-2R 
y sTNFR estaban relacionados entre sí y con otros parámetros de actividad clínica. 
El WBCS demostró ser util para medir la producción de citoquinas en pacientes con 
AR. Finalmente, las diferencias en niveles de citoquinas entre individuos subrayan 
la importancia de estudios longitudinales para medir los efectos de la terapia. 
Actualmente se usan de combinaciones de SAARDs para tratar a pacientes que no 
responden a la terapia con un solo S AARD, y recientemente se ha propuesto el uso 
de estas combinaciones también en pacientes con artritis de corta duración para 
prevenir la destrucción articular irreversible. Hasta hoy la terapia combinada se basa 
en la efectividad y toxicidad de cada S A ARD individualmente pero en muchos casos 
la elección es arbitraria. Un mayor conocimiento de los efectos de los SAARDs en 
las citoquinas y otros mediadores de la inflamación puede ayudar a construir futuras 
combinaciones de SAARDs o de estos agentes con tratamientos anticitoquina. 
En el Capítulo 6 se comparan los efectos del tratamiento con MTX con los de la 
combinación MTX y sulfasalazina (MTX 4- S ASP) en 26 pacientes con AR. Los 
resultados clínicos demuestran la superioridad de la terapia combinada sobre la de 
MTX solo. Ambos tratamientos resultaron en una disminución de las concentra-
ciones circulantes de IL-6 y sIL-2R pero solo la combinación de MTX + S ASP se 
acompañó de una disminución de los niveles de sTNFR y de la producción celular 
de IL-1 y su antagonista, el IL-IRa. Estos efectos adicionales de la terapia 
combinada pueden reflejar el mejor resultado clínico en este grupo de pacientes o 
quizas ser un efecto específico de la SASP. La secreción de IL-1 descendió 
ligeramente tras iniciar el tratamiento (ver capitulo 5) pero este efecto no es 
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progresivo y por tanto no parece contribuir al mecanismo de acción del MTX a 
largo plazo. 
Comparados con individuos sanos, las concentraciones circulantes de IL-6, sTNFRs, 
sIL-2R y IL-IRa y la producción espontánea de IL-1, TNF y IL-IRa están elevadas 
en pacientes con AR. El moderado exceso de antagonistas de las citoquinas IL-1 y 
TNF parece de nuevo insuficiente para contrarestar los efectos de estas citoquinas. 
La esclerosis sistèmica progresiva (SSc) es un trastorno del tejido conjuntivo 
caracterizado por fibrosis de piel y órganos internos y lesiones vasculares. Su causa 
es desconocida pero las citoquinas contribuyen a la inflamación, fibrosis y daño 
vascular presentes en este desorden. Aunque no existe un tratamiento indiscutido 
para la SSc, se han descrito mejoras clínicas durante la terapia con MTX. El 
Capítulo 7 describe los resultados de un estudio en 26 pacientes con SSc tratados 
con MTX o placebo durante 24 semanas. Los resultados demuestran que las 
concentraciones de IL-6, sIL-2R y sTNFRs están elevadas en pacientes con SSc, 
sobre todo en la fase temprana e inflamatoria de la enfermedad y en pacientes con 
afección muscular o esofágica. El tratamiento con MTX resultó en mejora subjetiva 
y de la fibrosis cutanea en cietos pacientes pero, en contraste con los hallazgos en 
AR, no en disminución de los niveles de citoquinas circulantes. 
El Capítulo 8 es un comentario sobre un articulo de Ward y otros donde se expone 
nuestra opinion sobre el valor de la mediciones de sIL-2R en pacientes con 
enfermedades reumáticas. 
En el Capítulo 9 se describe el uso de diálisis con cierto tipo de membranas para 
purificar el plasma de pequeñas cantidades de IL-1 y TNF. El plasma libre de 
citoquinas obtenido con este método fue usado para los radioimmunoensayos en 
nuestros estudios. 
Esta tesis se centra en el estudio de los efectos del MTX en las concentraciones 
circulantes y la producción de citoquinas en pacientes con enfermedades reumáticas, 
en especial la AR. Elegimos las determinaciones en sangre periférica por los 
siguientes motivos: primero, las muestras de sangre son fáciles de obtener y se 
prestan para estudios longitudinales y segundo, este tipo de estudios es necesario 
para identificar que citoquinas responden al tratamiento y pueden ser útiles para 
medir la actividad de las enfermedades reumáticas. Sin embargo en la AR, la 
información sobre lo que ocurre a nivel articular es esencial. Aunque las 
articulaciones son menos accesibles que la sangre, es posible obtener tejido sinovial 
por medio de punciones percutaneas. Este tipo de biopsias se esta usando ya para 
medir el efecto de nuevos tratamientos en la expresión de citoquinas a nivel local, 
pero los estudios sobre el efecto de SAARDs al respecto son todavía muy escasos. 
Futuras investigaciones sobre este tema ayudaran, no solo a comprender como 
actúan los tratamientos antireumáticos tradicionales, sino también a construir 
combinaciones óptimas de "viejas" y nuevas terapias. 
168 
DANKWOORD 
Na enkele jaren klinisch werk in Nederland kreeg ik de mogelijkheid om onderzoek 
te doen. Dit heeft niet alleen geleid tot dit proefschrift, maar ook tot mijn keuze 
voor het vak reumatologie. Veel mensen die hiertoe bijgedragen hebben, verdienen 
een pluim en mijn dank. In het bijzonder wil ik noemen: 
Mijn promotores Jos van der Meer, Leo van de Putte en Agnes Boerbooms, mijn 
copromotor, hebben het enthousiasme voor de immunologie en reumatische ziektes 
in mij geprikkeld. Jos, bedankt voor je aanstekelijke passie voor cytokines en je 
wetenschappelijke adviezen. Leo, de mogelijkheid om onderzoek met patiëntenzorg 
te combineren heb ik aan jou te danken. Agnes, pet af voor je regelmatige 
begeleiding en je steun bij het schrijven van de verschillende artikelen. 
De medewerkers van het laboratorium algemene interne geneeskunde, microbiologie 
en endocrinologie hebben mij geholpen bij ontelbare cytokinebepalingen. Liesbeth 
Seuren, Trees Verver-Jansen en Johanna van der Ven-Jongekrijg zijn de "vrouw-
kracht" achter de coulissen bij meerdere studies en hebben mij geleerd hoe een pipet 
werkt. Pierre Demacker stond altijd klaar om te helpen met de radioimmunoassays 
en de dialyse experimenten. Rob Sauerwein bracht de kennis over interleukine-6. 
Dankzij jullie bleek mijn onkunde in laboratoriumwerk overbrugbaar. 
Mijn collega's Maurice Jeurissen, Kees Haagsma, Frank van den Hoogen en 
Marjonne Cremers doen klinisch onderzoek met methotrexaat en hebben kostbaar 
patiëntenmateriaal bijgedragen. Hun steun was onontbeerlijk. 
Jan Mulder, Theo de Boo, Henk van Lier en Georges Borni zijn de "brains" geweest 
bij de statistische bewerkingen. 
Ik heb genoten van de vakkennis en het gevoel voor humor van het secretariaat en 
de collegialiteit en prettige werksfeer of de afdeling reumatologie. Veel dank aan 
Marion en Marian die mijn "staccato" in goed Nederlands wisten te vertalen. 
Over taal gesproken, de opbouwende kritiek en "the most beautiful Scottish touch" 
van mijn ganggenoot Peter Donnelly had ik voor geen goud willen missen. 
Mijn paranimfen en vrienden Marlies Overdijk en Kees Haagsma hebben mij 
geholpen met de laatste promotie-loodjes. 
Mijn erkenning en dank geldt de patiënten die aan de verschillende studies deel 
namen en Het Nationaal Reumafonds voor de subsidiëring van dit onderzoek. 
Zonder hun inzet was dit werk niet mogelijk geweest. 
Al final, in mijn moedertaal natuurlijk, gracias a mi madre, tia y hermanos porque 
son mi raices, y por haber venido y a Dick, mi compañero y conejo favorito. 
169 

CURRICULUM VITAE 
De schrijfster van dit proefschrift, Pilar Barrera Rico, werd geboren op 15 oktober 
1959 te Madrid, Spanje. Na het behalen van het middelbare schooldiploma in 1975, 
begon ze met de studie Geneeskunde aan de Universidad Complutense te Madrid, 
waar ze in 1982 afstudeerde. 
In 1983 volgde ze een cursus Nederlands op de toenmalige Katholieke Hogeschool 
te Tilburg en dankzij een beurs van het Spaanse Ministerie van Buitenlandse Zaken 
en de gastvrijheid van Prof. Dr. J.H.M, van Tongeren werkte ze tussen november 
1983 en december 1985 op de afdeling gastroenterologie van het Academisch 
Ziekenhuis Nijmegen. 
Vanaf 1 mei 1986 volgde zij de opleiding Interne Geneeskunde in het Academisch 
Ziekenhuis Nijmegen (opleiders Prof. Dr. A. van 't Laar en Prof. Dr. J.W.M, van 
der Meer) en werd in 1992 ingeschreven als intemiste. 
Sinds 1993 volgt zij de opleiding tot reumatoloog in het Academisch Ziekenhuis 
Nijmegen en vanaf november 1995 in het Rijnstate Ziekenhuis te Arhnem (opleiders 
Prof. Dr. L.B.A. van de Putte en Dr. M. Janssen). 
Het onderzoek hier beschreven werd verricht tussen 1991 en 1994 onder de leiding 
van Prof. Dr. J.W.M, van der Meer, Prof. Dr. L.B.A. van de Putte en Dr. 
A.M.Th. Boerbooms. Voor dit werk ontving ze in oktober 1195 de Prof. Dr. J. 
Goslingsprijs van de Nederlandse Vereniging voor Reumatologen. 
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STELLINGEN 
behorende bij het proefschrift 
METHOTREXATE, CYTOKINES 
AND RHEUMATIC DISEASES 
Pilar Barrera Rico 
Kennis over de effecten van langzaamwerkende antireumatische middelen 
(SAARDs) op cytokines kan helpen om deze op een rationele basis te 
combineren en om synergistische combinaties van SAARDs met anti-
cytokine therapieën te ontwerpen, (dit proefschrift) 
Bij patiënten met reuma leidt methotrexaat behandeling tot afname van de 
concentraties van bepaalde cytokines in de circulatie, (dit proefschrift) 
Woorden als cyto-kine (cel-beweging) bewijzen het hedendaagse nut van de 
klassieke talen. 
Bij metingen van cytokineconcentraties gebaseerd op hun biologische 
activiteit moet er rekening gehouden worden met storende effecten van 
medicatie, (dit proefschrift) 
De in de afgelopen jaren toegenomen gerapporteerde bijwerkingen van 
methotrexaat bewijzen dat alle goede wapens een keerzijde hebben. 
De bewering van klinici, dat kennis over cytokines nog in de kinder-
schoenen staat is onjuist. Deze schoenen zijn volwassen genoeg om 
therapeutische wegen te bewandelen. 
Cytokines behoren tot de lichaamstaal. Ze zijn "both friends and foes" 
afhankelijk van omstandigheden. 
Metingen van cytokines in de circulatie kunnen bruikbaar zijn als 
parameters van RA activiteit, maar zijn geen "superbezinking", (eigen 
waarneming) 
El computador personal es la lengua del alma, ofwel 
De personal computer is de tong van de geest, (vrij naar Cervantes) 
Si alguien no se contradice nunca es porque nunca dice nada. 
Als iemand zichzelf nooit tegenspreekt, komt dat doordat hij nooit iets zegt. 
(Miguel de Unamuno) 
Ongeluk maakt de mens volwassen. (Wim van der Sluys, NRC Handelsblad 
30-09-1995) 
De liefde tot syn lant is yeder aangeboren. (Joost van den Vondel) 
Het beste bewijs dat reizen in de tijd nooit mogelijk zal zijn is het feit dat 
nooit hordes toeristen uit de toekomst ons land zijn binnengevallen. 
(Stephen Hawking) 
Het toenemende aantal leesboeken dat onaangeraakt in mijn kast wacht doet 
mij verlangen naar het "hora est". 
Een gedachte is aanstekelijk. Bepaalde gedachten zijn zelf epidemisch. 
(Wallace Stevens) 
Geneeskunde beoefenen betekent grenzen overschrijden. 
Bij het afronden van een proefschrift duren "de laatste loodjes" te lang. 


